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Abstract 
The closely-related CC chemokine receptors 2B and 5 are seven-transmembrane domain 
receptors coupled to heterotrimeric G proteins. The two receptors bind inflammatory 
chemokines and play important complementary roles in the recruitment of specific 
leukocyte sub-populations to sites of infection. To enable fine-tuning of cellular 
responses to chemokines, CCR2B and CCR5, like other GPCRs, can be desensitised in 
response to agonist stimulation or cross-talk with other receptors. This involves down-
modulation of cell surface active receptor through two essential transportation events, 
endocytosis and recycling. The CCR5 endocytic and recycling pathways are well 
established and several mechanisms involved have been clearly defined. Conversely, 
less is known about the route followed by CCR2B upon stimulation. 
This study investigated the regulation, trafficking and fate of CCR2B in the context of 
THP-1 cells endogenously expressing the receptor and HEK293 transfectants. 
Comparison with CCR5 highlighted marked differences in the behavious of the two 
receptors. However, my initial findings indicate that certain aspects of the regulation of 
CCR5 as well as CCR2B may be cell type-dependent. 
Flow cytometry, immunofluorescence and biochemical analyses showed that unlike 
CCR5, internalised CCR2B can be both degraded and recycled following agonist 
stimulation. In HEK293, CCR2B follows an EGF receptor-like pathway, transiting 
through early endosomes containing EEA1, transferrin and Rab4, reaching CD63 and 
Lamp1 positive late endosomes/lysosomes before being degraded.  
Importantly, I showed that CCR2B cell surface molecules are N- and O-glycosylated, 
and only this glycosylated form of the receptor is targeted for agonist-induced 
degradation. 
This thesis also presents findings from proteomics approaches developed in an attempt 
to identify interacting proteins implicated in the trafficking of each receptor. 
This study brings new insights to the endocytic regulation of agonist-treated CC 
chemokine receptors, revealing receptor- and cell type-specific behaviours, which add 
complexity to a relatively conserved process. 
3 
Table of contents 
Abstract ..................................................................................................... 2 
Table of contents ...................................................................................... 3 
List of Figures ........................................................................................... 9 
List of Tables .......................................................................................... 12 
Acknowledgements ................................................................................. 13 
Author’s declaration .............................................................................. 14 
1 Introduction ..................................................................................... 15 
1.1 Chemokine receptors ........................................................................................ 15 
1.1.1 Definition and nomenclature ..................................................................... 15 
1.1.2 Roles .......................................................................................................... 15 
1.1.3 Structure .................................................................................................... 16 
1.1.4 Signalling .................................................................................................. 24 
1.2 Chemokine receptors and disease ..................................................................... 27 
1.2.1 Examples of diseases involving CCR2 and CCR5 ................................... 28 
1.2.2 Chemokine receptors as therapeutic targets .............................................. 30 
1.3 Chemokine receptor regulation ........................................................................ 33 
1.3.1 Long-term chemokine receptor regulation ................................................ 33 
1.3.2 Agonist-induced (homologous) ................................................................. 34 
1.3.3 Negative Cross-talk (heterologous desensitisation) .................................. 36 
1.3.4 Transactivation and Synergy ..................................................................... 37 
1.4 Receptor trafficking .......................................................................................... 38 
1.4.1 Internalisation ............................................................................................ 38 
1.4.2 Recycling and resensitisation .................................................................... 39 
1.4.3 Degradation ............................................................................................... 40 
4 
1.4.4 Factors determining chemokine receptor fate following agonist stimulation
 40 
1.5 Thesis aims ....................................................................................................... 45 
2 Materials and Methods .................................................................... 48 
2.1 Reagents ........................................................................................................... 48 
2.2 Receptor agonists/antagonists .......................................................................... 48 
2.3 Buffers and solutions ........................................................................................ 49 
2.4 Antibodies ........................................................................................................ 50 
2.5 Cell culture ....................................................................................................... 53 
2.6 Production of transfected HEK293 cell lines ................................................... 53 
2.6.1 Transfection methods ................................................................................ 53 
2.6.2 Production of stable cell lines ................................................................... 54 
2.7 Immunofluorescence staining ........................................................................... 55 
2.7.1 Endocytosis assay ..................................................................................... 55 
2.7.2 Down-modulation assay ............................................................................ 56 
2.7.3 Microscopy ................................................................................................ 56 
2.8 Flow cytometry ................................................................................................. 56 
2.8.1 Down-modulation assay ............................................................................ 56 
2.8.2 Detection of cell-surface receptor by flow cytometry ............................... 57 
2.8.3 Flow cytometry data analysis .................................................................... 58 
2.9 SDS-PAGE and western blot ........................................................................... 58 
3 The monocytic cell line THP-1 and transfected HEK293 cells as 
model cells to study chemokine receptor desensitisation ..................... 60 
3.1 Introduction ...................................................................................................... 60 
3.1.1 Chemokine receptor desensitisation in monocytes ................................... 60 
3.1.1.1 Agonist-induced desensitisation ........................................................ 60 
3.1.1.2 Cross-talk between TLR2 and CCR2/5 on leukocytes ...................... 61 
5 
3.1.2 The monocytic cell line THP-1 ................................................................. 61 
3.1.3 Requirement for a transfected cell line model .......................................... 62 
3.1.4 Overview of transfected HEK293 cell lines created ................................. 63 
3.1.5 Objectives .................................................................................................. 66 
3.2 Relevant Methodology ..................................................................................... 66 
3.2.1 Intracellular calcium mobilisation assay ................................................... 66 
3.2.2 Cell surface receptor quantification by flow cytometry ............................ 67 
3.2.3 Total receptor expression manipulation and detection by 
immunofluorescence staining ................................................................................. 67 
3.3 Results .............................................................................................................. 68 
3.3.1 Characterisation of the monocytic cell line THP-1 ................................... 68 
3.3.1.1 CCR2 and CCR5 expression ............................................................. 68 
3.3.1.2 Agonist-stimulated receptor signalling .............................................. 70 
3.3.1.3 Agonist-induced receptor desensitisation .......................................... 71 
3.3.2 Characterisation of transfected HEK293 cell lines ................................... 74 
3.3.2.1 CCR2B and CCR5 expression ........................................................... 74 
3.3.2.2 Comparative analysis of CCR2B and CCR5 internalisation in 
response to agonist treatment .............................................................................. 78 
3.3.2.3 Cross-talk between TLR2 and CCR2B/5........................................... 82 
3.3.2.4 Receptor signalling ............................................................................ 83 
3.4 Discussion ........................................................................................................ 84 
4 Characterisation of agonist-induced CCR2B trafficking .............. 88 
4.1 Introduction ...................................................................................................... 88 
4.1.1 Desensitisation of chemokine receptors as a consequence of agonist 
activation ................................................................................................................. 88 
4.1.2 Overview of CCR5 trafficking pathways following chemokine agonist 
treatment .................................................................................................................. 88 
4.1.3 Current knowledge of CCR2B trafficking pathways ................................ 88 
6 
4.1.4 Objectives .................................................................................................. 89 
4.2 Relevant Methodolgy ....................................................................................... 89 
4.2.1 Transferrin/EGF uptake ............................................................................ 89 
4.2.2 Recycling assay ......................................................................................... 89 
4.2.3 CCR2 degradation assay ........................................................................... 91 
4.2.4 Testing for post-translational modifications of HA-CCR2B .................... 91 
4.2.5 Detection of ubiquitinated chemokine receptors....................................... 92 
4.2.6 Subcellular fractionation ........................................................................... 92 
4.3 Results .............................................................................................................. 93 
4.3.1 Agonist-induced CCR2B internalisation................................................... 93 
4.3.1.1 Time course of CCR2B internalisation .............................................. 93 
4.3.1.2 Route of CCR2B internalisation ........................................................ 94 
4.3.1.3 CCR2B trafficking to early endosomes ............................................. 98 
4.3.2 Agonist-induced CCR2B recycling........................................................... 98 
4.3.2.1 Colocalisation with transferrin pathway and Rab4 ............................ 98 
4.3.2.2 Recycling Assay .............................................................................. 101 
4.3.3 Agonist-induced CCR2B degradation..................................................... 108 
4.3.3.1 Colocalisation with late endosomal and lysosomal markers ........... 108 
4.3.3.2 Biochemical analysis of agonist-induced degradation..................... 113 
4.3.3.3 Identification and characterisation of the different forms of CCR2B .... 
116 
4.4 Discussion ...................................................................................................... 123 
4.4.1 Comparison of CCR2B trafficking to CCR5 trafficking and overview of 
pathway  ................................................................................................................ 123 
4.4.2 CCR2B internalisation ............................................................................ 123 
4.4.3 CCR2B degradation ................................................................................ 125 
4.4.4 CCR2B recycling .................................................................................... 126 
4.4.5 Choice of recycling or degradation ......................................................... 127 
7 
4.4.6 Different forms of CCR2B ...................................................................... 127 
5 Identification of interacting partners ............................................ 130 
5.1 Introduction .................................................................................................... 130 
5.1.1 Choice of techniques ............................................................................... 131 
5.1.1.1 GST pull down ................................................................................. 133 
5.1.1.2 Immunoprecipitation ........................................................................ 134 
5.1.2 Objectives ................................................................................................ 135 
5.2 Relevant methodology .................................................................................... 136 
5.2.1 Molecular biology techniques ................................................................. 136 
5.2.1.1 Oligos ............................................................................................... 137 
5.2.1.2 PCR .................................................................................................. 137 
5.2.1.3 Annealing oligos .............................................................................. 138 
5.2.1.4 Restriction enzyme digests .............................................................. 138 
5.2.1.5 Ligation ............................................................................................ 139 
5.2.1.6 Transformation................................................................................. 139 
5.2.1.7 Purification of plasmid DNA ........................................................... 139 
5.2.1.8 DNA quantification.......................................................................... 140 
5.2.1.9 Agarose gel electrophoresis ............................................................. 140 
5.2.2 DNA sequencing ..................................................................................... 140 
5.2.3 GST fusion protein production and purification ..................................... 140 
5.2.4 GST pull down technique........................................................................ 142 
5.2.5 Protein identification by mass spectrometry ........................................... 142 
5.2.6 Immunoprecipitation ............................................................................... 142 
5.3 Results ............................................................................................................ 145 
5.3.1 GST pull down: Optimization of GST-fusion protein production and 
purification ............................................................................................................ 145 
5.3.1.1 GST fusion proteins are produced but are contaminated with GST 145 
8 
5.3.1.2 Approaches tested to reduce GST contamination ............................ 148 
5.3.1.3 The GST fusion proteins are partially insoluble .............................. 151 
5.3.1.4 GST fusion protein yields ................................................................ 153 
5.3.2 GST pull-down: Identification of interacting proteins ............................ 154 
5.3.3 Immunoprecipitation ............................................................................... 156 
5.3.3.1 Immunoprecipitation of receptors from monocytic cell lines .......... 156 
5.3.3.2 Immunoprecipitation of receptors from transfected HEK293 cells . 156 
5.4 Discussion ...................................................................................................... 161 
5.4.1 GST pull-down: successful outcomes ..................................................... 161 
5.4.2 GST pull-down: limitations .................................................................... 164 
5.4.3 CO-IP: outcomes and limitations ............................................................ 166 
5.4.4 Recommendations for future studies to identify binding partners for 
CCR2B  ................................................................................................................. 168 
6 General discussion .......................................................................... 171 
6.1 Biosynthesis .................................................................................................... 171 
6.2 Internalisation ................................................................................................. 172 
6.3 Degradation .................................................................................................... 175 
6.4 Recycling ........................................................................................................ 177 
6.5 Nuclear localisation ........................................................................................ 179 
6.6 Factors responsible for trafficking ................................................................. 180 
6.7 Conclusions .................................................................................................... 183 
6.8 Future experimental directions ....................................................................... 186 
Appendix ................................................................................................ 187 
Definitions .............................................................................................. 198 
References .............................................................................................. 204 
 
9 
List of Figures 
Figure  1.1 Chemokine receptor topology, post-translational modifications and 
important residues. .......................................................................................................... 17 
Figure  1.2 Homologous (A) and heterologous (B) chemokine receptor down-
modulation. ..................................................................................................................... 35 
Figure  1.3 Summary of the endocytic trafficking pathways followed by agonist-
stimulated chemokine receptors. ..................................................................................... 38 
Figure  1.4 Different trafficking routes proposed for agonist-treated CCR5. ................. 45 
Figure  1.5 Schematic of CCR2B topology showing comparison of the amino acid 
sequence with CCR5. ...................................................................................................... 47 
Figure  3.1 Comparison of the amino acid sequence of human and mouse TLR2 using 
SIM (http://expasy.org/tools/sim-prot.html). .................................................................. 65 
Figure  3.2 CCR2 expression in THP-1 cells. ................................................................. 69 
Figure  3.3 CCR5 expression in THP-1 cells. ................................................................. 69 
Figure  3.4 Delineation of the receptor responsible for CCL2 and CCL5 induced calcium 
signalling in THP-1 cells and monocytes. ...................................................................... 72 
Figure  3.5 Lack of CCR5 down-modulation in response to agonist treatment on THP-1 
cells. ................................................................................................................................ 73 
Figure  3.6 CCR2 down-modulation in response to agonist treatment on THP-1 cells. . 73 
Figure  3.7 HA-CCR2B and HA-CCR5 expression in transfected HEK293 cells. ........ 75 
Figure  3.8 Constitutive intracellular accumulation of HA-CCR2B and HA-CCR5 in 
transfected HEK293 cells. ............................................................................................... 77 
Figure  3.9 Treatment with cyclohexamide partially reduces HA-CCR2B intracellular 
accumulation in transfected HEK293 cells. .................................................................... 77 
Figure  3.10 Down-modulation of cell surface receptors in response to agonist treatment.
 ......................................................................................................................................... 79 
Figure  3.11 (A) Differential localisation of internalised HA-CCR2B and HA-CCR5 
upon agonist treatment in transfected HEK293 cells. (B) Lack of colocalisation of 
internalised HA-CCR2B with TGN46. ........................................................................... 80 
Figure  3.12 Internalisation of HA-CCR2B and HA-CCR5 upon agonist or LTA 
treatment in transfected HEK293 cells. .......................................................................... 81 
Figure  3.13 Comparison of cell surface receptor down-modulation in response to 
agonist, LTA and Pam3CSK4 treatment. ........................................................................ 83 
10 
Figure  4.1 Internalisation time course of HA-CCR2B in HEK HA-CCR2B cells. ....... 94 
Figure  4.2 Effect of endocytosis inhibitors on receptor down-modulation. .................. 96 
Figure  4.3 Colocalisation study using HEK HA-CCR2B cells and fluorescent 
transferrin. ....................................................................................................................... 97 
Figure  4.4 Colocalisation study using HEK HA-CCR2B cells and the early endosome 
marker EEA1. .................................................................................................................. 99 
Figure  4.5 Colocalisation study using HEK HA-CCR2B cells and fluorescent Rab4. 101 
Figure  4.6 HA-CCR2B recycling in HEK HA-CCR2B cells. ..................................... 102 
Figure  4.7 CCR2 recycling in THP-1 cells. ................................................................. 103 
Figure  4.8 Involvement of Rab4 in HA-CCR2B recycling in HEK HA-CCR2B cells.
 ....................................................................................................................................... 105 
Figure  4.9 Colocalisation study using HEK HA-CCR2B cells and fluorescent EGF. 107 
Figure 4.10 Colocalisation study using HEK HA-CCR2B cells, fluorescent transferrin 
and fluorescent EGF. ..................................................................................................... 108 
Figure  4.11 Colocalisation study using HEK HA-CCR2B cells and the late endosome 
marker CD63. ................................................................................................................ 110 
Figure  4.12 Colocalisation study using HEK HA-CCR2B cells and the lysosomal 
marker Lamp1. .............................................................................................................. 111 
Figure  4.13 Colocalisation study using leupeptin-treated HEK HA-CCR2B cells and the 
late endosome marker CD63. ........................................................................................ 112 
Figure  4.14 Colocalisation study using HEK HA-CCR2B cells and the late endosome 
marker CD63 following the down-modulation assay. .................................................. 113 
Figure  4.15 Degradation of HA-CCR2B in response to agonist treatment.................. 115 
Figure  4.16 Subcellular fraction of the HA-CCR2B forms in untreated HEK HA-
CCR2B cells. ................................................................................................................. 117 
Figure  4.17 Subcellular fraction of the HA-CCR2B forms in CCL2-treated HEK HA-
CCR2B cells .................................................................................................................. 118 
Figure  4.18 Testing for post-translational modifications of HA-CCR2B. ................... 119 
Figure  4.19 Glycosylation of HA-CCR2B ................................................................... 122 
Figure  4.20 Trafficking of internalised CCR2B. ......................................................... 129 
Figure  5.1 Production and purification of GST-CCR2B/5ct fusion proteins............... 146 
Figure  5.2 Production and purification of GST-CCR2B in different strains of E.coli. 147 
Figure  5.3 The GST-CCR2Bct fusion protein is degraded during production. ........... 148 
Figure  5.4 Production and purification of GST-CCR2B/5ct-HIS6. ............................. 150 
11 
Figure  5.5 Testing thrombin cleavage of fusion proteins. ........................................... 151 
Figure  5.6 Testing Prescission Protease cleavage of fusion proteins. ......................... 151 
Figure  5.7 Comparison of the solubility of the different GST fusion proteins for CCR2B  
(A) and CCR5 (B). ........................................................................................................ 152 
Figure  5.8 Changing the growth temperature (A) or bacterial density at the time of 
induction (B) gave no significant improvement in the fusion protein solubility. ......... 153 
Figure  5.9 GST pull down experiment. ........................................................................ 155 
Figure  5.10 Testing a selection of α-CCR2 (E68, H-40) and α-CCR5 (2D7, 3A9, CCR5 
NT, HEK/1/85a, MC5, T21/8) antibodies for immunoprecipitation of the receptors from 
the monocytic cell line MonoMac 1. ............................................................................ 156 
Figure  5.11 : Immunoprecipitation of HA-CCR2B and HA-CCR5 from transfected 
HEK293 cells using 12CA5 (CCR2B) or MC5 (CCR5). ............................................. 157 
Figure  5.12 Degradation of HA-CCR2B and HA-CCR5 in cell lysate over time. ...... 158 
Figure  5.13 Immunoprecipitation of HA-CCR2B using 12CA5 and different bead 
supports. ........................................................................................................................ 158 
Figure  5.14 Immunoprecipitation of HA-CCR2B from HEK HA-CCR2B cell lysates.
 ....................................................................................................................................... 159 
Figure  5.15 Recovery of immunoprecipitated HA-CCR2B following elution. ........... 160 
 
  
12 
List of Tables 
Table 1.1 Identified chemokine receptor homomers....................................................... 21 
Table 1.2 Identified chemokine receptor heteromers and their functional outcomes. .... 22 
Table 1.3 Chemokine receptors and their chemokine ligands. ....................................... 27 
Table 1.4 Reported protein interactions with chemokine receptors. ............................... 44 
 
Table  2.1 Chemokine receptor agonists and antagonists used in this project. ............... 49 
Table  2.2 Buffers and their compositions. ..................................................................... 49 
Table  2.3 Antibody specificities, sources and concentrations used. .............................. 50 
Table  2.4 Drugs tested for their effects on CCR2 down-modulation. ........................... 57 
 
Table  3.1 Summary of the transfected HEK293 cell lines created in this project. ........ 64 
Table 3.2 Number of HA-CCR2B or HA-CCR5 receptors per cell estimated for the 
transfected HEK293 cells using the QIFI kit. ................................................................. 74 
Table  3.3 Level of down-modulation in response to 60 minute agonist (CCL2 or CCL5) 
stimulation measured by flow cytometry for the different transfected HEK293 cell lines.
 ......................................................................................................................................... 80 
 
Table  5.1 Cellular proteins identified as interacting with CCR2B or CCR5 in previously 
published work. ............................................................................................................. 132 
Table  5.2 Constructs created or used in this project. ................................................... 136 
Table  5.3 Oligos used in this project. ........................................................................... 137 
Table  5.4 PCR reagents. ............................................................................................... 138 
Table  5.5 PCR programme used in this project. .......................................................... 138 
Table 5.6 Yields of GST fusion proteins following production in E.coli BL21 and 
purification on glutathione sepharose beads. ................................................................ 154 
 
  
13 
Acknowledgements 
Firstly, I would like to thank my supervisor, Nathalie Signoret, for giving me the 
opportunity to carry out this project and to develop as a scientist in a stimulating and 
challenging environment. Thank you for your constant support and encouragement 
throughout this process. I am also grateful to my training committee, James Chong and 
Paul Pryor, for their help and guidance throughout my PhD. 
I would like to thank all members of the Signoret Lab, past and present, in particular 
James Fox for his immense patience and always making the time to help me, and 
Richard Kasprowicz for help with analysis software and keeping me sane on a daily 
basis!  
I am grateful to everybody from the CII and beyond who have provided reagents and 
inspiration for this thesis. Many thanks in particular go to Paul Pryor, without whom, 
much of the work in Chapter 5 would not have been possible. Thank you for all your 
practical help and for always having just one more awkward question! 
I would like to thank all members of the Trafficking Group for stimulating discussions 
and for helping to improve my criticial thinking ability. 
Thank you to my family and friends for always being there. Finally, I am indebted to my 
partner Sam for all of his support, both practical and emotional, throughout the highs 
and lows of my PhD; I could not have done it without you. 
  
14 
Author’s declaration 
All data presented in this thesis is original. With the exception of Figures 3.3 and 3.5, 
which were compiled from data obtained by Laura Fell in the Laboratory of Dr Signoret, 
all the work here was performed by Laura Bennett. Figures 1.2 and 1.4, and Tables 1.1 
and 1.2 are modified from Bennett et al., (2011), a copy of which is included as an 
appendix to this thesis. 
 
  
15 
1 Introduction 
1.1 Chemokine receptors 
1.1.1 Definition and nomenclature 
Chemokine receptors belong to the G protein coupled receptor (GPCR) superfamily and 
are divided into classes based upon the type of chemokine with which they interact 
(IUIS/WHO 2003). The four classes of chemokines are named according to the motif 
displayed by their first two or single conserved N-terminal cysteines (CC, CXC and 
CX3C or XC respectively) that form disulfide bridges with other downstream conserved 
cysteine residues to stabilise the tertiary structure (Rossi and Zlotnik, 2000). Since the 
cloning of the interleukin-8 (CXCL8) receptor (Murphy and Tiffany, 1991), a total of 
ten CC, seven CXC, one CX3C and one XC classical chemokine receptors have been 
identified (IUIS/WHO 2003; Schall and Proudfoot, 2011). In addition there are at least 
four atypical scavenger chemokine receptors (Ulvmar et al., 2011). CCR2B and CCR5 
belong to the CC chemokine receptor subfamily. 
1.1.2 Roles 
Chemokine receptors are predominantly expressed in the immune system on a wide 
range of leukocytes, with some expression on other cell types including epithelial and 
stromal cells (Le et al., 2004). Individual cell types display a specific chemokine 
receptor expression profile that can be further modified during development and 
according to the local microenvironment experienced by the cell (Rossi and Zlotnik, 
2000). Chemokine receptors have a wide range of biological functions and can be 
grouped as constitutive or inflammatory receptors depending on the nature of the 
functional response induced by their chemokine ligands (Johnson et al., 2005). 
Homeostatic chemokines and their receptors regulate the basal trafficking of leukocytes, 
which influences lymphocyte development and immune surveillance as well as the 
development and organization of secondary lymphoid organs. In contrast, binding of 
inflammatory chemokines to their receptors is involved in the host response to 
inflammation and infection via the recruitment of specific leukocyte sub-populations to 
sites of injury. CCR2B and CCR5 are both inflammatory chemokine receptors and their 
main function is the recruitment of monocytes/macrophages, to sites of inflammation 
16 
(Boring et al., 1997; Weber et al., 2001). In addition, they have both been shown to be 
upregulated on murine neutrophils under certain inflammatory conditions, where they 
play an important role in the adherence and transmigration processes involved in 
neutrophil recruitment (Johnston et al., 1999; Maus et al., 2002; Reichel et al., 2006; 
Souto et al., 2011). Chemokine receptor functions are dependent on the ability of the 
receptor to induce chemotaxis in response to chemokine binding enabling directed 
migration of the cell towards the source of chemokine gradient. An additional group of 
atypical chemokine receptors can bind, internalise and either degrade or transcytose 
chemokines, whilst displaying an apparent inability to independently activate the 
classical signalling pathways that lead to chemotaxis (Ulvmar et al., 2011). 
1.1.3 Structure 
Chemokine receptors are seven-transmembrane receptors with an extracellular N-
terminus and an intracellular C-terminus (Figure 1.1). Until recently, no crystal 
structures for any chemokine receptors were available. However, despite low sequence 
homology, the high structural similarity observed between GPCRs for which crystal 
structures have been solved, has enabled homology modelling to be carried out for 
several chemokine receptors including CCR2 (Berkhout et al., 2003; Carter and Tebben, 
2009; Kim et al., 2011; Kimura et al., 2008; Mirzadegan et al., 2000; Shi et al., 2002) 
and CCR5 (Carter and Tebben, 2009; Castonguay et al., 2003; Fano et al., 2006; Garcia-
Perez et al., 2011; Kondru et al., 2008; Li et al., 2009; Maeda et al., 2006; Manikandan 
and Malik, 2008; Seibert et al., 2006; Shahlaei et al., 2011; Xu et al., 2004). 
Traditionally the high resolution bovine rhodopsin crystal structure (Palczewski et al., 
2000) or more recently the human β2 adrenergic receptor crystal structure (Cherezov et 
al., 2007), was used as a template. Then biochemical data, such as the effects of 
mutations on ligand binding, were typically used to improve the models (Carter and 
Tebben, 2009). Several crystal structures have now been solved for CXCR4 and they 
show important differences in the localisation and shape of the ligand binding sites 
compared to those observed for other typical GPCRs (Wu et al., 2010). The existence of 
an actual chemokine receptor crystal structure should provide a better base for 
homology mapping of other chemokine receptors. Indeed it was recently used for 
homology modelling of CCR2 and CCR5 to enable investigation of antagonist binding 
interactions (Kothandan et al., 2012). 
17 
 
 
Figure  1.1 Chemokine receptor topology, post-translational modifications and important 
residues. 
Chemokine receptors have seven transmembrane  regions (TM) linked by three intracellular (ICL) and 
three extracellular (ECL) loops. The N-terminus is located extracellularly and the C-terminus is 
intracellular. The four conserved extracellular cysteines that form disulfide bonds in CC, CXC and CX3C 
chemokine receptors are highlighted in black and the bonds are represented by dashed lines. Green 
asterisks (*) mark the locations of glycosylation and sulphation sites: CCR2 N-glycosylation site (N14), 
CCR2 sulphation site (Y26), major CCR5 O-glycosylation site (S6/S7) and CCR5 sulphation sites (Y3, Y10, 
Y14 and Y15). The DRY sequence, which is conserved as part of a larger motif in almost all chemokine 
receptors, is highlighted in the second intracellular loop. The cytoplasmic tail amino acid sequences of 
CCR2B and CCR5 are shown for comparison. The three cysteines that are palmitoylated in CCR5 are 
highlighted in blue. Phosphorylation sites are highlighted in red. The CCR5 PDZ domain and dileucine 
motif are underlined in purple and green respectively.  
The chemokine receptor tertiary structure provides different binding sites for orthosteric 
chemokine ligands, small molecule ligands, and in the case of CCR5 and CXCR4, the 
human immunodeficiency virus (HIV). The chemokine binding site is located on the 
extracellular side of the receptor and involves the N-terminus plus certain extracellular 
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loops (ECLs) and transmembrane domains. On receptors that bind multiple chemokines, 
the precise binding sites are usually distinct but overlapping (Blanpain et al., 2003; 
Jensen et al., 2008; Xanthou et al., 2003). It has been suggested that chemokine binding 
is a two-step process where the first step is important for ligand binding and the second 
step is more important for activation of the receptor and signalling (Allen et al., 2007). 
Firstly, the N-loop and the core domain of the chemokine bind to the chemokine 
recognition site 1, which consists of the N-terminus and extracellular loops of the 
receptor. Secondly, the chemokine N-terminus is inserted into chemokine recognition 
site 2, which is located within the transmembrane helical bundle/transmembrane domain 
of the receptor and may also involve some extracellular loops. In contrast, small 
molecule antagonists do not typically use the receptor N-terminus for binding. Instead 
they often have binding sites located deeper within the TM helix bundle, involving 
either TM1, 2, 3, 7 (minor binding pocket) or TM3, 4, 5, 6 (major binding pocket) or 
both (Scholten et al., 2012). Therefore, they can modulate their effect on chemokine 
binding not by competitive binding but by allosteric modulation of the receptor 
conformation. HIV gp120 binds sequentially to its primary receptor CD4 and then to a 
CCR5 or CXCR4 co-receptor using binding sites involving the N-terminus and second 
extracellular loop of the co-receptor (Brelot et al., 1997; Doranz et al., 1999; Wu et al., 
1997).  
Chemokine receptors can be subject to different types of post-translational modification 
that can impact both on the overall structure and on the various binding sites. CCR5, 
like many other GPCRs (Qanbar and Bouvier, 2003), has been shown to be 
palmitoylated on C-terminal tail cysteines, residues 321, 323 and 324, which is thought 
to enable interactions with plasma membrane lipids and lead to the formation of an extra 
fourth intracellular loop, thus reducing the flexibility of the tail (Figure 1.1; Blanpain et 
al., 2001; Kraft et al., 2001; Percherancier et al., 2001). Despite the presence of C-
terminal cysteines as potential palmitoylation sites in most but not all chemokine 
receptors, so far no other receptors have actually been demonstrated to be palmitoylated 
(Neel et al., 2005).  
Chemokine receptors can be N-glycosylated on asparagine residues or O-glycosylated 
on hydroxyl groups of serine/threonine residues located on their N-terminus or 
extracellular loops. The extent and type of glycosylation varies between receptors. 
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CCR2 (Figure 1.1, Preobrazhensky et al., 2000), CXCR2 (Ludwig et al., 2000), CXCR4 
(Berson et al., 1996; Chabot et al., 2000), the Duffy antigen receptor for chemokines 
(DARC) (Tournamille et al., 2003) and D6 (Blackburn et al., 2004) have been shown to 
undergo N-linked glycosylation. In contrast, despite the presence of potential sites in its 
third ECL, CCR5 is not N-glycosylated but does undergo O-linked glycosylation at 
serines 6 or 7 (Figure 1.1; Bannert et al., 2001; Farzan et al., 1999).  
The majority of chemokine receptors contain predicted N-terminal tyrosine sulphation 
sites (Liu et al., 2008) and sulphation has been demonstrated experimentally for human 
CCR2 (Figure 1.1; Preobrazhensky et al., 2000), CCR5 (Figure 1.1; Bannert et al., 2001; 
Farzan et al., 1999), CXCR3 (Colvin et al., 2006; Gao et al., 2009), CXCR4 (Farzan et 
al., 2002; Farzan et al., 1999), CX3CR1 (Fong et al., 2002), D6 (Blackburn et al., 2004) 
and DARC (Choe et al., 2005), and murine CCR8 (Gutierrez et al., 2004). In addition, 
chemokine receptors can also be modified by the attachment of sugar chains containing 
sulphate groups to the hydroxyl group of serine residues as has been shown for CXCR4 
(Farzan et al., 2002). 
Glycosylation has been reported to play an important role in cell surface expression of 
certain GPCRs (Dong et al., 2007; Duvernay et al., 2005). In contrast, despite being a 
common post-translational modification of secreted and transmembrane proteins 
(Moore, 2003), tyrosine sulphation appears to play no major role in the cell surface 
expression of most GPCRs, including chemokine receptors, studied to date (Choe et al., 
2005; Colvin et al., 2006; Costagliola et al., 2002; Farzan et al., 1999; Farzan et al., 
2001; Fieger et al., 2005; Fong et al., 2002; Preobrazhensky et al., 2000). However, 
tyrosine sulphation and glycosylation have both been shown to be important for 
chemokine binding to many chemokine receptors including CXCR4 and CCR5 (Neel et 
al., 2005). Additionally, tyrosine sulphation appears to have a positive impact on HIV 
gp120 binding to CCR5 (Farzan et al., 1999) and to a lesser extent to CXCR4 (Farzan et 
al., 2002). In contrast the impact of receptor glycosylation on HIV gp120 binding is less 
clear. No significant influence on HIV infection has been described for O-linked 
glycosylation of CCR5 (Bannert et al., 2001). However, N-linked glycosylation of 
CXCR4 has been differentially reported to have either no (Brelot et al., 2000; Picard et 
al., 1997) or a negative (Wang et al., 2004b) impact on HIV binding, or alternatively to 
be important for HIV X4 strain specificity (Chabot et al., 2000; Thordsen et al., 2002). 
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To be functionally active, in addition to being expressed at the cell surface with the 
correct post-translational modifications, chemokine receptors have to be presented in a 
conformation that is compatible with agonist binding and be coupled to a heterotrimeric 
G protein, so that they are ready to transmit intracellular signals (reviewed in Bennett et 
al., 2011, see Appendix). Other GPCRs are thought to reside in the plasma membrane in 
equilibrium between multiple active and inactive states (Vauquelin and Van Liefde, 
2005). This equilibrium is thought to depend on complex allosteric interactions and 
conformational changes affected by ligands, as well as cell-specific parameters such as 
receptor expression level, G protein and accessory protein availability, and local 
membrane environment (Gilchrist, 2007; Nelson and Challiss, 2007; Vauquelin and Van 
Liefde, 2005; Wess et al., 2008).This is still relatively uncharted territory for chemokine 
receptors but experimental findings suggest that they may be subject to similar 
regulation. Indeed, there is evidence for conformational heterogeneity in cell surface 
CCR2 (Berchiche et al., 2011), CCR5 (Berro et al., 2011; Lee et al., 1999a) and CXCR4 
(Baribaud et al., 2001; Sloane et al., 2005) receptor populations under either ligand-
stimulated or non-stimulated conditions. 
It is now accepted that GPCRs not only operate as single entities (monomers), but can 
also function as multimers regulated by allosteric mechanisms (Fuxe et al., 2010; Smith 
and Milligan, 2010). Chemokine receptors have been shown to form homomers as well 
as heteromers with other chemokine receptors, GPCRs or distinct types of cell surface 
receptors (Tables 1.1 and 1.2). Early work indicated that chemokine receptor 
dimerisation was ligand-induced, as described for CCR2 (Mellado et al., 2001; 
Rodriguez-Frade et al., 1999a), CCR5 (Rodriguez-Frade et al., 1999b; Vila-Coro et al., 
2000) and CXCR4 (Toth et al., 2004; Vila-Coro et al., 1999b) homodimers, and 
CCR2/CCR5 heterodimers (Mellado et al., 2001). However, the current view is that 
chemokine receptor dimers are constitutively formed (Tables 1.1 and 1.2), and that 
ligand binding stabilizes or reorganizes pre-existing complexes (Salanga et al., 2009; 
Thelen et al., 2010; Wang and Norcross, 2008). CXCR1 and CXCR2 exemplify this: a 
recent study revealed that CXCL8 binding stabilizes homodimers but alters 
heterodimers (Martinez Munoz et al., 2009). In fact, dimers are thought to assemble 
during biosynthesis prior to arriving at the cell surface, as shown for CCR5 homomers 
(Issafras et al., 2002) or CXCR1/CXCR2 heterodimers (Wilson et al., 2005). For 
oligomerisation with non-chemokine receptors, other factors, such as the type of 
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molecules complexed with the chemokine receptor or the cellular background, could 
affect where and how dimers form. For CCR5, there are reports of constitutive 
intracellular interactions with CD4 in a monocytic cell line (Achour et al., 2009) and 
stable cell surface CCR5/CD4 heteromers complexed with or without CXCR4 on 
transfected cells (Baker et al., 2007; Wang et al., 2004a) or blood-derived dendritic cells 
(Xiao et al., 2000). Other studies described CCR5 and CD4 as being co-localised but 
independent monomeric molecules (Steffens and Hope, 2003) and interacting upon 
binding of HIV-gp120 at the surface of transfected cells (Yi et al., 2006). 
Table 1.1 Identified chemokine receptor homomers. 
Modified from Bennett et al. (2011).  
Receptor Formation Methods                Cells  
------------------------- 
  Overexp.     Endog. 
Ref 
CCR2 Constitutive BRET HEK293  (El-Asmar et al., 2005; 
Percherancier et al., 2005) 
 Inducible IP HEK293 MM-1 (Mellado et al., 2001; 
Rodriguez-Frade et al., 
1999a) 
CCR5 Constitutive IP 
Y2H 
BRET 
FRET 
FLIM 
HeLa  
HEK293 
RBLs 
 (Benkirane et al., 1997; El-
Asmar et al., 2005; Hernanz-
Falcon et al., 2004; 
Huttenrauch et al., 2005; 
Issafras et al., 2002) 
 Inducible IP HEK293  
L1.2 
 (Hernanz-Falcon et al., 2004; 
Rodriguez-Frade et al., 
1999b; Vila-Coro et al., 2000) 
CXCR1 Constitutive CO-IP 
FRET 
BRET 
HEK293  (Wilson et al., 2005) 
CXCR2 Constitutive IP 
FRET 
BRET 
HEK293  (Wilson et al., 2005) 
 Constitutive IP 
WB 
HEK293 Neurons  (Trettel et al., 2003) 
CXCR4 Constitutive IP 
FRET 
BRET 
HEK293 
HEK-
tsA201 
 (Babcock et al., 2003; 
Percherancier et al., 2005; 
Toth et al., 2004; Wang et al., 
2006) 
 Inducible IP MOLT4  (Vila-Coro et al., 1999b) 
DARC Constitutive BRET HEK293  (Chakera et al., 2008) 
BRET, bioluminescence resonance energy transfer; CO-IP, co-immunoprecipitation; DARC, duffy 
antigen receptor for chemokines; FLIM, fluorescence lifetime imaging; FRET, fluorescence 
resonance energy transfer; IP, immunoprecipitation; Y2H, yeast-2-hybrid. 
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Table 1.2 Identified chemokine receptor heteromers and their functional outcomes. 
Modified from Bennett et al. (2011). 
 
 
 
  
CHEMOKINE RECEPTORS 
Receptors Formation Methods                Cells  
---------------------- 
 Overexp.   Endog. 
Cooperativity  
(Assays) 
Ref 
CXCR1/ 
CXCR2 
Constitutive CO-IP, 
FRET 
BRET 
HEK293  No (Martinez 
Munoz et al., 
2009; Wilson 
et al., 2005) 
CXCR3/CCR5 Constitutive FRET  Activated  
T cells 
Negative 
(chemotaxis) 
(O'Boyle et al., 
2012) 
CXCR4/ 
CXCR7 
Constitutive CO-IP, 
FRET 
HEK293 IM-9  Positive  
(Ca2+ flux) 
(Sierro et al., 
2007) 
CXCR4/ CCR2 Constitutive BRET CHO-K1 
HEK293 
 Negative  
(binding, 
chemotaxis) 
(Sohy et al., 
2007) 
CXCR4/ CCR5 Constitutive CO-IP NIH 3T3  Positive 
(chemotaxis) 
(Gouwy et al., 
2011; Wang et 
al., 2004a) 
CXCR4/CCR2/ 
CCR5 
Constitutive BRET HEK293  Negative  
(binding, 
chemotaxis) 
(Sohy et al., 
2009) 
CCR2/CCR5 Inducible CO-IP HEK293 PBMCs Positive  
(Ca2+ flux) 
(Mellado et al., 
2001) 
Constitutive CO-IP, 
BRET 
CHO-K1 
HEK293 
CD4
+
 T 
cells 
Negative  
(binding) 
(El-Asmar et 
al., 2005) 
DARC/ CCR5 Constitutive CO-IP, 
BRET 
HEK293 
 
 Negative  
(chemotaxis, 
Ca2+ flux) 
(Chakera et al., 
2008) 
GPCRs 
Receptors Formation Methods                Cells  
---------------------- 
 Overexp.   Endog. 
Cooperativity  
(Assays) 
Ref 
CCR5/ C5aR Constitutive CO-IP, 
BRET 
RBLs 
HEK293 
 Negative 
(co-
internalisation) 
(Huttenrauch 
et al., 2005) 
CXCR2/ DOP Constitutive CO-IP, 
FRET 
BRET 
HEK293  Positive 
(G protein 
activation) 
(Parenty et al., 
2008) 
CXCR4/DOP Constitutive  CO-IP, 
FRET 
HEK293 MM-1 
Monocytes 
 
Negative 
(chemotaxis, 
adhesion, Ca2+ 
flux) 
(Pello et al., 
2008) 
CCR5/ opioid 
receptors 
Constitutive CO-IP CHO CEMx174 Negative 
(chemotaxis) 
(Chen et al., 
2004; Suzuki 
et al., 2002) 
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Table 1.2 Identified chemokine receptor heteromers and their functional outcomes. 
 
  
OTHERS 
Receptors Formation Methods                Cells  
---------------------- 
 Overexp.   Endog. 
Cooperativity  
(Assays) 
Ref 
CXCR2/ AMPA 
GluR1 
Constitutive CO-IP HEK293 Neurons Negative  
(chemotaxis) 
(Limatola et 
al., 2003) 
CXCR4/ CD4 Inducible 
(HIV) 
CO-IP  PBMCs  N.D. (Lapham et al., 
1996; Lee et 
al., 2000) 
CXCR4/ TCR Inducible CO-IP, 
FRET 
Jurkat T PBMCs 
T cells 
Positive  
(Ca2+ flux) 
(Kumar et al., 
2006) 
CXCR4/IGF-R1 Constitutive CO-IP  MCF-7 
MDA-MB-
231 
Positive  
(chemotaxis) 
(Akekawatchai 
et al., 2005) 
CXCR4/CD63 Inducible CO-IP HEK293  N.D. (Yoshida et al., 
2008) 
CCR5/ CD4 Constitutive 
 
 
 
Inducible 
(HIV) 
FRET 
BRET, 
CO-IP 
 
FRET 
HEK293 
CHO K1 
 
 
HEK293 
 
 
 
 
DCs 
N.D. 
 
 
 
N.D. 
(Achour et al., 
2009; Baker et 
al., 2007; 
Gaibelet et al., 
2006) 
(Yi et al., 
2006) 
AMPA GluR1, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate-type glutamate receptor 1; 
BRET, bioluminescence resonance energy transfer; C5aR, complement component 5a receptor; CO-
IP, co-immunoprecipitation; DARC, duffy antigen receptor for chemokines; DCs, Dendritic cells; 
-opioid receptor; FRET, fluorescence resonance energy transfer; IGF-R1, insulin-like growth 
factor-1 receptor; PBMcs, Peripheral blood mononuclear cells. 
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1.1.4 Signalling 
Like other GPCRs, chemokine receptors present at the plasma membrane signal 
intracellularly in response to extracellular agonist binding. The most well-studied and 
characterized form of GPCR signalling is the canonical G protein-dependent signalling 
pathway where receptors signal via their associated heterotrimeric G proteins, which 
consist of a Gβ subunit, a Gγ subunit and one of several different Gα subunits. 
Traditionally it was thought that each receptor can only signal via a single specific G 
protein, however it has since been discovered that although receptors have a preferred G 
protein, different agonist binding can lead to signalling via different G proteins 
(Gilchrist, 2007; Oldham and Hamm, 2008). Agonist binding to the receptor results in 
conformational changes within the receptor that lead to dissociation of the G protein into 
guanosine triphosphate (GTP)-bound Gα and the Gβ/γ complex. These subunits can then 
activate or inhibit enzymes, such as phospholipase C-β (PLCβ) and adenylate cyclase 
(AC), and thus regulate downstream kinases, including protein kinase A (PKA) and 
protein kinase C (PKC), as well as other second messengers such as inositol-
trisphosphate (IP3), diacylglycerol (DAG) and Ca
2+
 (New and Wong, 2003). This G 
protein-mediated signalling can regulate transcription events in the nucleus via the 
activation of transcription factors such as nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), cAMP response element-binding (CREB), c-jun, c-fos and c-
myc. 
It is now established that GPCRs can also elicit G protein-independent signals through 
interaction with β-arrestins, which act as scaffolds for various signalling pathway 
proteins (DeFea, 2011).  β-arrestin signalling can activate and/or inhibit various 
pathways including those involving mitogen-activated protein kinases (MAPKs), LIM 
domain kinase 1 (LIMK)/chronophin/cofillin, PKA, and PI3K/Akt and can act 
independently of, in synergy with or in opposition to G protein-dependent signalling 
(DeFea, 2011). Whereas G protein-mediated signalling is thought to be mainly restricted 
to plasma membrane GPCRs, signalling utilising β-arrestin scaffolds can occur from 
receptors in the endocytic pathway (von Zastrow and Sorkin, 2007). Evidence of β-
arrestin- dependent signalling from chemokine receptors has been reported for CCR5 
(Cheung et al., 2009), CCR7 (Kohout et al., 2004), CXCR4 (Sun et al., 2002) and 
CXCR7 (Rajagopal et al., 2010). For CCR5, β-arrestin has been suggested to act as a 
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scaffold for extracellular signal-regulated kinase (ERK) and a multimeric complex 
consisting of Pyk2, PI3K and Lyn involved in CCL4 stimulated chemotaxis (Cheung et 
al., 2009).  
In addition to transcriptional regulation mediated by intracellular signalling cascades 
resulting from extracellular agonist binding to plasma membrane GPCRs, another more 
controversial form of direct nuclear GPCR signalling has been recently proposed for 
some receptors. This was suggested to involve GPCRs relocating to the nucleus where 
the receptors themselves or their ligands can regulate nuclear events, often with different 
or opposite outcomes to plasma membrane based signalling (Goetzl, 2007; Planque, 
2006). Some nuclear expression of CXCR4 in tumour cells (Na et al., 2008; Speetjens et 
al., 2009; Wang et al., 2009; Wang et al., 2005; Wang et al., 2010b; Woo et al., 2008; 
Xiang et al., 2009; Yao et al., 2011) and CCR2 in transfected HEK293 and HeLa cells 
(Favre et al., 2008) has been reported, although it remains to be established if this is true 
expression or an artefact due to the experimental conditions used. CXCR4 nuclear 
localisation has been linked to poor prognosis for cancer patients (Na et al., 2008; 
Speetjens et al., 2009; Wang et al., 2009; Wang et al., 2010b; Woo et al., 2008; Xiang et 
al., 2009; Yao et al., 2011) but if or how precisely CXCR4 and CCR2 might signal at 
the nucleus remains to be investigated. For both receptors, there is some limited 
evidence that nuclear localisation may be mediated by agonist stimulation (Favre et al., 
2008; Wang et al., 2009). However, nuclear localisation of GPCRs remains a debatable 
topic that challenges the traditional ideas of GPCR signalling, and no evidence has yet 
been provided for the mechanisms that would facilitate the necessary intracellular 
trafficking of the receptors.  
An additional group of atypical chemokine receptors often called scavenger or decoy 
receptors, consisting of DARC, D6, CCRL1 and CCRL2, bind a wide range of 
chemokines (Table 1.3) but are unable to activate classical G protein-dependent 
signalling pathways (Ulvmar et al., 2011). Scavenger receptors are believed to regulate 
the signalling activity of other typical chemokine receptors via modulation of the local 
chemokine concentrations, gradients and expression profiles, or through 
heterodimerisation with chemokine receptors (Ulvmar et al., 2011). Due to its inability 
to mediate chemotaxis or calcium mobilisation in response to CXCL12  binding, 
CXCR7 was originally thought to belong to this group of atypical chemokine receptors 
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(Burns et al., 2006; Thelen and Thelen, 2008). However, it has since been shown that in 
some circumstances it can signal via β-arrestin-mediated pathways in response to 
binding of its ligand CXCL11 (Rajagopal et al., 2010). Additionally, recent 
developments have suggested that it may also undergo Gi/o-dependent signalling in 
response to another ligand CXCL12 in astrocytes (Odemis et al., 2012). Thus it can act 
as a scavenger receptor, a β-arrestin signalling receptor and a classical chemokine 
receptor, and it has been proposed that the choice of role played by CXCR7 may be in 
part cell type dependent (Odemis et al., 2012). 
It has long been thought that there is much functional redundancy in the chemokine 
ligand/receptor system, as many chemokines bind multiple receptors of one class and 
more than one receptor can interact with each chemokine (Table 1.3). However, recently 
some groups have found different receptor signalling and trafficking responses to 
individual chemokines, suggesting that this redundancy may not be as widespread as 
previously thought (Borroni et al., 2010; Zidar, 2011). Functional selectivity or biased 
agonism, where binding of different agonists leads to differential activation of 
downstream signalling pathways, has been reported for several chemokine receptors 
including both CCR2 and CCR5 (Berchiche et al., 2011; Leach et al., 2007; Mueller et 
al., 2002b; O'Boyle et al., 2007; Odemis et al., 2012; Oppermann et al., 1999; Wain et 
al., 2002). For CCR2, the bias towards β-arrestin 1 or 2 binding following ligand 
stimulation and the stability of this interaction, which influences the endocytic fate of 
the receptor, have been reported to be dependent on the identity of the chemokine 
involved (Berchiche et al., 2011). In addition, the specific G protein utilisation of CCR2 
for chemotaxis and the kinetics of ERK and Akt activation vary dependent on the 
chemokine ligand engaged (O'Boyle et al., 2007; Wain et al., 2002). A range of CCR5 
chemokine ligands exhibit different abilities to induce Gα- and Gβγ-dependent 
signalling cascades and to induce Gαi/o-independent signalling, leading to different 
cellular responses (Leach et al., 2007; Mueller et al., 2002b; Oppermann et al., 1999). In 
addition, for several GPCRs (Violin and Lefkowitz, 2007) and recently the chemokine 
receptor CXCR7 (Odemis et al., 2012), different ligands have been reported to result in 
a bias towards either G protein-dependent or β-arrestin-dependent signalling. Finally, in 
vivo the expression of active chemokine receptors is tightly controlled in a spatial and 
temporal manner, thus limiting the actual signalling ability of a cell dependent on cell 
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type and the local microenvironment (Allen et al., 2007; Locati et al., 2005; Norment 
and Bevan, 2000; van der Veen et al., 2009). 
Table 1.3 Chemokine receptors and their chemokine ligands. 
This table is compiled from data from the IUPHAR database (Sharman et al., 2011), with the 
incorporation of additional data from other sources (Graham, 2009; Schall and Proudfoot, 2011; Scholten 
et al., 2012; Ulvmar et al., 2011; personal communication from James Fox, University of York, UK). 
 
 
1.2 Chemokine receptors and disease 
Chemokine receptors play roles in many infectious and non-infectious diseases that have 
a major impact on world-wide human health. Firstly, several receptors are exploited by 
viruses and parasites to gain entry into human cells. In the mid 1990s, CCR5 and 
CXCR4 were identified as major co-receptors for HIV entry (Alkhatib et al., 1996; 
Deng et al., 1996; Dragic et al., 1996; Feng et al., 1996). The transmission and 
asymptomatic stages of early infection predominantly involve CCR5 targeting by R5 
HIV-1 strains. In many individuals, more promiscuous R5X4 HIV-1 strains, targeting 
CCR5, CXCR4 and possibly other minor coreceptors, typically emerge later in 
infection, and in the terminal stages of disease X4 HIV-1 strains targeting only CXCR4 
Receptor Chemokine 
Agonist Antagonist Ligand 
CCR1 CCL2/3/5/7/8/13/14/15/16/23 CCL4  
CCR2 CCL2/7/8/11/13/16 CCL11/24/26  
CCR3 CCL2/5/7/8/13/15/24/26/28 CCL11  
CCR4 CCL17/22   
CCR5 CCL2/3/4/5/8/11/13/14/16 CCL7  
CCR6 CCL20   
CCR7 CCL19/21   
CCR8    
CCR9 CCL25   
CCR10 CCL27/28   
CXCR1 CXCL1/6/8   
CXCR2 CXCL1/2/3/5/6/7/8   
CXCR3 CCL5/7/13/19/20 
CXCL9/10/11/12 
CCL11  
CXCR4 CXCL12   
CXCR5 CXCL13   
CXCR6 CXCL16   
CXCR7 CXCL12   
XCR1 XCL1/1   
CX3CR1 CX3CL1   
D6   CCL2/3/4/5/7/8/11/13/17/22/23/24 
DARC   CCL2/5/7/8/11/13/14/15/16/17/18/22 
CXCL1/2/3/5/6/7/8/9/11/13 
CCRL1   CCL19/21/25 
CXCL13 
CCRL2   CCL2/5/19 
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can develop (Schuitemaker et al., 2010). Additionally, DARC is an atypical chemokine 
receptor expressed on erythrocytes, which is targeted by the human malaria parasite, 
Plasmodium vivax (Horuk et al., 1993). 
Secondly, the chemotactic property of chemokine receptors is thought to contribute to 
an array of non-infectious diseases where inappropriate recruitment of specific 
chemokine receptor-expressing subsets of leukocytes is observed. These pathologies 
include auto-immune and allergic inflammatory disorders such as rheumatoid arthritis 
(RA), multiple sclerosis (MS), atherosclerosis, psoriasis, asthma and irritable bowel 
diseases (reviewed in Koelink et al., 2012), in addition to allograft transplant rejection 
(reviewed in Tan and Zhou, 2005) and cancer (reviewed in Balkwill, 2012). The 
inappropriate or chronic inflammatory responses central to these diseases can be due to 
mis-regulation of specific chemokine receptors themselves or changes in availability of 
their chemokine ligands. 
1.2.1 Examples of diseases involving CCR2 and CCR5 
Most inflammatory disease pathologies involve multiple chemokine receptors and their 
relative contributions can change during disease progression. The importance of a 
specific chemokine receptor for any given disease generally correlates with the level of 
involvement of cell types expressing that receptor. Due to their key role in the 
recruitment of monocytes and T cells, CCR2 and CCR5 have been implicated as playing 
minor roles in many inflammatory diseases. This includes several allergic disorders 
where these cells are not the major players but do contribute in some capacity 
(Fuchimoto et al., 2011; Hogaboam et al., 2005; Medoff et al., 2005; Pease, 2011). In 
addition, they are thought to play major roles in inflammatory diseases that have a high 
dependence on monocyte and/or T cell recruitment. Of these diseases, RA, has received 
much attention over the last two decades due to the associated high expression levels of 
CCR2 (Ellingsen et al., 2007), CCR5 (Haringman et al., 2006b) and their main ligands 
(Haringman et al., 2006b; Koch et al., 1992). Although targeting these receptors 
individually showed promise in animal models (Brodmerkel et al., 2005; Gong et al., 
1997; Matsukawa et al., 1998; Ogata et al., 1997; Rafei et al., 2009; Schimmer et al., 
1998; Schrier et al., 1998; Shahrara et al., 2008; Shahrara et al., 2005; Vierboom et al., 
2005; Xia et al., 2007; Yang et al., 2002), years of failed clinical trials have given rise to 
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much debate over whether they are actually the best therapeutic targets for RA and if a 
multiple chemokine receptor blockade would be a better approach (Koelink et al., 2012; 
Lebre et al., 2011; Pease and Horuk, 2010; Proudfoot, 2008; Schall and Proudfoot, 
2011; Zhao, 2010). However, robust roles have been shown for CCR2 and CCR5 in 
other diseases including MS and atherosclerosis, which are discussed here (Koelink et 
al., 2012). 
CCR2, and to a lesser extent CCR5, is thought to play a major role in MS (Szczucinski 
and Losy, 2007), a chronic inflammatory disease of the central nervous system (CNS). 
The CNS is normally protected by the blood brain barrier, however in MS this barrier is 
broken down and CCR2 is thought to play a significant role in the recruitment of T cells 
and monocytes into the CNS (Koelink et al., 2012). T cells recognise myelin debris from 
apoptosed oligodendrocytes as being foreign and produce cytokines that stimulate 
macrophages and resident microglial cells and induce an inflammatory response causing 
further neuron demyelination and eventually development of MS lesions (Koelink et al., 
2012). The resultant axonal damage negatively affects the signalling ability of neurons 
leading to both physical and cognitive disabilities in the patient. The involvement of 
CCR2 and CCR5 in MS has been demonstrated both in the mouse model of MS, 
Experimental Autoimmune Encephalomyelitis (EAE), and in the human disease itself. 
Elevated expression levels of CCR2 and CCR5 within active human MS lesions on 
macrophages and microglia have been reported (Simpson et al., 2000). In addition, the 
presence of the main CCR2 agonist, CCL2 (McManus et al., 1998; Simpson et al., 1998) 
and three CCR5 agonists, CCL3, CCL4 and CCL5 (Simpson et al., 1998) has also been 
observed. CCR2-/- (Izikson et al., 2000) or CCL2-/- (Huang et al., 2001) mice were 
shown to be resistant to induction of EAE, whereas upregulation of the receptor or 
ligand was associated with relapse of the disease (Jee et al., 2002). 
Another type of chronic inflammatory disease, atherosclerosis, involves narrowing and 
hardening of the arteries that results in reduced blood flow and can lead to multiple 
different types of cardiovascular disease including myocardial infarction, ischemic 
coronary artery disease and ultimately congestive heart failure. Atherosclerosis is 
typified by the development of arterial plaques that consist of lipid deposits, connective 
tissue elements and inflammatory leukocytes (Stary et al., 1995). Multiple studies have 
confirmed that CCR2 and CCR5 play important complementary roles in the initiation 
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and progression of atherosclerosis. Agonists for both receptors (CCL2, CCL3, CCL4 
and CCL5) are present in atherosclerotic lesions in animal disease models (Veillard et 
al., 2004; von Hundelshausen et al., 2001; Yu et al., 1992) and human atherosclerosis 
patients (Nelken et al., 1991; Schecter et al., 2000; Wilcox et al., 1994; Yla-Herttuala et 
al., 1991), with CCL2 levels in particular being upregulated. Indeed, over expression of 
CCL2 in the ApoE-/- mouse atherosclerosis model increased disease progression (Aiello 
et al., 1999). Knocking out CCR2 in ApoE-/- mice (Boring et al., 1998; Dawson et al., 
1999) or CCL2 in LDLR-/- mice fed a high lipid diet (Gu et al., 1998), another 
atherosclerosis mouse model, resulted in reduced disease progression. Knocking out 
CCR5 in both ApoE-/- and LDLR-/- mice was also shown to protect against 
atherosclerosis disease progression (Braunersreuther et al., 2007; Potteaux et al., 2006; 
Quinones et al., 2007; Zernecke et al., 2006). However, the results were not as clear cut 
as for CCR2, as some groups showed that CCR5 only protected against later stages of 
the disease (Quinones et al., 2007) or had only a minor effect on lesion size (Potteaux et 
al., 2006). Furthermore, it has been suggested that the naturally occuring CCR5Δ32 
mutant may provide a level of protection against related cardiovascular diseases, 
including myocardial infarction (Gonzalez et al., 2001; Incalcaterra et al., 2010) and 
severe coronary artery disease (Szalai et al., 2001), in some human populations. In 
addition, FROUNT, a binding partner for CCR2B and CCR5 that positively regulates 
directional chemotaxis (Terashima et al., 2005; Toda et al., 2009), has been implicated 
as playing a role in inflammatory cardiovascular disease (Satoh et al., 2007). 
1.2.2 Chemokine receptors as therapeutic targets 
Despite the existence of licensed drugs to treat many of the diseases in which chemokine 
receptors have been implicated, the development of novel therapeutics is still required to 
treat non-responders and to tackle the increasing problem of drug resistance. Drugs 
acting on members of the GPCR super family make up more than 45 % of all drugs 
currently in use (Pease and Horuk, 2009b), thus setting a good precedent for targeting 
chemokine receptors. The involvement in many inflammatory diseases of CCR2 and 
CCR5 in particular, makes them attractive targets for the pharmaceutical industry. 
So far, at least 10 of the 19 classical chemokine receptors have been targeted for a 
variety of diseases by the development of either small molecule antagonists of the 
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receptor or therapeutic antibodies against the receptor or its chemokine ligands (Pease 
and Horuk, 2009a). However, to date only two anti-chemokine receptor drugs have been 
licensed. The CCR5 antagonist Maraviroc is used in HIV therapy (Westby and van der 
Ryst, 2010).  Plerixafor (AMD3100), a CXCR4 antagonist, is used in combination with 
granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells 
from the bone marrow to the peripheral blood for collection and subsequent autologous 
transplantation in patients with multiple myeloma and non-Hodgkin’s lymphoma 
(Wagstaff, 2009). Importantly, despite encouraging pre-clinical results in animal disease 
models and many phase I and II clinical trials in humans, there are currently no licensed 
drugs designed to modulate the negative roles of chemokine receptors in inflammatory 
diseases.  
Clinical trials have been carried out to test various CCR2 and CCR5 antagonists, and 
antibodies targeting CCR2 or CCL2 in RA, MS and atherosclerotic cardiovascular 
disease, with mostly negative results (Gerlag et al., 2010; Haringman et al., 2006a; 
Horuk, 2009; Pease and Horuk, 2009a; Scholten et al., 2012; van Kuijk et al., 2010; 
Vergunst et al., 2008). Recent reviews have discussed several different theories to try to 
explain why so many drugs targeting individual chemokine receptors, and in particular 
CCR2 and CCR5, have failed to show efficacy in clinical trials (Horuk, 2009; 
Proudfoot, 2008; Zhao, 2010). 
A common argument is the concept of redundancy within the chemokine system where 
a single chemokine may bind to multiple receptors and some receptors bind more than 
one chemokine. Whilst the traditional idea of complete redundancy is losing favour, the 
possibility that multiple chemokine/receptor combinations are involved in a particular 
disease and may potentially play the same or similar roles in different subtypes or stages 
of the disease, is accepted. Indeed in complex diseases such as MS and RA, several 
other chemokine receptors, in addition to CCR2 and CCR5, have been shown to help 
drive the pathophysiology of the diseases, and for MS the chemokine receptor 
expression profile can vary according to the disease subtype (Jalonen et al., 2002; 
Sorensen and Sellebjerg, 2001).  Thus, mis-targeting or partial compensation of 
therapeutically targeted chemokines/receptors may lead to an apparent lack of effect. 
Therefore, it has been suggested that promiscuous antagonists, targeting groups of 
receptors with significant homology, may be a better approach, and work is currently 
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underway developing dual-specific antagonists that target CCR2 and CCR5 (Norman, 
2011; Zheng et al., 2011)  
A major problem facing the development of antagonists targeting chemokines and their 
receptors is the fact that pre-clinical trial validation work is carried out using animal 
disease models that do not perfectly mimic human pathologies. The species differences 
of the immune system include variation in chemokine receptor expression. While the 
expression profile of CCR2 on murine leukocytes closely resembles that observed in 
humans, some variability is observed for CCR5 with a much greater population of 
murine NK cells expressing this receptor (Mack et al., 2001). In addition, rodent and 
human CCR2/CCL2 and CCR5 orthologues show relatively low sequence homology, 
suggesting that some antibodies and antagonists developed against human receptors or 
chemokines may exhibit lower affinities for the rodent equivalents, leading to species 
selectivity of drugs (Saita et al., 2007).  
Incomplete knowledge of chemokine receptor regulation has hindered the development 
of drugs targeting this system in several ways. Although in vitro studies have provided 
information on the drug concentration required to inhibit functional receptor responses 
on isolated cells, the level of receptor occupancy required to inhibit the role of the 
receptor in the disease in vivo has not been accurately defined (Horuk, 2009). In order to 
effectively block recruitment, it has been hypothesized that more than 90 % receptor 
coverage is needed (Schall and Proudfoot, 2011), however some clinical trials achieving 
this level have still been unsuccessful (Vergunst et al., 2008; Zipp et al., 2006). Current 
therapeutics are commonly targeted at a single chemokine receptor in isolation. 
However, as many chemokine receptors are subject to cross-regulation from other cell 
surface proteins, the full extent of which is still being uncovered, targeting a specific 
receptor can have knock-on effects.  
Despite the negative results so far, the future does look positive. There are currently 
many chemokine receptor drugs in clinical trials tackling some of these problems. The 
first crystal structures for a chemokine receptor, CXCR4, were recently published and 
will help improve future modelling of antagonist-receptor interactions. It has become 
apparent that better characterisation of the specific regulation of individual CRs is 
required in order to more accurately anticipate how the receptor will respond following 
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drug binding. Coupled with an improved understanding of the impact of chemokine 
receptor cross-talk, this knowledge will be vital to the future development of safe and 
effective therapeutics that target disease via manipulation of chemokine receptor 
activation states. 
1.3 Chemokine receptor regulation 
Tight regulation of the chemokine system is essential to enable individual cells to fine-
tune their responses according to the specific composition of the local environment 
(Weber and Koenen, 2006). This control can be exerted by mechanisms affecting the 
receptor and/or its chemokine ligands, and can have both positive and negative effects 
on the cell’s ability to respond to a given chemokine (Bennett et al., 2011).  
Regulation of chemokine receptor expression can be targeted at the level of gene 
regulation, mRNA and protein synthesis. However, these processes, taking many 
minutes to hours, are too slow to be solely responsible for the rapid changes in cellular 
responses that are typically observed (Thelen, 2001). Therefore, tight modulation of the 
presentation of functional chemokine receptors at the cell surface is essential, and can be 
achieved by affecting the activation state, signalling ability and/or cellular localization 
of the receptor. This rapid control can be mediated in response to ligand binding but also 
as a consequence of cross-talk from other receptors (Bennett et al., 2011). Some of the 
molecular mechanisms involved in the regulation are common to multiple chemokine 
receptors while others appear to be receptor-specific (Kelly et al., 2008). 
1.3.1 Long-term chemokine receptor regulation 
Long-term up- or down-regulation of chemokine receptors is achieved by controlling the 
cellular levels of receptor molecules through changes in gene expression, mRNA 
stability and protein degradation. With regards to leukocytes, the expression of 
chemokine receptors is tightly regulated on the different subtypes, and changes through 
the processes of cell differentiation, activation and polarization (Fantuzzi et al., 1999; 
Mantovani et al., 2004; Patel et al., 2001; Sallusto et al., 1999; Sallusto et al., 1998; 
Sebastiani et al., 2001). Chemokine receptors, including CCR2 and CCR5, are believed 
to be subject to epigenetic regulation in the form of histone modifications. CCR2 gene 
expression can be modulated by histone methylation in response to monocyte 
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differentiation (Tserel et al., 2010) or to stimulation with drugs such as 
methamphetamine (Ikegami et al., 2010). CCR5 transcription has been reported to be 
modulated by both histone methylation and acetylation in response to hypoxic 
conditions in macrophages (Tausendschon et al., 2011) or dependent on leukocyte cell 
type (Wierda et al., 2012). Host–pathogen interactions can also regulate chemokine 
receptor expression. For example, it was shown that bacterial lipopolysaccharide (LPS) 
interfered with CCL2-mediated recruitment of monocytes in vivo by down-regulating 
CCR2 expression (Zhou et al., 1999). LPS was found to act in vitro by affecting CCR2 
mRNA stability (Sica et al., 1997; Xu et al., 1997), as did the inflammatory cytokines 
interleukin-1 (IL-1), tumour necrosis factor (TNF-a) and interferon-gamma (IFN-γ) 
(Penton-Rol et al., 1998; Sica et al., 1997), but with no major effect on CCR5 
transcripts. In contrast, reactive oxygen intermediates produced by phagocytes for 
killing pathogens increased CCR2, CCR5 and CXCR4 mRNA expression and opposed 
the down-regulation induced by LPS (Saccani et al., 2000). Interestingly, chemokine 
receptor switch and modulation of mRNA expression has also been reported with 
Mycobacterium tuberculosis antigens and proposed to be part of a normal programme of 
cell co-ordination needed to contain infection (Arias et al., 2006). 
Desensitisation is a term that is widely and variably used to describe a range of different 
processes negatively regulating chemokine receptors. It can encompass both the long-
term negative regulation of receptor expression mentioned in the previous section and 
the more rapid process of down-modulation. Down-modulation is a feedback 
mechanism protecting cells from over-stimulation by transiently controlling the level of 
active receptors at the cell surface. The process of down-modulation can be either 
ligand-induced (homologous) or a result of cross-talk (heterologous), and various 
different mechanisms have been suggested (Kelly et al., 2008; Salanga et al., 2009). 
1.3.2 Agonist-induced (homologous) 
Receptors are typically desensitised in response to prolonged agonist stimulation via the 
process of homologous down-modulation (Figure 1.2A) (Kelly et al., 2008). Following 
agonist binding, signalling receptors are rapidly phophorylated on their cytoplasmic tail, 
usually by a member of the G protein receptor kinase (GRK) family, which uncouples 
the G protein from the receptor and prevents further activation. Phosphorylated 
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receptors typically then interact with one of the β-arrestins that act as a scaffold enabling 
interaction with adapter proteins and targeting receptors for internalisation. This can 
lead to a permanent or transient loss of cell surface receptors due to degradation or 
subsequent recycling back to the cell surface of internalised molecules, respectively 
(Borroni et al., 2010). 
 
Figure  1.2 Homologous (A) and heterologous (B) chemokine receptor down-modulation. 
(A) Following agonist binding, the signalling chemokine receptor is rapidly phosphorylated on its 
cytoplasmic tail, usually by a G protein receptor kinase (GRK); this uncouples the G protein, which 
dissociates into guanosine triphosphate (GTP)-bound Gα and the Gβγ complex. Phosphorylated receptors 
then interact with a β-arrestin, which acts as a scaffold targeting the receptor for internalisation. Once 
internalised, the receptor follows recycling or degradation pathways. (B) Receptor X mediates cross-
phosphorylation of the chemokine receptor, which may involve protein kinase C (PKC), leading to 
inhibition of chemokine-induced signalling and in some cases internalisation of the receptor. This figure 
was modified from Bennett et al., (2011). 
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1.3.3 Negative Cross-talk (heterologous desensitisation) 
A chemokine receptor can also be negatively regulated via indirect cross-talk from other 
cell surface proteins and receptors, which often leads to down-modulation (Salanga et 
al., 2009), or in some cases to down-regulation (McKimmie et al., 2009; Zhou et al., 
1999), of the chemokine receptor. The cross-talk can be targeted at the receptor itself, 
the heterotrimeric G protein it is coupled to or downstream signalling components, 
resulting in trans-inhibition of chemokine receptor activity. Heterologous down-
modulation (Figure 1.2B) often involves rapid signalling inactivation of surface 
chemokine receptors, inhibiting chemokine-induced intracellular calcium mobilization. 
It happens in both human cells and immortialized cell lines whether the cross-talk comes 
from another chemokine receptor such as for CXCR4 with CCR5 (Hecht et al., 2003; 
Honczarenko et al., 2002), another GPCR as for CCR5 with formyl peptide receptors 
(Le et al., 2001), or an unrelated surface receptor such as the T cell receptor (TCR) with 
CXCR4 (Schneider et al., 2009). In many reports, the inactivation has been linked to 
rapid cross-phosphorylation of the chemokine receptor, with some studies identifying 
protein kinase C (PKC) as the point of convergence between the different receptor 
pathways (Le et al., 2001; Nasser et al., 2005; Richardson et al., 1998; Richardson et al., 
2000). Alternatively, receptor inactivation can result from indirect effects as reported for 
CXCR4 either in pre-B cells, where CD24 altered its distribution in membrane lipid 
rafts by changing cholesterol levels (Schabath et al., 2006), or in leukaemia cells, where 
an oncoprotein has been shown to highjack kinases of the CXCR4-dependent calcium 
pathway (Ptasznik et al., 2002). The process of signalling inactivation involved in 
heterologous down-modulation can be, but is not always, followed by a reduction in cell 
surface expression of chemokine receptors believed to be due to internalisation (Finley 
et al., 2008; Le et al., 2001; Richardson et al., 2003). Conversely, cross-talk induced 
receptor internalisation can occur without prior desensitisation of chemokine-mediated 
signalling, as recently shown with the cross-regulation of CC chemokine receptors 1, 2 
and 5 by TLR2 on human blood monocytes (Fox et al., 2011). In this instance, 
activation of TLR2 via lipoteichoic acid (LTA) triggered relatively slow 
phosphorylation and removal of cell surface CCR5 molecules by activating the 
machinery used to support chemokine-dependent endocytosis (Fox et al., 2011). 
Different pathways of chemokine receptor desensitisation following TLR2 cross-talk 
have been suggested by other groups, supporting the view that desensitisation is a 
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ligand, receptor and cell type specific process (Alves-Filho et al., 2009; McKimmie et 
al., 2009). 
1.3.4 Transactivation and Synergy 
Cross-talk can also positively regulate chemokine receptors via transactivation or 
synergistic mechanisms. Chemokine receptors can transactivate or be transactivated by 
several different types of receptors, but one of the most well-studied is the case of 
receptor tyrosine kinases (RTKs) including various growth factor receptors (Salanga et 
al., 2009).  Stimulated RTKs transactivate chemokine receptors leading to functional 
signalling responses, either by modulating the availability and activity of their 
chemokine ligands via transcriptional or post-transcriptional regulation, or by as yet 
uncharacterised ligand-independent mechanisms potentially involving cytosolic tyrosine 
kinases and receptor phosphorylation. Reciprocally, chemokine receptors can 
transactivate RTKs. 
Some combinations of chemokines and cytokines can act synergistically to amplify 
inflammatory responses, probably due to integration of multiple different signalling 
pathways. The chemokinetic effect of cytokines is believed to prime cells to increase 
their migratory response to chemokines, as found with IL-5-enhancing eosinophil 
chemotaxis in response to CCL11 (Gouwy et al., 2005). In addition, synergy between 
different chemokine receptors has been involved in the migration of primary cells. For 
example, CXCL8 has been shown to increase monocyte migration towards suboptimal 
concentrations of CCL2 and CCL7 (Gouwy et al., 2008), while CCL2 and CCL7 can 
enhance neutrophil chemotaxis towards a suboptimal concentration of CXCL8 (Gouwy 
et al., 2004). Furthermore, cross-talk initiated from non-chemokine or cytokine receptors 
is also emerging as an important but complex phenomenon that modulates innate 
immune responses to pathogens. Synergy between CCR2 and N-formyl peptide receptor 
(FPR) agonists has recently been shown to co-operate with TLR4 for production of the 
inflammatory chemokine CXCL8 upon LPS stimulation, which in turn synergizes with 
CCL2 as described previously to mediate monocyte chemotaxis (Gouwy et al., 2009). 
Finally, synergy can also involve non-protein ligands, as demonstrated by the 
potentiation of calcium signalling reported for CXCR2 upon co-stimulation of the PY2 
nucleotide receptor (Werry et al., 2002).  
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1.4 Receptor trafficking 
 
Figure  1.3 Summary of the endocytic trafficking pathways followed by agonist-stimulated 
chemokine receptors. 
In response to prolonged agonist stimulation, chemokine receptors can be internalised via clathrin- or 
caveolin-dependent endocytosis, or other less well characterised independent pathways. Internalised 
receptors are then either sent for lysosomal degradation or recycled via one of a range of rapid or slow 
recycling pathways. CCP, clathrin coated pit; CCV, clathrin coated vesicle; EE, early endosome; ERC, 
endocytic recycling centre; LE, late endosome; LY, lysosome; MVB, multivesicular body; RE, recycling 
endosome. 
1.4.1 Internalisation 
In response to prolonged agonist stimulation, chemokine receptors can be internalised 
via clathrin- or caveolin-dependent endocytosis or other less well characterised 
independent pathways (Figure 1.3; Borroni et al., 2010). Clathrin-mediated endocytosis 
requires β-arrestin binding to the chemokine receptor, which interacts with the clathrin 
adapter molecule AP2. This enables localisation of the chemokine receptor into clathrin 
coated pits (CCPs), which are then cleaved from the plasma membrane by the action of 
dynamin to form clathrin coated vesicles (CCVs). The intracellular CCVs then deliver 
the chemokine receptors to early endosomes and subsequently sorting endosomes. 
Caveolin-mediated endocytosis involves recruitment into cholesterol-rich caveolin-
containing caveosomes that once internalised also fuse with early endosomes. 
Interestingly, CCR2 and CCR5 have been suggested to follow both clathrin- and 
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caveolin- dependent pathways and the route of endocytosis could be cell type-dependent 
(Andjelkovic et al., 2002; Garcia Lopez et al., 2009; Ge and Pachter, 2004; Mueller et 
al., 2002a; Signoret et al., 2005; Venkatesan et al., 2003). 
Chemokine receptors are not always internalised following agoinst stimulation and the 
choice of ligand can influence the ability of a receptor to internalise. A range of 
chemokine receptors, including CCR4 (Mariani et al., 2004) and CCR7 (Byers et al., 
2008), have been described to be efficiently internalised in response to some but not all 
of their chemokine ligands. In addition, the extent of internalisation observed for the 
same chemokine receptor stimulated with its different chemokine ligands can vary 
widely, as reported for CCR2 (Berchiche et al., 2011) and CXCR2 (Feniger-Barish et 
al., 2000). It appears that the strength and stability of receptor/β-arrestin interactions 
may be critical in determining whether or not an agonist-activated chemokine receptor is 
internalised, as described for CCR7 and CCR2 (Berchiche et al., 2011; Byers et al., 
2008; Zidar et al., 2009). Therefore, in some cases the chemokine may influence the 
internalisation outcome via modulating this receptor/β-arrestin interaction. For example, 
CCR7 is not internalised in response to stimulation with its ligand CCL21 but it is 
internalised in response to another ligand CCL19, which mediates a more robust 
interaction with β-arrestin 2 (Byers et al., 2008; Zidar et al., 2009). 
Once internalised, the intracellular path followed by a chemokine receptor determines its 
fate, i.e. being sent for degradation or being sequestered intracellularly before returning 
to the cell surface (Figure 1.3). Receptors can follow one path exclusively, such as 
CCR5 (Delhaye et al., 2007; Mack et al., 1998; Mueller and Strange, 2004; Signoret et 
al., 2000) or CXCR3 (Meiser et al., 2008), which are sent for recycling or degradation, 
respectively. Alternatively, they can enter either pathway depending on various factors 
discussed later, as reported for CXCR2 (Fan et al., 2003) and CXCR4 (Tarasova et al., 
1998; Zhang et al., 2004). In contrast to CCR5, relatively little research has been carried 
out regarding the fate of internalised CCR2.  
1.4.2 Recycling and resensitisation 
Internalised receptors can be returned to the cell surface in an active form via the 
processes of recycling and resensitisation, and both fast and slow pathways have been 
described. Fast recycling can take place directly from the early endosome or 
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alternatively the receptor can be sorted to the endocytic recycling centre and return to 
the plasma membrane via recycling endosomes (Figure 1.3; Grant and Donaldson, 2009; 
Hopkins et al., 1994). Internalised CCR5 has been shown to be recycled via recycling 
endosomes (Signoret et al., 2000) and two reports suggested that some internalised 
CCR2 may be recycled (Andjelkovic et al., 2002; Wang et al., 1993a). 
Most ligands are dissociated from their receptors during passage through the endosomal 
compartments, often due to the reduction in pH (Mellman et al., 1986). However, CCR5 
agonists only slowly dissociate in a pH-independent manner and receptor/agonist 
complexes can undergo multiple cycles of endocytosis and recycling (Signoret et al., 
2004; Signoret et al., 2000). CCR5 agonist removal requires < pH4, which is much 
below the physiological pH of endocytic organelles (Signoret et al., 2004). This is 
receptor specific, as the same agonists when bound to the atypical chemokine receptor 
D6 dissociate at endosomal pH (Weber et al., 2004). 
1.4.3 Degradation 
Alternatively, internalised receptors can be sent for degradation (Figure 1.3). For all 
reported chemokine receptors, with the exception of CXCR3 (Meiser et al., 2008), this 
degradation has been shown to be lysosome-mediated without proteasome involvement 
(Borroni et al., 2010). CCR5 is not degraded in response to agonist stimulation (Signoret 
et al., 2000). In contrast, a recent report showed some limited colocalisation of CCR2B 
with a lysosomal marker following agonist stimulation, suggesting that in some 
circumstances it may be degraded (Garcia Lopez et al., 2009). 
1.4.4 Factors determining chemokine receptor fate following agonist stimulation 
The decision between entry into the recycling or degradative pathway can be dependent 
on receptor-specific factors, as must be the case for chemokine receptors that uniquely 
enter one pathway. Alternatively for receptors that can enter either pathways, external 
factors such as the cell type and duration of ligand treatment could be responsible, as 
reported for CXCR2 (Fan et al., 2003) and CXCR4 (Tarasova et al., 1998; Zhang et al., 
2004). 
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Endocytosis and subsequent sorting of internalised chemokine receptors to the recycling 
or degradative pathways requires complex interactions of the receptors with the 
machinery mediating endocytosis and movement of molecules between intracellular 
compartments. Some protein interactions implicated in modulating the fate of 
chemokine receptors have been described (Table 1.4). The C-terminal cytoplasmic tail 
domains of the receptors are critical for many of these interactions. Whereas, there is 
only one form of CCR5, two alternatively spliced isoforms of CCR2 exist (CCR2A and 
CCR2B) and they differ only in their cytoplasmic tails (Charo et al., 1994). CCR2B is 
the predominant isoform present in monocytes (Tanaka et al., 2002; Wong et al., 1997).  
Adaptor proteins recognise specific determinants, mainly short peptide sequence motifs 
and post-translational modifications, in the cytoplasmic domains of membrane proteins 
and receptors including chemokine receptors (Borroni et al., 2010; Marchese et al., 
2008). Some short peptide sequence motifs, such as dileucine- or tyrosine-based motifs, 
bind to various adaptor proteins and can regulate different steps in internalisation, 
intracellular trafficking and sorting to subcellular compartments (Pandey, 2010). One of 
the major roles of the dileucine motif is its interaction with AP2, which is a key protein 
for clathrin-mediated endocytosis. Several, but not all, chemokine receptors contain 
dileucine motifs in their cytoplasmic tails (Borroni et al., 2010; Marchese et al., 2008). 
The SSLKIL motif located in the CXCR4 tail has been shown to be important for 
ligand-independent phorbol ester-mediated internalisation of this receptor involving 
PKC (Orsini et al., 1999, 2000; Signoret et al., 1997; Signoret et al., 1998). Dileucine 
motifs lacking the preceding serines have been shown to be required for agonist-induced 
CXCR2 internalisation (Fan et al., 2001b) and to contribute towards the early phase of 
agonist-induced CCR5 internalisation (Figure 1.1; Kraft et al., 2001). No functional 
dileucine motifs have yet been identified in the cytoplasmic tails of either CCR2 isoform 
(see Figure 1.1 for CCR2B). As dileucine motifs also interact with other adaptor 
proteins, their potential involvement in intracellular trafficking of endocytosed 
chemokine receptors remains to be explored. 
To date, three major types of tyrosine-based motifs, NPXY, GDAY and YXX Φ, where 
X is any residue and Φ is a residue with a large bulky hydrophobic side chain, have been 
recognised (Pandey, 2010). The tyrosine in the fourth position of NPXY and GDAY 
motifs is critical for receptor endocytosis via interaction with clathrin adaptor proteins 
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including AP2 and Dab-2 (Pandey, 2010). Due to their interaction with a wider range of 
adaptor proteins, YXXΦ motifs can be involved in endocytosis or lysosomal sorting, 
and this appears to be dependent on localisation of the motif and the identity of the X 
residues (Bonifacino and Traub, 2003). Although, some chemokine receptors have 
potential tyrosine based motifs in their cytoplasmic tails (Marchese et al., 2008), no 
functional roles have yet been assigned to them in this case. 
Two other determinants, the PDZ ligand motif and ubiquitination, have received much 
interest recently, and were shown to support recycling or degradation of chemokine 
receptors, respectively. At least 12 chemokine receptors have been identified as 
containing potential PDZ ligand motifs in their extreme C-terminal cytoplasmic tail 
(Marchese et al., 2008). The PDZ ligand motifs are presumed to interact with PDZ 
domain containing proteins of the sorting machinery, but only a few of these interactions 
have been unveiled. CCR5 post-endocytic sorting to the recycling pathway is dependent 
on its PDZ ligand motif (Figure 1.1; Delhaye et al., 2007), which has been shown to 
interact with a protein implicated in receptor recycling called ERM Binding Protein 50 
or Na+/H+ Exchanger Regulatory Factor (EBP50/NHERF-1; Hammad et al., 2010). For 
CXCR2 that can be both recycled following short ligand exposure and degraded 
following more prolonged ligand treatment (Fan et al., 2003), the PDZ ligand motif 
serves to delay degradation by preventing lysosomal sorting, due probably to interaction 
with an as yet unknown PDZ-containing protein (Baugher and Richmond, 2008). 
Notably, no PDZ ligand motif has been identified in the CCR2 cytoplasmic tail (Figure 
1.1).  
Ubiquitination has emerged as an important modification for sending the chemokine 
receptor CXCR4 (Marchese and Benovic, 2001) and other GPCRs (Marchese et al., 
2008) to degradation. For CXCR4, CXCL12 stimulation leads to ubiquitination of cell 
surface receptors as well as ubiquitin-dependent endocytosis and trafficking of 
ubiquitinated CXCR4 to lysosomes (Marchese et al., 2003; Mines et al., 2009).  
However, ubiquitination does not seem to be required for the degradation of all 
chemokine receptors (Baugher and Richmond, 2008; Meiser et al., 2008). The 
ubiquitination state has recently been shown to play an important role in the intracellular 
trafficking of another related receptor, CXCR7, which in contrast to CXCR4 is recycled 
to the cell surface after internalisation (Canals et al., 2012). CXCR7 is constitutively 
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ubiquitinated and has been shown to be reversibly de-ubiquitinated in response to 
CXCL12 treatment (Canals et al., 2012). 
The affinity of chemokine receptor interactions with β-arrestins can influence the fate of 
internalised receptors. Indeed, GPCRs that rapidly recycle (Class A) preferentially bind 
β-arrestin 2 with low affinity and dissociate from it upon internalisation, whereas those 
that slowly recycle or are degraded (Class B) bind both β-arrestins with high affinity and 
remain β-arrestin-bound inside the cell (Oakley et al., 2000). So far, only class B 
chemokine receptors have been described, with evidence for β-arrestins binding to 
agonist-treated CCR2 and CCR5 in internal compartments (Fox et al., 2011; Minsaas et 
al., 2010).  
In addition to the duration of agonist treatment, the identity of the agonist itself can 
impact upon the fate of a receptor. For instance, with CCR5, any agonist-stimulated 
receptors seem to follow the recycling route but the distribution of receptors along the 
pathway could be agonist-specific (Figure 1.4). Following internalisation, CCR5 
receptors treated with the natural chemokine CCL5 are located in recycling endosomes 
(RE) before re-accumulating in the plasma membrane (Signoret et al., 2000). In contrast, 
they keep cycling back from the cell surface to the RE after exposure to the chemically 
modified aminooxypentane-regulated on activation, normal T cell expressed and 
secreted (AOP-RANTES; Signoret et al., 2000), become trapped in the trans-Golgi 
network (TGN) after passage through RE with N
α
-(n-nonanoyl)-des-Ser
1
-[l-
thioproline
2
,l-α-cyclohexylglycine3]-RANTES (PSC-RANTES; Escola et al., 2010), and 
appear to bypass the RE to accumulate in the TGN with a N terminal Methionine 
RANTES (MET-RANTES; Kiss et al., 2009). 
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Table 1.4 Reported protein interactions with chemokine receptors. 
 
Interacting Protein Chemokine 
Receptor  
Suggested Function Ref 
AIP4 CXCR4 Ubiquitination/Degradation (Bhandari et al., 
2009)  
α-catenin CCR5 Receptor organisation at plasma membrane (Schweneker et 
al., 2004) 
AP2 CXCR2 Internalisation (Fan et al., 
2001b) 
β-arrestins Multiple 
including CCR2 
and CCR5 
Desensitisation/Internalisation/Signalling (Aragay et al., 
1998; Vila-
Coro et al., 
1999a) (DeFea, 
2011) 
DRiP78 CCR5, CXCR4 Membrane localisation/Receptor signalling 
complex formation 
(Kuang et al., 
2012) 
EBP50/NHERF-1 CCR5 Recycling (Hammad et al., 
2010) 
Filamin A CCR2 Internalisation (Minsaas et al., 
2010) 
FROUNT CCR2, CCR5 Clustering to leading edge of lamellipodia/Link 
to signalling cascade leading to chemotaxis 
(Terashima et 
al., 2005; Toda 
et al., 2009) 
GASP CXCR2 Lysosomal sorting for degradation (Heydorn et al., 
2004) 
GRKs Multiple 
including CCR2 
and  CCR5 
Receptor Phosphorylation (Aragay et al., 
1998)(Opperma
nn et al., 
1999)(Vila-
Coro et al., 
1999a) 
Hip CXCR2,CXCR4 Regulation of trafficking including 
internalisation 
(Fan et al., 
2002) 
Importin 7 CCR2 Nuclear import (Favre et al., 
2008) 
IQGAP1 CXCR2 Signalling (Neel et al., 
2011) 
JM4 CCR5 Membrane localisation (Schweneker et 
al., 2005) 
Myosin Vb CXCR2 Regulating recycling (Fan et al., 
2004) 
NMMHC-IIA  CCR5 May have a role in cell migration (Rey et al., 
2002) 
PKC Multiple, 
including CCR2 
Receptor phosphorylation (Oppermann et 
al., 1999) 
PP2A core enzyme CXCR2 Receptor desphosphorylation (Fan et al., 
2001a) 
Rab11-FIP CXCR2 Regulating recycling (Fan et al., 
2004) 
TRN-1 CCR2 Nuclear import (Favre et al., 
2008) 
USP14 CXCR4 Deubiquitination/Degradation (Mines et al., 
2009)  
AIP4, E3 ubiquitin ligase atrophin interacting protein 4; AP2, Adaptin 2; DRiP79, Dopamine receptor-
interactin protein 78; GASP, G protein-coupled receptor-associated sorting protein; GRK, G protein 
receptor kinase; Hip, Hsc70-interacting protein; JM4, Jena-Muenchen4; NMMHC-IIA, nonmuscle myosin 
H chain-IIA; PKC, protein kinase C; Rab11-FIP, Rab11 family interacting protein; TRN-1, transportin-1; 
VPS4, vacuolar protein sorting-associated protein 4A 
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Figure  1.4 Different trafficking routes proposed for agonist-treated CCR5. 
Following agonist-stimulation , CCR5 trafficks through the early endocytic pathway towards recycling 
and avoiding degradation. However, there are suggestions that the route followed by CCR5 may be 
ligand-dependent as summarised here for CCL5 (Signoret et al., 2000) and three of its chemical 
derivatives, AOP-RANTES (Signoret et al., 2000), PSC-RANTES (Escola et al., 2010) and MET-
RANTES (Kiss et al., 2009). EE/SE, early endosome/sorting endosome; ERC, endocytic recycling centre; 
MVB/LE/LY, multivesicular body/late endosome/lysosome; N, nucleus; RE, recycling endosome; TGN, 
trans Golgi network. This figure is modified from Bennett et al., (2011). 
 
1.5 Thesis aims 
It is established that GPCRs undergo desensitisation in response to prolonged agonist 
stimulation, a process that often involves internalisation and intracellular transport of 
stimulated receptors. General intracellular trafficking routes followed by GPCRs have 
been described, and for some well-studied receptors details of the proteins involved are 
known. However, how generic these routes actually are remains to be established. Are 
the pathways tailored to individual receptors and does each receptor have its own unique 
network of interacting proteins involved in desensitisation? 
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This thesis aimed to add to the current knowledge of chemokine receptor regulation and 
to address the above questions by focusing on the case of the chemokine receptors 
CCR2B and CCR5. Although these receptors bind different ligands, they are both 
inflammatory chemokine receptors and play complementary roles in the recruitment of a 
subset of leukocytes to sites of infection. In addition to their ability to heterodimerise 
and negatively cross-regulate each other, they are both also subject to cross-
desensitisation by LTA. Do these similarities imply that they may follow the same 
intracellular trafficking pathways? However, despite having high overall sequence 
homology (Figure 1.5), CCR2 and CCR5 differ in their C-terminal cytoplasmic tail 
(Figures 1.1 and 1.5), which is key for GPCR trafficking. Does this variation result in 
differing responses to agonist stimuli and if so, are these differences due to interactions 
with different proteins? 
I took a two pronged approach to answer these questions. Chapter 3 describes initial 
studies carried out with the objective of determining a suitable cell system in which to 
tackle these questions. Then the first approach described in Chapter 4 compares and 
contrasts the intracellular trafficking response of CCR2B to what is known about the 
well-studied CCR5 showing distinct differences in the pathways followed by the two 
receptors and also expanding upon the current knowledge for CCR2B. During this 
thesis, multiple forms of CCR2B were identified and thus this chapter also aimed to 
characterise these forms to determine why they exist and what their individual roles are. 
In Chapter 5, I describe two complementary proteomic studies carried out with the 
objective of identifying proteins interacting with these receptors.  
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Figure  1.5 Schematic of CCR2B topology showing comparison of the amino acid sequence 
with CCR5. 
The amino acid sequence of human CCR2B is depicted and residues that are identical to 
those in human CCR5 are indicated in grey. The probable CCR2B topology shown in 
this schematic is based upon a two-dimensional topology model for CCR5 (Oppermann, 
2004). There is some inconsistency in the precise transmembrane domain boundaries 
between the published CCR2B models (Kim et al., 2011; Mirzadegan et al., 2000; Shi et 
al., 2002), with one recent model exhibiting some very short intra- and extra-cellular 
loops (Kim et al., 2011). 
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2 Materials and Methods 
2.1 Reagents 
All chemicals were from Sigma-Aldrich (Gillingham, UK) unless otherwise specified. 
The complete protease inhibitor cocktail and ethylenediaminetetraacetic acid (EDTA)-
free protease inhibitor cocktail were from Roche Diagnostic Ltd (Burgess Hill, UK). 
Chemokines were from R&D Systems (Abingdon, UK) with the exception of CCL4, 
which was purchased from PeproTech (London, UK). PSC-RANTES was a gift from 
Oliver Hartley (University of Geneva, Switzerland). Purified LTA from Staphylococcus 
aureus was purchased from Invivogen (Toulouse, France). TAK-779 was obtained from 
the NIH AIDS Research and Reference Reagent Program (Germantown, MD, USA). 
UCB35625 and GF109203 (bisindolylmaleimide) were purchased from Tocris 
Bioscience, (Bristol, UK) and Calbiochem (Nottingham, UK), respectively. All tissue 
culture medium and supplements were from GIBCO
®
 (Life Technologies Ltd, Paisley, 
UK) with the exception of foetal bovine serum (FBS), which was from PAA (Yeovil, 
UK) or HyClone (Fisher Scientific UK Ltd, Loughborough, UK). All tissue culture 
plastic-ware was from Costar
®
/Corning
®
 (Corning Life Sciences, Amsterdam, The 
Netherlands). 5 ml polypropylene tubes used for flow cytometry were from BD 
Biosciences (Oxford, UK). 
2.2 Receptor agonists/antagonists 
The standard and other names for the chemokine receptor agonists and antagonists used 
in this project are given in Table 2.1. Chemokines were used at 100 nM for down-
modulation and endocytosis assays and 10 nM for calcium signalling assays unless 
otherwise specified. 
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Table  2.1 Chemokine receptor agonists and antagonists used in this project. 
 
 
2.3 Buffers and solutions 
Table  2.2 Buffers and their compositions. 
 
 
Standard Name Other Names Specificity 
CCL2 MCP-1, MCAF-1 CCR2 agonist 
CCL4 MIP-1β CCR5 agonist 
CCL5 RANTES CCR1 and CCR5 agonist 
PSC-RANTES N-nonanoyl, des-Ser1[L-thioproline2, L-cyclo- 
hexylglycine3]-RANTES(2–68) 
N-terminally modified 
synthetic analogue of CCL5 
(Hartley 2004) 
TAK-779 N,N- dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-
dihydro-5H-benzo- cyclohepten-8-
yl]carbonyl]amino]benzyl]tetrahydro-2H- pyran-4-
aminium chloride 
CCR5 and, to a lesser extent, 
CCR2 antagonist (Baba 
1999) 
UCB35625  trans-isomer J113863 CCR1 and CCR3 antagonist 
(Sabroe 2000) 
Buffer Composition 
1 % NP-40 lysis buffer 150 mM NaCl, 20 mM Tris-HCl (pH8.0), 2 mM EDTA, 1 % 
Igepal (NP-40 replacement) 
1 % Triton lysis buffer 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM EDTA, 1 % 
Triton X-100 
binding medium (pH7.1) 1X RPMI without bicarbonate, 10 mM HEPES, 0.2 % BSA, 
pH7.1  
coomassie solution 0.1% Phast Gel
TM
 Blue K (Healthcare, Buckinghamshire UK) in 
30 % methanol, 10 % acetic acid 
elution medium 1X RPMI, 10 mM MES, 0.2 % BSA, pH3.5 
FACS buffer 1 % BSA, 0.05 % sodium azide in PBS 
glutathione elution buffer 20 – 50 mM reduced glutathione, 100 mM Tris-HCl (pH 8.0), 120 
mM sodium chloride 
homogenisation medium 0.25 M sucrose, 1 mM EDTA, 10 mM HEPES-NaOH, pH 7.4 
LB 10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract 
LB Agar 17.5 g/L agar, 10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract 
PBS 0.14 M NaCI, 0.01 M PO4 Buffer, 0.003 M KCI 
quenching solution 50 mM ammonium chloride in PBS 
RIPA buffer 150 mM NaCl, 50 mM Tris-HCl (pH8.0), 5 mM EDTA (pH8.0), 1 
% NP-40, 0.5 % sodium deoxycholate, 0.1 % SDS, pH8.0 
sample buffer 62.5 μM Tris-HCl pH 6.8, 35 % glycerol, 2 % SDS, 0.16 % 
bromophenol blue, +/- 5 % β-mercaptoethanol (reducing/non-
reducing) 
saponin staining buffer  0.05 % saponin,1% BSA, 1 % FBS, in PBS 
staining buffer (for intact cells) 1 % BSA, 1 % FBS, in PBS 
stripping buffer 50 mM Tris-HCL, 2% SDS, 100 mM β-mercaptoethanol 
TAE buffer 40 mM Tris-acetate, 1 mM EDTA 
ubiquitination lysis buffer 50 mM Tris-HCl (pH8.0), 150 mM NaCl, 5 mM EDTA, 0.5 % 
(w/v) sodium deoxycholate, 1 % Igepal, 0.1 % (w/v) SDS, 20 mM 
NEM, protease inhibitor cocktail  
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2.4 Antibodies 
The antibodies used in this project are described in Table 2.3 and were purchased from 
AbD Serotec (Kidlington, UK), BD Pharmingen
TM
 (BD Biosciences), BD Transduction 
Laboratories (BD Biosciences), Covance (Princeton, NJ, USA), eBioscience Ltd 
(Hatfield, UK), Epitomics (Burlingame, CA, USA), GE Healthcare (Little Chalfont, 
UK), Invitrogen (Paisley, UK), Jackson Immuno Research Laboratories Inc (West 
Grove, PA, USA), Molecular Probes (Invitrogen), Novus Biologicals (Cambridge, UK), 
ProSci Inc (Poway, CA, USA), R&D Systems, Roche Diagnostic Ltd, Santa Cruz 
Biotechnology Inc (Heidelberg, Germany), Sigma-Aldrich and Stratech Scientific Ltd 
(Newmarket, UK) as indicated. 
Table  2.3 Antibody specificities, sources and concentrations used. 
 
 
  
ANTIBODIES AGAINST CHEMOKINE RECEPTORS 
Specificity Antibody  
Species & 
Isotype 
Application & 
Concentration 
Source & Catalogue Number (#) 
CCR2 
N-term 
 
R&D α-CCR2 
Mouse 
IgG2b 
FC 5 μg/ml unless 
otherwise stated 
R&D Systems,  # MAB150 
E68 
Rabbit 
monoclonal 
IP 1:50 Epitomics  # 2068-1 
H-40 
Rabbit 
polyclonal 
IP 2  µg/sample 
WB 1 µg/ml 
Santa Cruz Biotechnology Inc, # sc-
30031 
CCR2B 
C-term 
 CCR2 C-20 
Goat 
polyclonal 
WB 0.67 µg/ml 
Santa Cruz Biotechnology Inc, # sc-
6228 
CCR5 
N-term 
 
MC5 
Mouse 
IgG2a 
FC 5 μg/ml unless 
otherwise stated 
IF 5 5 μg/ml 
IP 7.5 µg/sample 
WB 2.15 µg/ml 
Produced in-house 
T21/8 Mouse IgG1 IP 2 µg/sample 
Santa Cruz Biotechnology Inc, # sc-
53792 
CCR5 NT 
Rabbit 
polyclonal 
IP 5 µg/sample ProSci Inc, # 1112 
CCR5  
2D7 
Mouse 
IgG2a 
IP 5 µg/sample BD Pharmingen
TM
, # 555990 
3A9 
Mouse 
IgG2a 
IP 5 µg/sample BD Pharmingen
TM
, # 556041 
HEK/1/85a Rat IgG2a IP 5 µg/sample AbD Serotec # MCA2175 
CCR5 
C-term 
 
CCR5 C-20 
Goat 
polyclonal 
WB 0.67 – 1 µg/ml 
Santa Cruz Biotechnology Inc, # sc-
6128 
R-C10 Mouse IgG1 WB 1 µg/ml 
Santa Cruz Biotechnology Inc, # sc-
57072 
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Table 2.3 Antibody specificities, sources and concentrations used. 
 
 
 
ANTIBODIES AGAINST TAGS 
Specificity Antibody  
Species & 
Isotype 
Application & 
Concentration 
Source & Catalogue Number (#) 
HA 
 
HA.11 Mouse IgG1 
FC 5 μg/ml 
WB 4 µg/ml 
IF 5 μg/ml 
Covance, # MMS101P/MMS-101R 
12CA5 
Mouse 
IgG2b 
FC as stated 
WB 1 µg/ml 
IP  5 - 100 µg/sample 
IF 5 μg/ml 
Gift from Paul Pryor (CII, 
University of York, UK) and bought 
from Roche Diagnostic Ltd, # 
11583816001  
3F10 (anti-HA 
high affinity) 
Rat 
monoclonal 
WB 0.1 µg/ml 
IF 5 μg/ml 
Roche Diagnostic Ltd, # 1867423 
HA-7 Mouse IgG1 IF 5 μg/ml Sigma-Aldrich, # H9658 
HA-7 FITC 
Mouse 
ascites 
IF 5 μg/ml Sigma-Aldrich, # H7411 
FLAG  FLAG M2 Mouse IgG1 
WB 1 µg/ml 
IP 10 µg/sample 
Sigma-Aldrich, # F1804 
OTHER PRIMARY ANTIBODIES 
Specificity Antibody  Species & 
Isotype 
Application & 
Concentration 
Source & Catalogue Number (#) 
EEA1 α-EEA1 Mouse IgG1 IF 5 μg/ml BD Transduction Laboratories, # 
610456 
CD63 α-CD63, 
clone IB5 
Mouse 
IgG2b 
IF 5 μg/ml Gift from Mark Marsh, (MRC-
LMCB, UCL, London, UK) 
Lamp1 α-Lamp1  Rabbit 
polyclonal 
IF 1/1000 dilution 
WB 1/1000 dilution 
Gift from Ashley Toye 
(Department of Biochemistry, 
University of Bristol, UK) 
Human 
TGN46 
α-TGN46 Sheep 
polyclonal 
IF 5 μg/ml 
WB 0.5 µg/ml 
AbD Serotec, # AHP500G 
Human 
transferrin 
receptor 
α -transferrin 
receptor 
Mouse IgG1 IF 5 μg/ml 
WB 1 µg/ml 
Invitrogen, # 13-6800 
Rab4 α-Rab4 Mouse IgG1 IF 5 µg/ml BD Transduction Laboratories, # 
610888 
Rab11 α-Rab11 Mouse 
IgG2a 
IF 5 µg/ml BD Transduction Laboratories,  # 
610656 
Nucleoporin 
p62 
α-nucleoporin 
p62 
Mouse 
IgG2b 
IF 5 μg/ml 
 
BD Transduction Laboratories, # 
610497 
Na,K-
ATPase α1 
subunit 
α-Na/K 
ATPase α 
Mouse IgG1 
κ 
WB 1/5000 dilution Novus Biologicals, # NB300-146 
CD49b α-CD49b Mouse 
IgG2a 
WB 1 µg/ml BD Transduction Laboratories, # 
611016 
Caveolin 1 α-caveolin 1 Mouse IgG1 WB –0.25 – 0.5 µg/ml BD Transduction Laboratories, # 
610406 Clone 2297 
Lamp1 α-Lamp1 Mouse 
IgG2b 
IF 5 μg/ml 
WB 1 µg/ml 
BD Transduction Laboratories, # 
611042 
BiP/GRP78 α-BiP Mouse 
IgG2a 
WB 1 µg/ml BD Transduction Laboratories, # 
610978 
β-catenin Anti- β-
catenin 
Mouse IgG1 WB 0.5 µg/ml BD Transduction Laboratories, #  
610153 
GST α-GST Goat 
polyclonal 
WB 1/2000 –1/ 5000 
dilution 
GE Healthcare, # 27-4577-01 
52 
 
Table 2.3 Antibody specificities, sources and concentrations used. 
 
 
ISOTYPE CONTROL ANTIBODIES 
Antibody  Species & 
Isotype 
Application & 
Concentration 
Source & Catalogue Number (#) 
Mouse IgG1 isotype control Mouse IgG1 FC 5 μg/ml 
IF 5 μg/ml 
IP 5 µg/sample 
eBioscience Ltd, # 14-4714 
Mouse IgG1 isotype control 
B (MOPC-31c) 
Mouse IgG1 FC 5 μg/ml 
IF 5 μg/ml 
Sigma-Aldrich, # M9035 
Mouse IgG2a isotype 
control 
Mouse 
IgG2a 
FC 5 μg/ml 
IF 5 μg/ml 
IP 5 µg/sample 
eBioscience, # 14-4724 
Mouse IgG2b isotype 
control 
Mouse 
IgG2b 
FC 5 μg/ml 
IF 5 μg/ml 
IP 10 µg/sample 
eBioscience, # 14-4732 
Mouse IgG2b isotype 
control B (MOPC-141) 
Mouse 
IgG2b 
FC 5 μg/ml 
IF 5 μg/ml 
Sigma-Aldrich, # M8894 
Rabbit IgG control Rabbit IP 5 µg/sample Stratech Scientific Ltd, # 
SECONDARY ANTIBODIES 
Specificity Antibody  Species & 
Isotype 
Application & 
Concentration 
Source & Catalogue Number (#) 
Goat 
IgG 
 α-goat HRP Mouse WB 80 ng/ml Jackson Immuno Research 
Laboratories Inc, # 205-035-108 
 
 
 
 
 
Mouse 
IgG 
 Goat α-mouse 
HRP 
Goat 
polyclonal 
WB 1/10000 dilution  
Rabbit α-
mouse HRP 
Rabbit WB 0.2-0.4 µg/ml Sigma-Aldrich, # A9044 
GAM-488 Goat FC 4 μg/ml 
IF 4 μg/ml 
Molecular Probes, # A11017 or 
A11001 
GAM-594 Goat FC 4 μg/ml 
IF 4 μg/ml 
Molecular Probes, # A11020 or 
A11005 
GAM-647 Goat FC 4 μg/ml 
IF 4 μg/ml 
Molecular Probes, # A21237 or 
A21235 
α-mouse-PE Sheep 
polyclonal 
FC 4 μg/ml Sigma-Aldrich, # P8547 
Mouse 
IgG1 
 GAM IgG1-
488 
Goat 
polyclonal 
IF 4 μg/ml Molecular Probes, # A21121 
Mouse 
IgG2b 
 GAM IgG2b-
647 
Goat 
polyclonal 
IF 4 μg/ml Molecular Probes, # A21242 
Rabbit 
IgG 
 α-rabbit HRP Goat 
polyclonal 
WB 0.62 µg/ml Sigma-Aldrich, # A0545 
GAR-488 Goat IF 4 μg/ml Molecular Probes, # A11008 
Rat 
IgG  
 α-rat HRP Goat WB 1/5000 dilution Sigma-Aldrich, # A9037 
Sheep 
Ig 
 α-sheep HRP Donkey, 
polyclonal 
WB 1/2000 dilution R&D Systems, # HAF016 
DAS-488 Donkey IF 4 μg/ml Molecular Probes, # A11015 
BiP, binding immunoglobulin protein; EEA1, early endosome antigen 1; FC, flow cytometry; HA, 
hemagglutinin; HRP, horse radish peroxidise; IF, immunofluorescence; Ig, immunoglobulin; IP, 
immunoprecipitation; PE, phycoerythrin; TGN, trans Golgi network; WB, western blot  
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2.5 Cell culture 
The human monocytic cell line THP-1 was purchased directly from the American Type 
Culture Collection (ATCC, Manassas, VA, USA) and was cultured at 37 °C in a 5 % 
CO2 in air atmosphere in RPMI medium supplemented with 10 % fetal bovine serum 
(FBS), 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 2 mM 
glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin (all from from GIBCO
®
). 
The human monocytic cell line Mono Mac 1 was obtained from the German Collection 
of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany) and was 
cultured at 37 °C in a 5 % CO2 in air atmosphere in RPMI medium supplemented with 
10 % FBS, 2 mM glutamine, 1x non-essential amino acids, 1 mM sodium pyruvate, 100 
U/ml penicillin and 0.1 mg/ml streptomycin (all from from GIBCO
®
). THP-1 and Mono 
Mac 1 cells were maintained in a non-differentiated, monocytic state at densities of 
between 1 x 10
5
 -  6 x 10
5 
cells/ml and 0.3 – 1 x 106 cells/ml respectively, in 175 cm2 
tissue culture flasks (Corning Life Sciences). 
The human embryonic kidney HEK293 cell line was provided by Dr Daniel Ungar 
(Department of Biology, University of York, UK) and originally obtained from the 
ATCC. The HEK293 TLR1/2 and HEK293 TLR2/6 cell lines were a gift from Dr 
Marika Kullberg (Centre for Immunology and Infection, University of York, UK) and 
originally obtained from Invivogen. All HEK293 cell lines were cultured at 37 °C in a 5 
% CO2 in air atmosphere in Dulbecco's Modified Eagle Medium (DMEM) containing 
4.5 g/L glucose and 4 mM L-glutamine supplemented with 10 % FBS, 100 U/ml 
penicillin and 0.1 mg/ml streptomycin and maintained at 20 – 90 % confluent in 10 cm 
culture dishes. HA-CCR2B and HA-CCR5 transfected cell lines were maintained under 
selection using 500 μg/ml G418 (Merck, Darmstadt, Germany). HEK293 TLR cell lines 
were maintained under selection using 10 μg/ml blasticidin (Autogen Bioclear UK Ltd, 
Calne, UK or Invivogen). 
2.6 Production of transfected HEK293 cell lines 
2.6.1 Transfection methods 
For transfection of HEK293, HEK293 TLR1/2 and HEK293 TLR2/6 for transient or 
stable expression of HA-CCR2B or HA-CCR5, 2 x 10
6
 cells per sample were 
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transfected by nucleofection with 2.5 µg DNA using the Amaxa cGMP Nucleofector  
Kit V (Lonza, Cologne, Germany) following the manufacturer’s optimised HEK293 
nucleofection  protocol. pcDNA3.1+HA3CCR2B, pcDNA3.1+HA3CCR5 (Missouri 
S&T cDNA Resource Centre, Rolla, MO, USA) or control pmaxGFP (Lonza) constructs 
were used for the transfections. 
For transient transfection of HEK293 cell lines for expression of fluorescent Rab 
constructs (a gift from Mark Marsh, MRC-LMCB, UCL, London, UK) or a FLAG-
Ubiquitin construct (a gift from Sylvie Urbe, Institute of Translational Medicine, 
University of Liverpool, UK), one or more 60 % confluent wells of a 24-well plate were 
transfected with 0.5 µg DNA using 1 µl jetPRIME
TM
 reagent (Polyplus-transfection SA, 
Ilkirch, France) following the maufacturer’s protocol. Cells were typically incubated for 
24 hours at 37 °C, 5 % CO2 to allow protein expression before being used for 
colocalisation, flow cytometry or co-immunoprecipitation (CO-IP) assays. 
2.6.2 Production of stable cell lines 
Preliminary experiments showed that transient transfection for expression of HA-
CCR2B or HA-CCR5 was not suitable for this project as the transfection level was too 
low and so selection with 1 mg/ml G418 was used to create more stable cell lines. 
Immunofluorescence staining after 24 hours, and periodic immunofluorescence staining 
and flow cytometry over the month following transfection, showed that G418 selection 
resulted in mixed populations of cells with varying expression levels of HA-CCR2B or 
HA-CCR5. Therefore, cloning by limited dilution was carried out to obtain more 
homogeneous populations. Cells were seeded in a 96-well plate at a density of 10, 5, 1 
or 0.1 cells/well in growth medium containing G418 and incubated at 37 °C, 5 % CO2. 
The next day, after the cells had adhered, the number of cells in each well was counted 
by visual inspection using a brightfield microscope. The plates were visually inspected 
every 2 – 3 days, and when wells containing colonies originating from a single cell 
reached approximately 90 % confluency these cells were transferred to 24-well plates. 
Duplicate plates were prepared to enable characterisation of each clone for HA-CCR2B 
or HA-CCR5 expression by flow cytometry, 
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2.7 Immunofluorescence staining 
2.7.1 Endocytosis assay 
Cells were seeded on poly-D-lysine coated glass coverslips in a 24-well plate at 2.5 x 
10
4
 cells/well and incubated at 37 °C, 5 % CO2 for approximately 36 hours. Surface 
HA-CCR2B or HA-CCR5 was pre-labelled using the specified antibody (usually HA.11 
for HA-CCR2B and MC5 or HA.11 for HA-CCR5) at 5 μg/ml for 90 minutes at 4 °C. 
Unbound antibody molecules were removed by washes and cells were incubated in 
binding medium or growth medium containing 100 nM CCL2 or CCL5 and incubated 
for the specified time at 37 °C. The cells were then fixed in 3 % para-formaldehyde 
(PFA) in phosphate buffered saline (PBS) for 5 minutes on ice followed by 20 minutes 
at room temperature (RT) before free aldehyde groups were quenched by treatment with 
quenching solution for 20 minutes at RT. Fixed cells were subsequently permeabilised 
by incubation with saponin staining buffer at RT for 20 minutes under gentle shaking 
(40 rpm) and then incubated with 4 μg/ml Alexa Fluor-conjugated secondary antibody 
in saponin staining buffer at RT for 60 minutes. Initial experiments showed high 
background binding on HEK293 cells and so the saponin staining buffer contained both 
FBS and bovine serum albumin (BSA) as blocking reagents. 
After washes with 0.05 % saponin in PBS and a final wash in PBS containing 1 µg/ml 
DAPI (4’,6-diamidino-2-phenylindole, Invitrogen), the coverslips were mounted on to 
glass slides using Mowiol. 
For colocalisation experiments, labelling with additional primary antibodies was carried 
out after fixation before secondary antibody staining. When colabelling with a mouse 
monoclonal antibody of the same isotype as HA.11 (IgG1) or MC5 (IgG2a), the other 
antibody was labelled using fluorescent Zenon
®
 Fab fragments (Molecular Probes) 
following the manufacturer’s instructions. Staining steps using these antibodies were 
carried out after secondary antibody staining and an extra 15-minute fixation step using 
4 % PFA in PBS was added afterwards to avoid transfer of the non-covalently bound 
Zenon
®
 fab fragment. 
56 
2.7.2 Down-modulation assay 
Cells were seeded on poly-D-lysine coated glass coverslips in a 24-well plate at 2.5 x 
10
4
 cells/well and incubated at 37 °C, 5 % CO2 for approximately 36 hours. The 
medium was replaced with binding medium containing 100 nM chemokine and 
incubated at 37 °C for 60 minutes. The cells were then fixed and stained as described in 
Section 2.7.1.  For colocalisation experiments, labelling with additional primary 
antibodies was carried out at the same time as labelling with HA.11, 12CA5 or MC5.  
2.7.3 Microscopy 
Cells were imaged using Zeiss LSM 510 or Zeiss LSM 710 confocal microscopes and 
either Zeiss LSM or ZEN imaging software (Zeiss, Welwyn Garden City, UK). 
Acquired images were subsequently analysed using Zeiss LSM Image Browser (Zeiss), 
ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, MD, 
USA, http://imagej.nih.gov/ij/, 1997-2011), Photoshop CS3 (Adobe Systems Europe 
Ltd., Uxbridge, UK) and/or Volocity 3D Image Analysis Software (PerkinElmer, 
Cambridge, UK). All images presented in this thesis are confocal slices.  
2.8 Flow cytometry  
2.8.1 Down-modulation assay 
For down-modulation assays, 1 – 2 x 105 THP-1 cells per sample were re-suspended in 
binding medium and aliquoted into 5 ml polypropylene tubes. Binding medium alone or 
supplemented with chemokine to reach a final concentration of 100 nM, was added to 
the cells and samples were incubated at 37 °C for 60 minutes. Samples were 
subsequently labelled for cell-surface receptor as described in Section 2.8.2.  
Initial experiments carried out on HEK293 cells treated and labelled in suspension 
showed that the cells did not survive the process very well and so later experiments were 
carried out on cells kept adhered for the treatment step and detached prior to 
immunolabelling, which shortened the procedure. In the suspension cell assay, cells 
were detached from a 10 cm plate using 10 mM EDTA in PBS and 1 x 10
5
 cells per 
sample were aliquoted into 5 ml polypropylene tubes and incubated in binding medium 
with 100 nM chemokine at 37 °C for 60 minutes. For the adhered cell assay, cells were 
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seeded in a 24-well plate at 2.5 x 10
5
 cells/well and incubated at 37 °C, 5 % CO2 for 36 
hours or until they were approximately 90 % confluent. The medium was replaced with 
medium alone or containing 100 nM chemokine, and the cells were incubated at 37 °C 
for 60 minutes before washes with PBS and detachment using 10 mM EDTA in PBS. In 
both assays, the cells were then labelled for cell-surface receptor using either R&D α-
CCR2, MC5 or HA.11 as described in section 2.8.2. Experiments were carried out in 
triplicate. 
In order to look at the role Rab4 plays during CCR2 down-modulation, HEK HA-
CCR2B cells were transiently transfected to express YFP-tagged wild type Rab4 
(Rab4WT), dominant negative Rab4 (Rab4N121I), constitutively active Rab4 or, as a 
control, GFP as described in Section 2.6.1, and used for the down-modulation assay. For 
this assay only, single replicates were used. 
For assays testing the effects of drugs on CCR2 down-modulation, HEK HA-CCR2B 
cells were incubated with the drugs described in Table 2.4 for 60 minutes prior to 
chemokine treatment, and the drug was maintained in subsequent steps up to fixation. 
Table  2.4 Drugs tested for their effects on CCR2 down-modulation. 
 
 
Down-modulation is expressed as percent reduction in cell surface expression of the 
receptor for chemokine-treated cells compared to cells kept in medium. For experiments 
using HEK HA-CCR2B cells transiently transfected to express YFP-tagged Rab4s or 
GFP, the ratio of down-modulation in FITC positive cells compared to FITC negative 
cells within the same sample was calculated. 
2.8.2 Detection of cell-surface receptor by flow cytometry 
Prior to labelling, THP-1 cells were incubated in binding medium containing 30 µg/ml 
human IgG for 20 minutes on ice to saturate the cells’ Fc receptors and subsequent 
Drug Final Concentration Control 
Ikarugamycin 3 µM DMSO 
Sucrose 0.4 M Binding medium 
Methyl-β-cyclodextrin (MβCD) 10 mM Binding medium 
Nystatin 50 µg/ml DMSO 
Filipin 5 µg/ml Binding medium 
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staining steps were carried out in the presence of 5 µg/ml human IgG to avoid non-
specific binding of mouse monoclonal antibodies. Cells were labelled with primary 
antibody, either R&D α-CCR2, MC5 or HA.11 at 5 μg/ml (down-modulation assay) or 
10 µg/ml (recycling assays), in binding medium for 90 minutes (down-modulation) or 
60 minutes (recycling) before fixation with 3 % PFA in PBS and quenching. Fixed cells 
were labelled with 4 μg/ml Alexa Fluor-conjugated secondary antibody in FACS buffer. 
For assays testing the effects of glycosylation inhibitors on cell-surface expression of 
CCR2, HEK HA-CCR2B cells were pretreated with growth medium containing 
dimethyl sulfoxide (DMSO), 2 mM benzyl α-N-Acetylgalactosamine (benzyl –
GalNAC), 10 µg/ml tunicamycin or tunicamycin and benzyl α-GalNAC for 24 hours at 
37 °C, 5 % CO2 prior to labelling. 
2.8.3 Flow cytometry data analysis 
Most flow cytometry data was gathered on the BD FACS Array
TM
 (BD Biosciences), 
using the custom software, although where indicated the Cyan flow cytometer 
(Beckman Coulter, High Wycombe, UK) and Summit version 4.3 (Dako, Fort Collins, 
CO, USA) were used instead. Data were then exported and analysed in FlowJo 7.2.2 
(Tree Star Inc, Ashland, OR, USA), which was used to generate histograms. The main 
population of cells was gated to remove cellular debris and a cut-off was applied so that 
only samples with at least 1000 cells were analysed. In some experiments, other gates 
were applied as described. Analysis of the FlowJo-generated data was carried out in 
Microsoft Excel and graphs were produced using GraphPad Prism 5 (GraphPad 
Software Inc, La Jolla, CA, USA). 
2.9  SDS-PAGE and western blot 
Cell lysates and protein samples prepared as described in the results chapters were either 
heated to 95 °C or incubated at RT for 5 minutes in the presence of reducing or non-
reducing sample buffer as indicated. The samples were analysed by SDS-PAGE (sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis) using a 10 % (or 8 % for GST 
pull-down experiments) acrylamide gel, followed by Coomassie staining or transfer to 
membranes for western blotting. 
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Proteins were transferred to nitrocellulose transfer membrane (from Geneflow Ltd, 
Lichfield, UK) using a Transblot SD semi dry electrophoretic transfer cell (Bio-Rad 
Laboratories Ltd, Hemel Hempsted, UK ) at 20 V for 40 minutes in transfer buffer (25 
mM Tris, 192 mM glycine, 20 % methanol). Western blotting was carried out following 
the PBS or TBS protocols. In the PBS protocol, the membrane was blocked with 5 % 
Marvel milk powder or 10 % FBS in PBS 0.1 % Tween-20 for 1 hour at RT (RT). The 
membrane was incubated with the primary antibody in blocking buffer overnight at 4 °C 
under agitation. The membrane was washed 1 – 4 times in PBS 0.5 % Tween at RT 
under agitation followed by 3-4 washes in PBS 0.1 % Tween. The membrane was 
incubated with the secondary antibody for 1 hour at RT under agitation and then washed 
1 – 2 times with PBS 0.5 % Tween-20 at RT under agitation followed by 3 – 4 washes 
with PBS 0.1 % Tween-20. In the TBS protocol, 5 % Marvel in TBS 0.1 % Tween was 
used as the blocking buffer and TBS 0.1 % Tween was used as the wash buffer. The 
primary antibody incubation was carried out for 1 hour at RT under agitation. All other 
steps were as for the PBS protocol. The ECL Western Blotting Substrate, the Super 
Signal
®
 West Pico kit (Pierce, Perbio Science UK Ltd, Cramlington, UK) or the EZ-
ECL Chemiluminescence dectection kit for horse radish peroxidise (HRP; Beit-Haemek, 
Israel) were used for detection. Various exposures were taken using X-ray film 
(Fujifilm, Milton Keynes, UK; ThermoFisher Scientific, Loughborough, UK; 
Amersham, GE Healthcare). Where required for re-blotting, membranes were stripped 
by two incubations in stripping buffer for 30 minutes at 70 °C, followed by two washes 
in TBS 0.1 % Tween. 
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3 The monocytic cell line THP-1 and transfected HEK293 
cells as model cells to study chemokine receptor 
desensitisation 
3.1 Introduction 
Traditionally, there was believed to be much apparent redundancy in the chemokine 
system, as a single receptor may have multiple ligands and a single chemokine may bind 
to multiple receptors (Table 1.3). However the chemokine receptors expressed by a cell, 
and thus the signalling experienced within the cell, appear to be highly regulated and 
dependent on the cell type, differentiation state and local environment, suggesting that 
redundancy may not be a major factor in vivo (Allen et al., 2007). The processes of 
desensitisation and resensitisation enable this regulation by altering the cell’s ability to 
respond to receptor ligands. Desensitisation can be either agonist-induced (homologous) 
or a result of cross-talk with another cell surface receptor (heterologous) (Kelly et al., 
2008; Salanga et al., 2009). Monocytes co-express the inflammatory chemokine 
receptors CCR2B and CCR5, which play complementary roles in their recruitment from 
the bloodstream to sites of infection and inflammation within the tissues (Boring et al., 
1997; Weber et al., 2001). This essential process requires tight regulation by receptor 
desensitisation and resensitisation in order to prevent excessive or inappropriate immune 
responses.  
3.1.1 Chemokine receptor desensitisation in monocytes 
3.1.1.1 Agonist-induced desensitisation  
Following extended agonist-stimulation, chemokine receptors, like other GPCRs, can 
undergo desensitisation (Bennett et al., 2011). An important step in this process is 
agonist-induced down-modulation, which involves removal of chemokine-activated 
receptor from the cell surface by endocytosis (Kelly et al., 2008). It had been shown that 
monocytes down-modulate CCR2 (Fox et al., 2011) and CCR5 (Mack et al., 1998) from 
the cell surface in response to their respective agonistic ligands CCL2 and CCL5. 
61 
3.1.1.2 Cross-talk between TLR2 and CCR2/5 on leukocytes 
Chemokine receptors can also undergo cross-regulation via stimulation of another  
receptor. The so-called heterologous desensitisation of chemokine receptors by bacterial 
compounds has been shown on various cells of the immune system (Alves-Filho et al., 
2009; Fox et al., 2011; McKimmie et al., 2009; Sica et al., 1997). Down-regulation of 
the inflammatory chemokine receptors CCR1, CCR2, CCR5 and CXCR2 at the gene 
level in response to TLR2 stimulation with bacterial lipoprotein (Pam3CSK4) has been 
shown to occur after four hours of treatment on mouse bone marrow-derived 
macrophages, neutrophils, T cells and dendritic cells (DCs; Juffermans et al., 2002; 
McKimmie et al., 2009). Studies using a different TLR2 ligand, lipoteichoic acid (LTA), 
showed that rapid (within minutes) down-modulation occurs for all of these CC 
chemokine receptors on human monocytes (Fox et al., 2011) and CXCR2 on mouse 
neutrophils (Alves-Filho et al., 2009). LTA stimulation of TLR2 leads to internalisation 
of CCR5 on monocytes by utilising the machinery involved in agonist-induced 
internalisation, but following a much slower kinetic (Fox et al., 2011). The pathways 
downstream of TLR2 that lead to the recruitment of this machinery remain to be 
elucidated although several proteins that may be involved have been suggested. It is 
possible that TLR2 signalling feeding into homologous desensitisation pathways may be 
a general mechanism, as GRK2, the G protein kinase involved in agonist-induced 
internalisation of many chemokine receptors, has also been implicated in TLR2-
mediated down-modulation of CXCR2, although further investigations are required 
(Alves-Filho et al., 2009).  
3.1.2 The monocytic cell line THP-1 
A range of myelomonocytic cell lines that represent different stages along the monocyte 
to macrophage maturation pathway have been described, and are commonly used to 
complement studies on human monocytes or monocyte-derived macrophages (Cassol et 
al., 2006). The THP-1 cell line is human monocytic leukemia cell line (Tsuchiya et al., 
1980) and was chosen for the present study as its characteristics mimic best an early 
monocytic phenotype and it had been described as expressing both CCR2 (Charo et al., 
1994; Garcia Lopez et al., 2009; Minsaas et al., 2010; Phillips et al., 2005; Tanaka et al., 
2002; Van Riper et al., 1993; Wang and O, 2001; Wang et al., 1993c; Wong et al., 1997; 
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Xu et al., 1997; Yamamoto et al., 1999) and CCR5 (Achour et al., 2009; Cassol et al., 
2006; Mueller and Strange, 2004; Wang et al., 1993c). CCR2 expression on THP-1 cells 
was originally shown by the ability of the cells to bind the main CCR2 ligand CCL2 
(Van Riper et al., 1993; Wang et al., 1993c). Subsequent studies showed the presence of 
CCR2 mRNA (Charo et al., 1994; Wang and O, 2001; Xu et al., 1997; Yamamoto et al., 
1999) and the recognition of CCR2 protein by specific antibodies by flow cytometry 
(Garcia Lopez et al., 2009; Phillips et al., 2005), immunofluorescence (Minsaas et al., 
2010) and western blot (Wang and O, 2001). There are two isoforms of CCR2, namely 
CCR2A and CCR2B, and in THP-1 cells, like in monocytes, CCR2B is the 
predominantly expressed form at both the mRNA and protein level (Tanaka et al., 2002; 
Wong et al., 1997). For CCR5, evidence for expression on THP-1 cells was based on 
their ability to be infected by R5 HIV strains (Cassol et al., 2006; Kitano et al., 1990; 
Meylan et al., 1993), which use CCR5 as a co-receptor for entry into monocytes (Berger 
et al., 1998). Ligand binding studies (Van Riper et al., 1994; Van Riper et al., 1993; 
Wang et al., 1993b; Wang et al., 1993c) have been inconclusive due to the promiscuity 
of commonly used CCR5 ligands, and antibody binding studies have shown both 
positive (Achour et al., 2009; Mueller and Strange, 2004) and negative (Wu et al., 1997) 
results for CCR5 expression on THP-1 cells. 
3.1.3 Requirement for a transfected cell line model  
Previous work by our group on agonist- and LTA-induced CCR2 and CCR5 
desensitisation had been carried out on primary human monocytes, however these were 
not suitable for the studies proposed in this project. For studying receptor intracellular 
trafficking, monocytes and monocytic cell lines are not ideal due to their small size 
coupled with the fact that their nucleus forms a large proportion of the cell, and most 
importantly the lack of availability of good antibodies recognising endogenous CCR2.  
For proteomic studies, the main problem would be the difficulty and expense involved 
in obtaining sufficient quantities of cells if using monocytes. Monocytes make up only 
approximately 10% of the peripheral blood mononuclear cells found in whole blood 
(Jones et al., 1989), which results in a yield of no more than 4 x 10
7
 monocytes per 
single donor sample from the UK National Blood Service. Immunoprecipitation (IP) 
experiments carried out to confirm the presence of a protein by western blot and 
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chemiluminescence, typically use a starting number of 0.5 – 2 x 107 cells per experiment 
(Bonifacino, 1998). For identification of novel co-immunoprecipitated proteins using 
mass spectrometry, it it recommendend that sufficient protein is used to enable 
visualisation on SDS-PAGE gels by Coomassie staining, which more than 100 fold less 
sensitive than western blotting (Gillespie and Hudspeth, 1991).Thus in order to obtain 
sufficient numbers of cells, the use of multiple different donor blood samples would be 
required for each immunopreciptation experiment. 
Although using monocytic cell lines would appear to be the best compromise, as will be 
described later in this chapter, the CCR5 expression on the common monocytic cell lines 
does not sufficiently mimic what is observed on monocytes. Therefore, in order to study 
and compare both CCR2 and CCR5 a better approach would be to create stably 
transfected cell lines expressing tagged versions of CCR2 and CCR5. This system 
would have the major advantage of enabling the use of well tested antibodies against the 
tag instead of the endogenous receptor.  
This project chose to use the human HEK293 cell line, which does not endogenously 
express CCR2 or CCR5, to generate transfected cell lines enabling the individual study 
and comparison of the two receptors, for several reasons. Firstly, HEK293 cells have 
been previously used successfully for trafficking studies as they are relatively large and 
can be easily transfected to express intracellular markers. Secondly, they have been 
successfully used for the identification of novel chemokine receptor-protein interactions 
by co-immunoprecipitation (Favre et al., 2008). Thirdly, HEK293 cells stably 
expressing TLR2, were available.  
3.1.4 Overview of transfected HEK293 cell lines created 
Transfected HEK293 cell lines expressing TLR2 with either HA-CCR2B or HA-CCR5 
were created (Table 3.1) with the view of further dissection of the heterologous 
desensitisation between CCR2 or CCR5 and TLR2 uncovered in our lab (Fox 2011). 
TLR2 can act in conjunction with TLR1 (Wyllie et al., 2000), TLR6 (Takeuchi et al., 
2001) or the less widely expressed TLR10 (Hasan et al., 2005), however it is not known 
which of TLR1 or TLR6 is involved in the TLR2 cross-talk with CCR2 and CCR5 in 
monocytes (personal communication from Nathalie Signoret, University of York, UK). 
Therefore, in addition to the standard HEK293 cell line, HEK293 cell lines stably 
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expressing mouse TLR2 with either of its heterodimerisation partners, TLR1 and TLR6 
were available. The mouse and human TLR2 sequences show high sequence homology 
in the cytoplasmic domain TIR region (Figure 3.1), which is responsible for interaction 
with adaptor proteins involved in TLR2 signalling. They also both respond to the same 
ligands and can be recognised by the same antibodies suggesting that the mouse TLR2 
should be a good substitute for human TLR2. As it is not known which heterodimer is 
required for LTA-induced TLR2 cross-desensitisation of the chemokine receptors, three 
different HEK293 cells lines (HEK293, HEK293 stably expressing TLR1 and TLR2 and 
HEK293 stably expressing TLR2 and TLR6) were stably transfected with either CCR2B 
or CCR5 giving a total of six as described in Table 3.1. Pre-made constructs encoding 
triple HA-tagged versions of human CCR2B and CCR5 in the pcDNA3.1+ vector, and 
obtained from the UMR cDNA Resource Centre (Missouri, USA) were used. 
 
Table  3.1 Summary of the transfected HEK293 cell lines created in this project. 
 
Name TLR Chemokine Receptor 
HEK HA-CCR2B N/A Human HA-CCR2B 
HEK HA-CCR5 N/A Human HA-CCR5 
HEK TLR1/2 HA-CCR2B Mouse TLR1 & TLR2 Human HA-CCR2B 
HEK TLR1/2 HA-CCR5 Mouse TLR1 & TLR2 Human HA-CCR5 
HEK TLR2/6 HA-CCR2B Mouse TLR2 & TLR6 Human HA-CCR2B 
HEK TLR2/6 HA-CCR5 Mouse TLR2 & TLR6 Human HA-CCR5 
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Figure  3.1 Comparison of the amino acid sequence of human and mouse TLR2 using SIM 
(http://expasy.org/tools/sim-prot.html). 
The cytoplasmic TIR domain (highlighted in yellow), which is involved in protein-protein interactions 
with the adaptor protein TIRAP leading to TLR signalling via MyD88, shows 91 % sequence identity. 
Asterisks indicate identical amino acids.  
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3.1.5 Objectives 
The present study aimed firstly to investigate both whether we can study endogenous 
CCR2 on THP-1 cells and whether the CCR5 present on these cells is functional, in 
order to determine the utility of these cells for studying desensitisation of the receptors. 
The second aim was to characterise the six transfected HEK293 cells lines in order to 
determine how closely their CCR2 and CCR5 expression and behaviour mimics that 
observed in primary human monocytes. This would enable us to determine how useful 
THP-1 cells and the transfected HEK293 cell lines would be for studying receptor 
trafficking in response to agonist stimulation or LTA cross-talk and for identifying novel 
receptor-protein interactions. 
3.2 Relevant Methodology 
3.2.1 Intracellular calcium mobilisation assay 
THP-1 cells, human monocytes (purified as in Fox et al., 2011) or transfected HEK293 
cells were washed in PBS, loaded with 2.5 μM Fluo-8 AM (at a density of 2 x 106 
cells/ml) for 30 minutes, then washed and resuspended in HBSS at a density of 1 x 10
6
 
cells/ml. 400 μl aliquots of cells were either untreated or pretreated with 400 nM TAK-
779 or 100 nM UCB35625 where indicated. After obtaining a baseline fluorescence 
reading for 30 seconds, an identically-treated aliquot of cells were treated with PBS, 400 
nM TAK-779 or 100 nM UCB35625 (as controls) or the indicated concentration of 
chemokine and analysed. Changes in the intracellular calcium concentration were 
measured as changes in the fluorescence of the cells on a CyAn flow cytometer 
(Beckman Coulter) using an argon laser at a wavelength of 488 nm. 
The data was analysed using Summit version 4.3. Firstly, cells were gated based on 
FSC/SSC to exclude dead cells and cellular debris. Then additional gates were used to 
divide the data in to 10 second time slots and the median fluorescence at 488 nm was 
analysed for each gate. The average of the first 30 seconds was typically used to 
calculate the baseline fluorescence and all other fluorescence values were normalized to 
the baseline to enable comparison between samples. Due to the time needed for cells to 
reach the flow chamber for analysis, there was a time delay after finishing the baseline 
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recording before recording resumed after addition of the chemokine or control, and so 
data from this time frame was excluded. Graphs were plotted using GraphPad Prism 5. 
3.2.2 Cell surface receptor quantification by flow cytometry 
Antibody titrations were carried out by flow cytometry by incubating 2 x 10
5
 transfected 
HEK293 cells with serial dilutions of monoclonal antibodies (20 - 0.5 μg/ml) for 90 
minutes at 4 °C before fixation and labelling with secondary antibody as described in 
section 1.7.2. Antibody binding saturated at a concentration of 10 μg/ml, which was 
therefore used to quantify the cell surface receptor levels using the QIFI kit (Dako, 
Stockport, UK) following the manufacturer’s instructions, and analysed using a Cyan 
flow cytometer (Beckman Coulter).  
3.2.3 Total receptor expression manipulation and detection by 
immunofluorescence staining 
Serum starvation and treatment with cycloheximide or sodium butyrate were tested for 
their effect on HA-CCR2B and HA-CCR5 expression in transfected HEK293 cells. 
Cells were seeded on coverslips in a 24-well plate at 2.5 x 10
4
 cells/well and incubated 
in growth medium (DMEM, 10 % FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 
10 μg/ml blasticidin, 500 μg/ml G418) or serum-deprived medium (DMEM, 100 U/ml 
penicillin, 0.1 mg/ml streptomycin, 0.1 % BSA, 10 mM HEPES, 1 mM sodium 
pyruvate, 10 μg/ml blasticidin, 500 μg/ml  G418) at 37 °C, 5 % CO2 for approximately 
36 to 48 hours before use. When using sodium butyrate, it was added to the growth 
medium used in this step at a final concentration of 10 mM. When using cycloheximide, 
cells were first adhered to the coverslips as described and then a second incubation in 
growth medium containing 10 µg/ml cycloheximide was carried out for the indicated 
time.  
The cells were then fixed, quenched and permeabilised as described in Secion 2.7.1. 
Total HA-CCR2B or HA-CCR5 was labelled by incubation with 5 μg/ml HA.11, 
12CA5 or MC5 in saponin staining buffer for 90 minutes at room temperature. The cells 
were washed in 0.05 % saponin in PBS, and then incubated with 4 μg/ml Alexa Fluor 
conjugated secondary antibody. After washes in 0.05 % saponin in PBS and a final wash 
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in PBS containing 1 μg/ml DAPI, the coverslips were mounted on to glass slides using 
Mowiol. 
3.3 Results 
3.3.1 Characterisation of the monocytic cell line THP-1 
3.3.1.1 CCR2 and CCR5 expression 
Flow cytometry analysis using R&D α-CCR2 on non-permeabilised cells confirmed the 
presence of cell surface CCR2 on our THP-1 cells (Figure 3.2A). However, as the 
antibody recognises the N-terminus, it was not able to distinguish between the CCR2A 
and CCR2B isoforms. An antibody against the C-terminus of CCR2B (CCR2B C-20) 
was available and so this antibody and others (E68, H-40 and R&D α-CCR2) were used 
to probe THP-1 cell lysate samples by immunoblotting (Figure 3.2B). All of the 
antibodies except R&D α-CCR2 showed a large amount of non-specific binding under 
the conditions used, and  none gave a dominant band at 41 kDa, which corresponds to 
the predicted molecular weight of CCR2 based on it amino acid sequence. Other anti-
CCR2 antibodies were also tested by our lab and did not work by western blot, which 
limits the use of THP-1 cells for our study. 
Testing of a broad spectrum of antibodies against CCR5 by our lab has identified the 
presence of two forms of the receptor (the MC5 form and the CTC5 form) that show 
different membrane distribution characteristics, responses to agonist treatment and 
levels of staining on monocytes and monocytic cell lines. This investigation has found 
barely detectable levels of the MC5 form on THP-1 cells by immunofluorescence and 
flow cytometry but more staining of the CTC5 form (Figure 3.3). 
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Figure  3.2 CCR2 expression in THP-1 cells. 
(A) THP-1 cells were immunolabelled for cell surface CCR2 using R&D α-CCR2 (black) and analysed by 
flow cytometry. Other THP-1 cells were labelled with the relevant isotype control antibody (grey). (B) 10
6
 
THP-1 cells per sample were lysed in reducing sample buffer and non-boiled samples were analysed for 
the presence of CCR2 by SDS-PAGE and immunblotting using the indicated α-CCR2 antibodies. Arrows 
show the predicted molecular weight of CCR2B, based on the amino acid sequence (41 kDa).  
Figure  3.3 CCR5 expression in THP-1 cells. 
THP-1 cells were immunolabelled for cell surface CCR5 (black) using MC5 (A) or CTC5 (B) and 
analysed by flow cytometry. Other THP-1 cells were labelled with the relevant isotype control antibody 
(grey). These histograms each show a single set of representative samples from two (A) or three (B) 
separate experiments each carried out in triplicate. This figure was created using data obtained by Laura 
Fell (University of York, UK).    
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3.3.1.2 Agonist-stimulated receptor signalling 
Flow cytometry work carried out in this study and by other members of our lab has 
showed that the THP-1 cells used in this project express CCR2 and some CCR5, but are 
these receptors actually capable of signalling? One way of measuring chemokine 
receptor signalling is to monitor the intracellular calcium levels following agonist 
stimulation. This has been done successfully for human monocytes and has shown that 
both CCR2 and CCR5 respond to agonist stimulation via calcium signalling (Fox et al., 
2011), and therefore we applied the same technique to study THP-1 cells. 
For calcium signalling studies, THP-1 cells were loaded with Fluo-8 AM and changes in 
intracellular calcium concentration in response to treatment with different chemokines 
were determined by analysis of the changes in cell fluorescence at 488 nm. Treatment 
with the CCR2 agonist, CCL2, led to a spike in the intracellular calcium concentration 
representing receptor signalling (Figure 3.4C). This response was specific as treatment 
with PBS, which was used as a carrier for the chemokines, or chemokine receptor 
antagonists alone did not give a noticeable response (Figure 3.4A and 3.4B). The CCL2-
induced calcium signalling could be inhibited by pre-treatment with TAK-779 (Figure 
3.4C), which is known to antagonise CCR5 when used at low concentrations and both 
CCR5 and CCR2 at high concentrations (Baba et al., 1999). 
 Many commonly used CCR5 agonists also bind to CCR1 making it difficult to 
distinguish which receptor is responsible for signalling. To avoid this problem, my study 
used both the common agonist CCL5 in conjunction with receptor-specific antagonists 
and also a CCR5-specific agonist, CCL4. As CCL4 is a weaker CCR5 agonist than 
CCL5 (Mueller et al., 2006), a range of CCL4 concentrations from 1 nM to 40 nM was 
tested (Figure 3.4D). Treatment with CCL4 did not give any change in the intracellular 
calcium concentration at any of the concentrations tested, which suggests that the CCR5 
on THP-1 cells does not signal. The CCL4 was tested by our lab on CHO cells stably 
transfected to express CCR5 to confirm that it was capable of eliciting a response. In 
contrast, treatment of THP-1 cells with CCL5 resulted in calcium signalling (Figure 
3.4E). However, as pre-treatment with a CCR5 antagonist (TAK-779) only leads to an 
insignificant reduction in the CCL5-induced signalling (Figure 3.4E), whereas pre-
treatment with a CCR1 antagonist, UCB35625 (Sabroe et al., 2000), lead to an almost 
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complete reduction in signalling (Figure 3.4F), it is likely that in THP-1 cells the CCL5 
actually signals via its other receptor CCR1. These results were supported by those 
using the synthetic CCL5 analogue, PSC-RANTES, which gives a much stronger 
agonist response than CCL5 (Hartley et al., 2004). PSC-RANTES treatment leads to 
calcium signalling in both THP-1 cells (Figures 3.4G and 3.4H) and monocytes (Figure 
3.4I), however whereas this signalling is partially inhibited by TAK-779 in monocytes, 
TAK-779 has no inhibitory effect in THP-1 cells. In addition, the PSC-RANTES-
induced calcium signalling is inhibited by the CCR1 antagonist, UCB35625, in THP-1 
cells (Figure 3.4H). 
Taken together, these results suggest that the CCR2 present on THP-1 cells is capable of 
signalling via the calcium pathway, however the CCR5 either is not capable of 
signalling or the amount of CCR5 present that is capable of signalling is too low to give 
a detectable signal. 
3.3.1.3 Agonist-induced receptor desensitisation 
Work by other members of the lab showed that our THP-1 cells do not down-modulate 
CCR5 in response to its main agonistic ligand CCL5 (Figure 3.5) and I therefore 
concentrated on the CCR2 response in these cells. A reduction in THP-1 cell surface 
CCR2 epitope of 74 %, measured by flow cytometry, in response to 1 hour treatment 
with 100 nM CCL2 showed that the receptor is down-modulated in response to 
prolonged agonist stimulation (Figure 3.6). This level of down-modulation is slightly 
higher than previously published for CCR2 on primary human monocytes tested in 
comparable conditions (Fox et al., 2011). 
 
 
 
 
 
 
72 
 
 
 
 
 
Figure  3.4 Delineation of the receptor responsible for CCL2 and CCL5 induced calcium 
signalling in THP-1 cells and monocytes. 
THP-1 cells (A-H) or human monocytes (I) were loaded with Fluo-8 AM. After obtaining a baseline 
fluorescence reading for 30 seconds, the cells were treated with PBS, 400 nM TAK-779 or 100 nM 
UCB35625 (as controls) or the indicated concentration of chemokine. Changes in the intracellular calcium 
concentration were determined by analysis of the fluorescence of the cells on a CyAn flow cytometer 
using an argon laser at a wavelength of 488 nm. The fluorescence was normalised to the baseline to 
enable comparison between samples. Where indicated (C, E, F, G, H and I), cells were either untreated 
(medium) or pretreated with 400 nM TAK-779 or 100 nM UCB35625  for 10 minutes prior to obtaining 
the baseline fluorescence reading.  
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Figure  3.5 Lack of CCR5 down-modulation in response to agonist treatment on THP-1 
cells. 
THP-1 cells were treated with medium (black) or 100 nM CCL5 (red) for 60 minutes at 37 °C then 
immunolabeled for cell surface CCR5 using MC5 (A) or CTC5 (B) and analysed by flow cytometry. 
Other medium treated THP-1 cells were labelled with an isotype control antibody (grey). These 
histograms each show a single set of representative samples from two (A) or three (B) separate 
experiments each carried out in triplicate. This figure was created using data obtained by Laura Fell 
(University of York, UK).  
 
Figure  3.6 CCR2 down-modulation in response to agonist treatment on THP-1 cells. 
(A) THP-1 cells were treated with medium (black) or 100 nM CCL2 (red) for 60 minutes at 37 °C then 
immunolabeled for cell surface CCR2 using α-CCR2 and analysed by flow cytometry. Other medium 
treated THP-1 cells were labelled with an isotype control antibody (grey). (A) shows a single set of 
representative samples from two separate experiments each carried out in triplicate. (B) represents the 
mean ± SD down-modulation in response to medium and CCL2 treatment for these experiments. he 
receptor down-modulation (reduction in cell surface epitope availability) is expressed as a percentage of 
that observed for medium-treated cells. 
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3.3.2 Characterisation of transfected HEK293 cell lines 
3.3.2.1 CCR2B and CCR5 expression 
Transfected HEK293 cell lines were generated by nucleofection of HEK293, HEK293 
TLR1/2 and HEK293 TLR2/6 cells with constructs encoding triple-HA tagged forms of 
CCR2B and CCR5, followed by selection for expressing cells using G418, as described 
in Section 2.6. The cell surface receptor levels were tested by flow cytometry (Figure 
3.7), and quantified using the QIFI kit (Dako). The number of receptors per cell is 
reported for each transfected HEK293 cell line in Table 3.2. These values are 
comparable to those published for monocytes, which fall within the range of 1000 to 
20000 CCR2 and CCR5 receptors per cell (Denholm and Stankus, 1995; Grimm et al., 
1998; Hladik et al., 2005; Lee et al., 1999b; Mine et al., 2006; Wang et al., 1993a; Wang 
et al., 1993c; Yoshimura and Leonard, 1990; Zhang et al., 1994). Clonal populations 
were obtained for all cell lines with the exception of HEK TLR1/2 HA-CCR5. The 
presence of faster growing HA-CCR5 non-expressing cells meant that repeated 
passaging lead to an overall gradual loss of HA-CCR5 expression in this cell line over 
time.  
Table  3.2 Number of HA-CCR2B or HA-CCR5 receptors per cell estimated for the 
transfected HEK293 cells using the QIFI kit. 
 
Cell Line HA-CCR2B Receptors Per Cell HA-CCR5 Receptors Per Cell 
HEK HA-CCR2B 4718  
HEK HA-CCR5  10496 
HEK TLR1/2 HA-CCR2B 7159  
HEK TLR1/2 HA-CCR5  16527 
HEK TLR2/6 HA-CCR2B 8659  
HEK TLR2/6 HA-CCR5  6525 
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Figure  3.7 HA-CCR2B and HA-CCR5 expression in transfected HEK293 cells. 
The indicated transfected HEK293 cells were immunolabelled for cell surface receptor using HA.11 (A), 
α-CCR2 (B, CCR2-transfected cells) or MC5 (B, CCR5-transfected cells) and analysed by flow 
cytometry. Other aliquots of transfected HEK293 cells were labelled with an isotype control antibody 
(grey).  
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However, immunofluorescence imaging revealed a large accumulation of receptors in 
the biosynthetic pathway of transfected HEK293 cells as shown by intercalation of the 
receptors with TGN46 (Figure 3.8). Treating the cells with cycloheximide for up to 6 
hours, to block de novo protein synthesis (Kerridge, 1958) and enable transport of 
existing receptors through the biosynthetic pathway, reduced but did not completely 
remove the intracellular receptor accumulation (Figure 3.9). The presence of serum has 
been shown to increase the rate of protein synthesis in cells leading to accumulation of 
protein (Ballard, 1982; Kaminskas, 1972). Therefore, serum-deprivation was tested as a 
method of reducing protein synthesis to allow time for the backlog of receptors to traffic 
through the biosynthetic pathway. However, it had little effect on the intracellular 
accumulation of the receptor. Sodium butyrate is an inhibitor of histone deacetylase 
(Boffa et al., 1978; Candido et al., 1978; Sealy and Chalkley, 1978) and has been shown 
to inhibit cell growth whilst repressing the expression of some genes and enhancing the 
expression of others (Davie, 2003). Treatment with sodium butyrate enhanced the 
receptor expression both at the cell surface and intracellularly (data not shown) and so 
was not useful for reducing the biosynthetic pathway accumulation. Although 
intracellular accumulation of the expressed transfected receptor does not appear to 
impact on the growth rate or morphology of transfected cells, it does mean that assays 
need to be designed to selectively study the fate of cell surface receptors. 
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Figure  3.8 Constitutive intracellular accumulation of HA-CCR2B and HA-CCR5 in 
transfected HEK293 cells. 
The cells were co-labelled with HA.11 (HA-CCR2B, red) or MC5 (HA-CCR5, red) and TGN46 (green), 
and counterstained with DAPI (blue). Image settings are optimised for the intracellular receptor. Scale bar 
= 10 μm. Arrows indicate the location of inset 2X zoom panels. 
 
Figure  3.9 Treatment with cyclohexamide partially reduces HA-CCR2B intracellular 
accumulation in transfected HEK293 cells. 
Cells were untreated or treated with 10 μg/ml cycloheximide for 6 hours before fixation and 
permeabilisation. HA-CCR2B was labelled using HA.11 (grey) and cells were counterstained with DAPI 
(blue). Scale bar = 10 μm. Arrows indicate intracellular accumulation of HA-CCR2B. 
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3.3.2.2 Comparative analysis of CCR2B and CCR5 internalisation in response to 
agonist treatment 
Both receptors are internalised in all of the transfected HEK293 cell lines in response to 
1 hour agonist treatment as shown by flow cytometry and immunofluorescence assays 
(Figures 3.10, 3.11A, 3.12). The reduction in cell surface epitope measured by flow 
cytometry was used as a measure of the receptor down-modulation. In response to 1 
hour agonist treatment, between 51 % and 80 % down-modulation was observed for 
CCR2B and CCR5 in the different cell lines (Table 3.3, Figure 3.10). These down-
modulation levels are comparable to those published for primary human monocytes 
(Fox et al., 2011) and similar to the CCR2 down-modulation level measured on THP-1 
cells.   
Binding of some chemokines to their receptors can mask the epitope recognised by the 
antibody (Klasse et al., 1999; Navenot et al., 2001). N-terminal residues of CCR2 and 
CCR5 have been reported to contribute to high affinity binding of their chemokine 
ligands (Bannert et al., 2001; Blanpain et al., 1999; Datta-Mannan and Stone, 2004; 
Hemmerich et al., 1999; Monteclaro and Charo, 1996, 1997). The antibodies used in my 
experiments (R&D α-CCR2 and MC5) bind to the N-termini of the two receptors. 
Therefore, to confirm that binding of the ligands used in this experiment (CCL2 and 
CCL5) does not affect the binding of these antibodies, the assay was repeated using 
HA.11, a monoclonal antibody recognising the triple HA tag added at the N-terminus, 
and which should not be implicated in ligand binding.  Indeed with HA.11, very similar 
down-modulation values, 69 % for CCR2B and 45 % for CCR5, were observed (Figure 
3.10B) implying that epitope masking is not an issue. 
Any replenishment of cell surface receptor from internal stores could reduce the level of 
down-modulation observed by flow cytometry. An endocytosis immunofluorescence 
assay, in which cell surface receptors were pre-labelled with HA.11 antibody prior to 
treatment of the cells with chemokine, enabled us to only follow the fate of cell surface 
receptors. This assay shows that the majority of both cell surface receptors are 
internalised in response to 60 minutes of agonist treatment, however we observed a 
difference in the localisation of internalised receptors (Figure 3.11A and 3.12). HA-
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CCR5 is seen clustered in the perinuclear area, as previously described for human 
monocytes (Fox 2011) and other transfected cells (Signoret et al., 2000). Conversely, 
internalised HA-CCR2B appears to be present in vesicles spread out in the cytoplasm 
and does not accumulate into perinuclear structures or colocalise with TGN46 as has 
been reported for CCR5 (Escola et al., 2010).   
 
Figure  3.10 Down-modulation of cell surface receptors in response to agonist treatment. 
The indicated transfected HEK293 cells were treated with medium or 100 nM agonist (CCL2 for HA-
CCR2B and CCL5 for HA-CCR5) for 60 minutes at 37 °C then immunolabeled for cell surface receptor 
expression using antibodies to the receptor itself [R&D α-CCR2 or MC5, (A)] or to the HA-tag [HA.11, 
(B)] and analysed by flow cytometry. The receptor down-modulation (reduction in cell surface epitope 
availability) is expressed as a percentage of that observed for medium-treated cells. (A) represents the 
means ± SD of the indicated number of separate experiments each carried out in triplicate. (B) represents 
the means ± SD of single experiments carried out in triplicate. 
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Table  3.3 Level of down-modulation in response to 60 minute agonist (CCL2 or CCL5) 
stimulation measured by flow cytometry for the different transfected HEK293 cell lines. 
 
 
 
 
 
 
 
 
Figure  3.11 (A) Differential localisation of internalised HA-CCR2B and HA-CCR5 upon 
agonist treatment in transfected HEK293 cells. (B) Lack of colocalisation of internalised 
HA-CCR2B with TGN46. 
(A) The receptors were pre-labeled using HA.11 (HA-CCR2B, grey) or MC5 (HA-CCR5, grey) and the 
cells were either untreated or treated with 100 nM CCL2/CCL5 for 1 hour at 37 °C. Scale bar = 10 μm. 
(B) HA-CCR2B was pre-labeled using HA.11 (red) and the cells were treated with 100 nM CCL2  for 60 
minutes at 37 °C. After fixation the cells were co-labelled with TGN46 (green) and counterstained with 
DAPI (blue). Scale bar = 10 μm. 
Cell Line % Down-modulation (mean ± SD) 
HEK HA-CCR2B 72 ± 6     n=3 
HEK HA-CCR5 51 ± 6     n=3 
HEK TLR1/2 HA-CCR2B 66 ± 7     n=2 
HEK TLR1/2 HA-CCR5 80 ± 3     n=2 
HEK TLR2/6 HA-CCR2B 67 ± 14   n=3 
HEK TLR2/6 HA-CCR5 78 ± 8     n=2 
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Figure  3.12 Internalisation of HA-CCR2B and HA-CCR5 upon agonist or LTA treatment 
in transfected HEK293 cells. 
The receptors were pre-labeled using HA.11 (HA-CCR2B, grey) or MC5 (HA-CCR5, grey) and the cells 
were either untreated or treated with 100 nM CCL2/CCL5 or 10 µg/ml LTA as indicated for 1 hour at 37 
°C. Cells were counterstained with DAPI. Scale bar = 10 μm. 
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3.3.2.3 Cross-talk between TLR2 and CCR2B/5 
The effect of LTA on HA-CCR2B and HA-CCR5 cell surface expression in transfected 
HEK293 cells was investigated to determine if these cells could be used to further 
dissect the TLR2/CC chemokine receptor cross-talk pathway discovered in monocytes 
(Fox et al., 2011). Some limited internalisation in response to 1 hour LTA treatment is 
observed for all of the transfected HEK293 TLR2 cell lines using the 
immunofluorescence endocytosis assay (Figure 3.12). However, unlike in monocytes, 
where the LTA-induced CCR5 internalisation is similar to that following agonist-
stimulation (Fox et al., 2011), the LTA-induced changes in HA-CCR2B and HA-CCR5 
receptor distribution are discrete with only few vesicles observed inside the transfected 
HEK293 cells. Although in monocytes the LTA-induced CCR2/5 internalisation follows 
a slower kinetic than agonist-induced internalisation (Fox et al., 2011), in transfected 
HEK293 cells the LTA-induced CCR2/5 internalisation is not increased by longer (2 
hour) treatment (data not shown). Additionally, CCR5 internalised in response to 1 hour 
LTA treatment appears to be in vesicles in the cytoplasm (Figure 3.12), not clustered at 
the perinuclear area as is described in monocytes (Fox et al., 2011). The LTA-mediated 
CCR2 and CCR5 down-modulation observed in human monocytes was concentration 
dependent, with 10 µg/ml LTA resulting in 30 – 40 % receptor down-modulation (Fox 
et al., 2011). Therefore, flow cytometry was used to assess the level of down-
modulation in the presence of different concentrations of LTA in the transfected 
HEK293 cells. In contrast to the immunofluorescence data, there was no down-
modulation of cell surface HA-CCR2B or HA-CCR5 levels following a 1 hour treatment 
with a range of LTA concentrations (0.5 µg/ml – 50 µg/ml) (Figure 3.13B). To check if 
the lack of cross-talk is TLR2 ligand specific, another receptor agonist, Pam3CSK4, was 
tested on HEK TLR1/2 HA-CCR2B and HEK TLR2/6 HA-CCR2B. Unlike for LTA, 
dose-dependent down-modulation of CCR2 was observed at relatively high Pam3CSK4 
concentrations in both cell lines (Figure 3.13C) with an average of 43 % (HEK TLR1/2 
HA-CCR2B) or 25 % (HEK TLR2/6 HA-CCR2B) down-modulation following 
treatment with 20 µg/ml Pam3CSK4. These results suggest that the TLR2 is functional 
and that a TLR2-CCR2B cross-talk pathway is present but it may be ligand-dependent 
and may not fully reproduce what is seen in monocytes. 
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Figure  3.13 Comparison of cell surface receptor down-modulation in response to agonist, 
LTA and Pam3CSK4 treatment. 
The indicated transfected HEK293 cells were treated with medium, 100 nM agonistic ligand (A), varying 
concentrations of LTA (B) or varying concentrations of Pam3CSK4 (C) as indicated for 60 minutes at 37 
°C then immunolabeled for cell surface receptor using antibodies to the receptor (α-CCR2 or MC5) or 
isotype control antibodies and analysed by flow cytometry. The histograms shown are representative of at 
least two experiments (except HEK TLR1/2 HA-CCR2B treated with LTA) carried out in triplicate, with 
the exception of treatment with 40 μg/ml Pam3CSK4, for which a single sample was used. 
3.3.2.4 Receptor signalling 
As LTA did not appear to cross-talk with CCR2 and CCR5 on the transfected HEK293 
TLR2 cell lines, experiments were carried out to check if the TLR2 is functional for 
calcium signalling using the calcium flux technique that was successfully employed for 
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THP-1 cells. Each cell line was tested at least twice, often with multiple replicates in 
each test, however, the results were inconclusive.  The HA-CCR2B expressing cell lines 
gave some response to LTA stimulation but the HA-CCR5 expressing versions did not. 
Additionally, both transfected HEK293 TLR2 cell lines expressing HA-CCR2B 
responded to CCL2 stimulation in some but not all replicates, however, no response to 
CCL5 was detected for either HEK293 TLR2 cell line expressing HA-CCR5. This 
variability and inconsistency mean that no conclusions about the calcium signalling 
abilities of these cells can be drawn from this study. Work carried out during this thesis 
has shown that the large, adherent HEK293 cells are less suited to flow cytometry than 
the smaller non-adherent THP-1 cells, as they are often easily damaged during the 
procedure leading to a higher proportion of dead cells and so calcium imaging may be a 
better technique. HEK293 cells are often easily damaged by the mechanical stresses 
introduced by the procedure, such as detachment and declumping by manual pipetting, 
and the physical forces on the cell created by the flow rate necessary for dectection 
using a flow cytometer. This is evidenced by the relatively high proportion of dead cells 
and the leak of the Fluo-8 AM dye over time. 
3.4 Discussion  
Neither of the two cell options discussed here, the monocytic cell line THP-1 or 
transfected HEK293 cells, offer a complete solution for studying the aims of this thesis, 
however they can each be used to answer specific questions. 
Based on the calcium signalling study, the CCR5 present on our THP-1 cells does not 
appear to be functional. This is in agreement with other studies carried out in our group 
showing that our THP-1 cells do not migrate in response to CCR5 specific stimulation. 
These findings suggest that our THP-1 cells are not suitable for studying processes 
downstream of CCR5 agonist stimulation or cross-talk of this receptor with TLR2. In 
the limited studies carried out by our group, another monocytic cell line, MonoMac1, 
was tested and also appears to have low CCR5 functionality suggesting that monocytic 
cell lines may not be good models for studying CCR5. However, based upon the 
positive CCR2 expression, calcium signalling and down-modulation results, THP-1 cells 
can be used to study some aspects of CCR2 down-modulation/desensitisation in 
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response to agonist stimulation using flow cytometry but not immunofluorescence or 
immunoblotting methods with the antibodies currently available.  
THP-1 cells have been cultured and used by many groups since their original 
development over thirty years ago. THP-1 cells can be differentiated towards more 
macrophage-like phenotypes by stimulation with phorbol myristate acetate (PMA) or 
vitamin D (Daigneault et al., 2010). However, it has also been shown that continuous 
culture of THP-1 cells can lead to changes in the cellular characteristics, such as 
adherence (Tominaga et al., 1998; Tsuchiya et al., 1982), suggesting that the THP-1 
cells used in different laboratories may not be exactly the same. This potential 
heterogeneity of THP-1 cells may give an explanation for the conflicting reports on 
CCR5 expression on THP-1 cells detailed in the introduction to this chapter. Our THP-1 
cells were purchased directly from the ATCC and were not subjected to any conditions 
known to induce uncontrolled differentiation. 
Transfected HEK293 cells can be used to compare the agonist-induced desensitisation 
and associated intracellular trafficking of both receptors. The intracellular localisation of 
internalised CCR5 agrees with what has been published for monocytes. Internalised 
CCR2B localises differently to CCR5 however this appears to be a general 
phenomenon, not just a result of expression in HEK293 cells, as a similar pattern has 
been observed in the nerve astrocyte cell line A7 (Minsaas et al., 2010). This group also 
reported an agonist-induced change from uniform cell surface to punctate CCR2 
staining in their THP-1 cells suggestive of internalisation, but the nature of these 
intracellular vesicles has not been determined. 
HEK293 cells are more suitable than THP-1 for further immunofluorescence studies of 
receptor intracellular trafficking due to their larger size, volume of cytoplasm and 
cleaner staining using the α-HA antibody HA.11 than some of the anti-CCR2 antibodies 
available commercially. The initial chemokine receptor transfections showed that the 
HEK293 cells give a reproducible sufficient transfection efficiency of approximately 30 
% and so dominant negative and consitutively active forms of proteins involved in 
intracellular trafficking, such as Rabs, can be easily expressed to investigate their 
involvement in trafficking of the receptors.  
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This study also showed that whilst HEK293 cells can be analysed by flow cytometry, 
they are not well suited for this technique. Therefore, for studies of CCR2 it would be 
useful to use THP-1 that endogenously express CCR2 for flow cytometry studies to 
provide complementary information. 
Neither the THP-1 cell line, due to the lack of CCR5 functionality, nor the transfected 
HEK293 cells are suitable for the study of LTA-induced TLR2 cross-talk with both 
CCR2 and CCR5. There could be multiple reasons for the different LTA response 
observed in the transfected HEK293 TLR2 cells lines and monocytes. Firstly, 
transfected HEK293 TLR2 cells may be missing a part of the LTA-induced TLR2-
CCR2/5 cross-talk pathway as the pathway is yet to be fully identified but has been 
shown to be independent of the canonical TLR2 signalling via TIRAP and instead to 
involve PLC and Rac1 (Fox et al., 2011). As a non-moncytic cell line, HEK293 cells, do 
not endogenously express either TLR2 or chemokine receptors and so may not express 
all the members of the signalling pathways associated with the receptors and required 
for cross-talk.  
As is observed for agonist-stimulated cells, CCR5 is also phosphorylated on the GRK-
specific phosphorylation site S349 in response to LTA-stimulation, however, the 
phosphorylation follows a slower kinetic (Fox et al., 2011). This suggests that one or 
more GRK is involved in the LTA-induced cross-desensitisation of the chemokine 
receptor. Overexpression of various GRKs can lead to agonist-induced phosphorylation 
of CCR5, however, it is thought that GRK2 and GRK3 are the main GRKs that 
phosphorylate CCR5 in cells where they are endogenously expressed (Oppermann, 
2004). Additionally, CCR2 is also phosphorylated by GRK2 during agonist-induced 
desensitisation (Aragay et al., 1998) and GRK2 has been implicated in the TLR2-
mediated down-modulation of CXCR2 (Alves-Filho et al., 2009). GRK2 and GRK3, but 
not GRK5 or GRK6, are highly expressed in human monocytes (Olbrich et al., 1999). In 
contrast, a recent study (Atwood et al., 2011) carried out microarray analysis of mRNA 
levels of GPCR related signalling proteins in HEK293 cells and showed that they 
express detectable mRNA for GRK3, GRK4 and GRK5 but not for GRK1 and GRK2. 
Therefore, the potential involvement of GRK2 may explain the lack of LTA-induced 
cross-desensitisation of CCR2B and CCR5 in transfected HEK293 cells. 
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The ratio of chemokine receptor to TLR2 molecules present in monocytes may be a 
limiting factor for cross-desensitisation and this is unlikely to be conserved in the 
transfected HEK293 cell lines. Indeed, the chemokine receptor level does differ slightly 
between the cell lines. Additionally, CCR2 has been shown to hetero-oligomerise with 
CCR5, CXCR4 and various other GPCRs (see Bennett et al., 2011 for review) that are 
not expressed in HEK293 cells and such hetero-oligomerisation could be relevant to 
cross-desensitisation by TLR2. It is possible that the spatial arrangement of the 
transfected receptors in the HEK293 cell plasma membrane differs from that of 
endogenous receptors in monocytes.  
Secondly, mouse TLR2, despite displaying good homology to human TLR2 and binding 
the same ligands, may not be capable of cross-desensitisation of human chemokine 
receptors. Thirdly, it is possible that the LTA-induced TLR2-CCR2/5 cross-talk 
pathway is present but less efficient in transfected HEK293 TLR2 cells than in 
monocytes. If this is the case, it is possible that rapid replenishment of the internalised 
cell surface receptor from the large intracellular accumulation of receptors at the trans-
golgi network could provide an explanation for the conflicting results seen by 
immunofluorescence endocytosis experiments and flow cytometry down-modulation 
experiments. However, this is unlikely, as in transfected HEK293 cells agonist-induced 
CCR2 and CCR5 down-modulation levels are similar to or higher than those observed in 
monocytes, suggesting that replenishment of cell surface receptor from the intracellular 
stores does not have a major impact. However, as LTA-induced internalisation of CCR2 
and CCR5 follows a slower kinetic than that of agonist-induced internalisation, 
replenishment from intracellular stores could have more influence, although this is 
probably not the full explanation. 
Although no down-modulation was observed in response to LTA by flow cytometry, 
some down-modulation of CCR2 was observed when using high concentrations (≥ 20 
μg/ml) of Pam3CSK4, a ligand that has been suggested to cross-talk with CCR2 via two 
pathways that differ from that described for LTA cross-regulation on monocytes (Fox et 
al., 2011). These are down-regulation of CCR2 at the RNA transcript level (McKimmie 
et al., 2009) and induction of autocrine chemokine production that results in down-
modulation of CCR2 (Parker et al., 2004). It is possible that HEK293 cell express the 
machinery for one but not all of these pathways. 
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4 Characterisation of agonist-induced CCR2B trafficking 
4.1 Introduction 
4.1.1 Desensitisation of chemokine receptors as a consequence of agonist 
activation 
Following agonist binding,  the intracellular signalling cascade results in rapid 
phosphorylation of the receptor’s cytoplasmic tail, usually by a member of the G protein 
receptor kinase (GRK) family, which uncouples the G protein from the receptor and 
prevents further activation. Phosphorylated receptors interact with one of the β-arrestins 
acting as a scaffold targeting receptors for internalisation via clathrin-mediated 
endocytic pathways. Caveolin-mediated and other clathrin-independent endocytic 
pathways have also been reported (Borroni et al., 2010). The internalised receptors then 
traffic through the endocytic pathway and are either sent for degradation or recycled to 
the cell surface. Different chemokine receptors follow either uniquely one route or 
different pathways depending on a number of influencing factors. Although the 
trafficking trend appears conserved between chemokine receptors, the mechanisms 
involved vary and thus cannot be considered generic. 
4.1.2 Overview of CCR5 trafficking pathways following chemokine agonist 
treatment 
As CCR5 acts as a HIV co-receptor, a wide range of tools are available and so its 
trafficking in response to ligand stimulation has been well studied. It has been shown 
that CCR5 is internalised via clathrin-mediated endocytosis to early endosomes 
(Signoret et al., 2005), although in some cell types there may be a contribution of 
clathrin-independent internalisation pathways (Mueller et al., 2002a; Venkatesan et al., 
2003). Once internalised, CCR5 enters recycling endosomes from which it returns to the 
plasma membrane without entering the degradative pathway (Signoret et al., 2000). 
4.1.3 Current knowledge of CCR2B trafficking pathways 
CCR2 has been shown to be internalised in response to stimulation with its main ligand 
CCL2 in monocytes (Fox et al., 2011), astrocytes (Andjelkovic et al., 2002) and several 
transfected cell lines (Minsaas et al., 2010). In the previous chapter, I showed that HA-
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CCR2B expressed in transfected HEK293 cell lines also internalised in response to 
CCL2, as expected. It has been suggested that CCR2 internalisation involves both 
clathrin-mediated and caveolar endocytic pathways, and that dynamin (Garcia Lopez et 
al., 2009) and filamin A (Minsaas et al., 2010) are important for the endocytosis. 
Unfortunately, the antibodies and tools available for studying CCR2B are more limited 
than for CCR5 and thus relatively little is known about post-endocytic trafficking of 
CCR2B. However, the differential localisation of internalised HA-CCR2B and HA-
CCR5 observed in transfected HEK293 cells, as reported in the previous chapter, 
suggests that the intracellular routes followed by these two receptors may not be 
comparable. A study using Cherry-CCR2B showed colocalisation with the early 
endosome marker, early endosome antigen 1 (EEA1) and the lysosomal marker Lamp1 
(Garcia Lopez et al., 2009), however this receptor was tagged with the large cherry tag 
on the C-terminus and it has been shown that the C-terminal cytoplasmic tail plays an 
important role in the intracellular trafficking of chemokine receptors (see Bennett et al., 
2011 for review). This highlights the requirement for further study of CCR2B using 
complementary conditions.  
4.1.4 Objectives 
The main objective of this chapter was to characterise the intracellular trafficking of 
CCR2B in response to stimulation with CCL2, and to compare it to that of CCL5-treated 
CCR5. These objectives were carried out using HEK293 cells transfected to stably 
express HA-CCR2B or HA-CCR5.  
4.2 Relevant Methodolgy 
4.2.1 Transferrin/EGF uptake  
Fluorescent transferrin and epidermal growth factor (EGF; both from Molecular Probes) 
were used for colocalisation assays. 25 μg/ml transferrin-488 or transferrin-594 or 2 
μg/ml EGF-488 was added to the binding medium at the same time as the chemokine.  
4.2.2 Recycling assay 
Recycling assays using THP-1 and HEK HA-CCR2B cells were carried out in triplicate 
whereas recycling assays using HEK HA-CCR2B cells transiently transfected to express 
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GFP or Rab4s used single replicates. HEK HA-CCR2B cells were either used directly or 
transiently transfected to express YFP-tagged wild type Rab4 (Rab4WT), dominant 
negative Rab4 (Rab4N121I), constitutively active Rab4 or, as a control, GFP as 
described in Section 2.6.1. Adhered HEK HA-CCR2B cells were treated with either 
binding medium alone or in the presence of 100 nM CCL2 for 60 minutes at 37 °C. The 
cells were then subjected to an acid-strip wash to remove cell-surface bound CCL2. The 
acid strip wash consisted of two rinses in ice-cold pH3.5 elution medium followed by 
two 3-minute washes in pH3.5 elution medium and then neutralisation using binding 
medium at pH7.1. At this point, samples of CCL2-treated (i) and non-chemokine-treated 
(ii) cells were detached and immunolabelled for cell-surface CCR2 using R&D α-CCR2 
or using an irrelevant mouse IgG2b as an isotype control. Some CCL2-treated samples 
(iii) were further incubated in binding medium at 37 °C for 60 minutes, to enable cell-
surface CCR2 recovery, prior to immunolabelling as described in Section 2.8.2. THP-1 
cells were treated with either either binding medium alone or in the presence of 100 nM 
CCL2 for 60 minutes at 37 °C. The cells were then subjected to an acid-strip wash to 
remove cell-surface bound CCL2. The acid strip wash consisted of two 3-minute washes 
in pH3.5 elution medium and then neutralisation using binding medium at pH7.1. For 
non-stripped cells, the same washes were carried out using binding medium. Non-
chemokine-treated cells were then incubated again in binding medium at 37 °C for 60 
minutes (ii). CCL2 treated cells were further incubated in 100 nM CCL2 (i), binding 
medium (iii) or with 400 nM TAK-779 at 37 °C for 60 minutes. Cells were 
immunolabelled for cell surface CCR2 using R&D α-CCR2 as described above. 
The cell surface expression for samples (i) and (iii) was expressed as a percent of the 
expression in samples (ii), and the recycling was expressed as fold recovery of cell-
surface CCR2 expression during the recycling period, i.e., (cell surface expression of 
[iii])/(cell surface expression of [i]). For experiments using HEK HA-CCR2B cells 
transiently transfected to express YFP-tagged Rab4s or GFP, the ratio of recycling in 
FITC positive cells compared to FITC negative cells within the same sample was 
calculated. 
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4.2.3 CCR2 degradation assay 
HEK HA-CCR2B cells were seeded in a 24-well plate at 7 x 10
5
 cells/well and 
incubated at 37 °C, 5 % CO2 for 24 hours. The medium was replaced with growth 
medium containing 10 µg/ml cycloheximide and the cells were incubated at 37 °C, 5 % 
CO2 for 4 hours. A sample was taken after four hours for T0 and then the medium was 
replaced with binding medium containing 10 µg/ml cycloheximide with or without 100 
nM CCL2 and the cells were incubated for the indicated time. Cells were then lysed in 
non-reducing sample buffer and analysed by SDS-PAGE and western blotting using 
HA.11 as described in Section 2.9. Densitometry analysis of the three HA-CCR2B 
bands and a loading control was carried out using ImageJ following the protocol from 
Luke Miller (http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-
with-image-j/). Briefly, the relative density profile plots of identically sized boxes 
containing the loading control bands were measured. After removal of background noise 
by closing off peaks, the peak area of each band was calculated as a percentage of the 
total area of all measured peaks. The T0 peak was used as the standard and assigned a 
relative density of 1. All other peaks were assigned relative densities based on 
comparison of their peak area to that of T0. This analysis was repeated with the HA-
CCR2B bands. Finally, each HA-CCR2B band relative density was divided by the 
appropriate loading control relative density to give an adjusted density, which was then 
expressed as a percentage showing the percentage of the intial receptor present at T0 
that remained at the timepoint tested.  
4.2.4 Testing for post-translational modifications of HA-CCR2B 
To test for PKC-mediated phosphorylation, HEK HA-CCR2B cells from one 90 % 
confluent well of a 24 well plate were either untreated or pre-treated with 5 µM 
GF109203X (bisindolylmaleimide, PKC inhibitor) or 100 ng/ml PMA for 60 minutes at 
37 °C, 5 % CO2. The cells were washed in PBS and lysed by scraping into 1 % NP-40 
lysis buffer containing a protease inhibitor cocktail, left to incubate for 20 minutes on 
ice and centrifuged at 13000 xg to remove unbroken cells. Samples were analysed by 
SDS-PAGE and western blotting using HA.11 to detect HA-CCR2B as described in 
Section 2.9. 
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To test for glycosylation, HEK HA-CCR2B cells from one 70 % confluent well of a 24 
well plate were either  untreated or pretreated with DMSO, 10 µg/ml tunicamycin or 2 
mM benzyl α-N-Acetylgalactosamine (GalNAc) for 24 hours at 37 °C, 5 % CO2. The 
cells were then lysed as described above and, where indicated, the cell lysate was 
incubated with 50 mU neuraminidase for 20 hours at 37 °C. Samples were analysed by 
SDS-PAGE and western blotting using HA.11. 
4.2.5 Detection of ubiquitinated chemokine receptors 
The immunoprecipitation (IP) protocol for detection of ubiquitinated chemokine 
receptors was adapted from a protocol by Marchese et al. (Marchese 2009), using an 
antibody against the FLAG tag on the transiently expressed ubiquitin. HEK and HEK 
HA-CCR2B cells were plated in a 24-well plate at 2 x 10
5
 cells/well and incubated at 37 
°C, 5 % CO2 for 24 hours before transfection with pcDNA3.1 FLAG-Ub using 
jetPRIME
TM
 reagent to give HEK, HEK HA-CCR2 and FLAG-Ub and HEK FLAG-Ub 
cells. 24 hours later, 4 wells per sample were washed in PBS and scraped into 400 µl 
ubiquitination lysis buffer and incubated at 4 °C for 30 minutes followed by 10 s 
sonication at 20 % amplitude and centrifugation to removed unbroken cells and debris. 
The cell lysate was pre-incubated with 10 µg of the FLAG M2 antibody for 1 hour at 4 
°C, then a 10 µl bed volume of Amintra protein G-coated agarose beads (Expedeon, 
Harston, UK) was added and incubated for a further 1 hour at 4 °C. Following two 
washes with lysis buffer, bound proteins were eluted by incubation with reducing 
sample buffer for 30 minutes and then analysed by SDS-PAGE and western blotting 
with both HA.11 and FLAG M2. 
4.2.6 Subcellular fractionation 
Two 70 % confluent 10 cm plates of HEK HA-CCR2B were used for each experiment. 
The cells were either untreated, to study the normal state of the receptor, or treated with 
100 nM CCL2 in binding medium for 30 minutes at 37 °C, to study the agonist-
stimulated receptor. The cells were washed in ice-cold PBS and homogenization 
medium containing a protease inhibitor cocktail and then scraped into homogenization 
medium and lysed by 35 - 40 passes through a ball bearing homogenizer (Isobiotech, 
Heidelberg, Germany) with a 12 µm clearance. A 10.5 ml 1 – 22 % continuous Optiprep 
gradient was prepared by over-layering equal volumes of 1 %, 8 %, 15 % and 22 % 
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Optiprep solutions into a thinwall polyallomer tube (Beckman Coulter) and incubating 
at 4 °C for 14 hours to enable diffusion. The cell lysate was loaded on to the top of this 
gradient and centrifuged at 200000 xg, 3 hours, 4 °C in an Ultra Beckman X100 
(Beckman Coulter). 1 ml or 0.5 ml fractions were harvested manually by aspiration from 
the meniscus using a 1 ml Gilson pipette. Non-reducing sample loading buffer was 
added to 100 µl aliquots to lyse the organelles and the samples were frozen at – 80 °C 
and later analysed by SDS-PAGE on a 10 % acrylamide gel followed by western 
blotting with antibodies against the HA-tag and various organelle and intracellular 
trafficking pathway markers. Up to four replicate gels were run for each experiment and 
the membranes were cut into sections for analysis with different antibodies. 
Densitometry analysis of the marker and HA-CCR2B bands present in each fraction was 
carried out as described in Section 4.2.3, except that no loading control was used and the 
most intense band for each set of marker/HA-CCR2B bands was used as the standard. 
An identical control Optiprep gradient loaded with homgenisation medium instead of 
sample was harvested in the same way and used to measure the refractive index of each 
fraction using an Abbe 5 refractometer (Bellingham and Stanley Ltd, Kent, UK). This 
data was plotted using GraphPad Prism 5 to check the linearity of the gradient. 
4.3 Results 
4.3.1 Agonist-induced CCR2B internalisation 
4.3.1.1 Time course of CCR2B internalisation 
The agonist-induced internalisation of CCR2B and CCR5 was described in the previous 
chapter. An initial time course experiment was carried out to assess the time taken for 
internalisation and how the internalised CCR2B intracellular localisation changes over 
time. Pre-labelling of cell surface HA-CCR2B on HEK HA-CCR2B cells with HA.11 
was used to follow the internalisation of cell surface receptor in response to treatment 
with 100 nM CCL2 for up to 60 minutes (Figure 4.1). In untreated cells only cell surface 
HA-CCR2B staining is observed. After 5 minutes of treatment, vesicular staining at the 
edge of the cell starts to become apparent. At 15 minutes many of these vesicles can be 
seen further inside the cell and by 30 and 60 minutes of treatment the majority of the 
HA-CCR2B is internalised. The kinetics of CCR2 internalisation on monocytes have not 
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been fully described, however, the internalisation time course shown in Figure 4.1 is 
comparable to that observed for CCR2 in other cell types including THP-1 (Andjelkovic 
et al., 2002; Dzenko et al., 2001; Garcia Lopez et al., 2009; Wang et al., 1993a) and for 
CCR5 on monocytes (Fox et al., 2011). 
 
Figure  4.1 Internalisation time course of HA-CCR2B in HEK HA-CCR2B cells. 
HA-CCR2B was pre-labeled using HA.11 (grey) and the cells were either untreated or treated with 100 
nM CCL2 for the indicated time at 37 °C. Scale bar = 10 μm.  
4.3.1.2 Route of CCR2B internalisation 
Immunofluorescence colocalisation studies and flow cytometry down-modulation assays 
coupled with various drug and inhibitor treatments were used to address the clathrin or 
lipid dependency of the HA-CCR2B down-modulation process. 
The HA-CCR2B down-modulation level of cells pre-treated with the clathrin-mediated 
endocytosis inhibitor ikarugamycin (Luo et al., 2001) was measured by flow cytometry 
and found to be significantly reduced compared to the DMSO control (Figure 4.2). This 
result agrees with the reduction in the down-modulation level observed following pre-
treatment with 0.4 M sucrose (Figure 4.2), which has been previously used to show 
clathrin-dependency for endocytosis of various chemokine receptors (Bruhl et al., 2003; 
Luker et al., 2010; Otero et al., 2006; Rose et al., 2004). Transferrin uptake has been 
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extensively studied and has been shown to proceed mainly via clathrin-mediated 
endocytosis of the molecule and its receptor (Harding et al., 1983). The 
immunofluorescence endocytosis assay, used previously for the time course in Section 
4.3.1.1, was repeated and the cells were treated with fluorescent transferrin in addition 
to CCL2. Partial colocalisation of internalised HA-CCR2B with fluorescent transferrin 
was observed at early time points following agonist stimulation (Figure 4.3), supporting 
the suggestion that endocytosis of HA-CCR2B may be clathrin-dependent.  
However, flow cytometry assays using inhibitors of the cholesterol-dependent pathways 
showed different impacts of the drugs on the level of HA-CCR2B down-modulation, 
and results can be interpreted in two different ways. Pre-treatment with the cholesterol-
extracting drug methyl-β-cyclodextrin (Klein et al., 1995) leads to a large reduction in 
the down-modulation in response to agonist treatment (Figure 4.2). A smaller reduction 
is also observed following treatment with nystatin, which binds to and sequesters 
cholesterol (Smart and Anderson, 2002). However, pretreatment with filipin, another 
cholesterol sequestering drug (Smart and Anderson, 2002), had no effect on the down-
modulation. These results could be due to the difference in the stringency of the 
inhibitors. Filipin and nystatin are less stringent than methyl-β-cyclodextrin as they 
disrupt but do not completely remove cholesterol from the membrane and so they may 
not have a sufficient effect on the lipid composition to impact much on the receptor 
down-modulation. The concentration of cholesterol modulating drugs requires careful 
optimisation for each cell type (Smart and Anderson, 2002) and thus the conditions used 
for filipin treatment may have been less suitable than those used for methyl-β-
cyclodextrin and nystatin. The removal or oxidation of cholesterol  can impact on the 
conformation of receptors and thus has been shown to affect ligand binding to some 
chemokine receptors including CCR5 (Nguyen and Taub, 2002; Nguyen and Taub, 
2003a, b; Signoret et al., 2005). The reduction in agonist-induced down-modulation 
observed following methyl-β-cyclodextrin treatment could be an indirect effect due to a 
reduction in agonist-binding. 
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Figure  4.2 Effect of endocytosis inhibitors on receptor down-modulation. 
Stably transfected HEK HA-CCR2B cells pretreated with  the indicated drug for 60 minutes at 37 °C were 
treated with medium (black histogram) or 100 nM CCL2 (coloured histogram) in the presence of the drug 
for 60 minutes at 37 °C then immunolabeled for cell surface HA-CCR2B using R&D α-CCR2 or the 
relevant isotype control antibody and analysed by flow cytometry. The % of receptor down-modulation 
(reduction in cell surface epitope availability) is expressed as a percentage of that observed for medium-
treated cells. (A) shows histograms of individual replicates from a single experiment performed in 
triplicate and all of the mean down-modulations ± SD from that experiment are summarised in (B). (C) 
represents the means ± SD of two separate experiments each carried out in triplicate. A 1-way ANOVA 
followed by a Bonferroni multiple comparisons test was used to compare drug and control treated cells. *, 
p<0.05. 
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Figure  4.3 Colocalisation study using HEK HA-CCR2B cells and fluorescent transferrin. 
HA-CCR2B was pre-labeled using HA.11 (red) and the cells were treated with 100 nM CCL2  and 25 
µg/ml transferrinn-488 (green) for the indicated time at 37 °C. The cells were counterstained with DAPI 
(blue). Scale bar = 10 μm. Open arrow heads indicate examples of colocalisation. 
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4.3.1.3 CCR2B trafficking to early endosomes 
Immunofluorescence colocalisation studies were carried out using two different 
markers, EEA1 and transferrin, to investigate how HA-CCR2B traffics through the 
endocytic pathway following agonist stimulation. The majority of the internalised HA-
CCR2B colocalises with EEA1 at 5 minutes after agonist stimulation (Figure 4.4) 
suggesting that internalised HA-CCR2B traffics to early endosomes. Additionally, at 5 
minutes a large proportion of the internalised HA-CCR2B colocalises with internalised 
fluorescent transferrin (Figure 4.3) confirming that the receptor is in the early endocytic 
pathway. Partial colocalization of HA-CCR2B and EEA1/transferrin is seen at later time 
points and this gradually decreases over time with the HA-CCR2B and EEA1/transferrin 
dots moving from being completely overlapping to being adjacent to each other (Figures 
4.3 and 4.4).  
4.3.2 Agonist-induced CCR2B recycling 
4.3.2.1 Colocalisation with transferrin pathway and Rab4 
CCR5 is known to recycle via the recycling endosome to the cell surface following 
internalisation induced by its natural ligands. As the intracellular localisation of 
internalised CCR2B is different to that of CCR5 as described in the previous chapter, 
experiments were carried out to see what impact this has on the eventual fate of the 
receptor. Endocytosed transferrin and its receptor are recycled by both a rapid and a 
slow recycling pathway (Hopkins et al., 1994) and therefore fluorescent transferrin is 
commonly used as a marker for receptor recycling. In this study HEK HA-CCR2B cells 
were treated with both CCL2 and fluorescent transferrin. Some partial colocalisation 
with transferrin remains even after 60 minutes of agonist treatment (Figure 4.3). The 
presence of HA-CCR2B in early endocytic/recycling structures may indicate that the 
receptor can recycle.  
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Figure  4.4 Colocalisation study using HEK HA-CCR2B cells and the early endosome 
marker EEA1. 
HA-CCR2B was pre-labeled using HA.11 (red) and the cells were treated with 100 nM CCL2  for the 
indicated time at 37 °C. After fixation the cells were co-stained with an antibody against EEA1 (green) 
and counterstained with DAPI (blue). Scale bar = 10 μm. Open arrow heads indicate examples of 
colocalisation.  
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Endocytosed receptors are delivered to the early/sorting endosome.  Fast recycling can 
take place directly from the early/sorting endosome or alternatively the receptor can be 
sorted to the endocytic recycling centre and be recycled to the plasma membrane via 
recycling endosomes (Grant and Donaldson, 2009; Hopkins et al., 1994). This slower 
recycling has been shown to be Rab11-dependent for many receptors (Fan et al., 2003; 
Grimsey et al., 2011; Moore et al., 2004; Ullrich et al., 1996). Although Rab11 is found 
in multiple different types of endosomes, a large proportion is found marking the 
endocytic recycling compartment localised near to the microtubule organising centre 
and Golgi complex in most cell types (Grant and Donaldson, 2009; Sonnichsen et al., 
2000). Thus Rab11 normally shows predominantly perinuclear staining, which contrasts 
with the vesicular staining of internalised receptors observed in our transfected HEK293 
cells and so the involvement of Rab11 in HA-CCR2B recycling was not investigated. 
Another Rab protein that is key for receptor recycling is Rab4, which is found at both 
the early/sorting endosome and the recycling endosome (Sonnichsen et al., 2000). Rab4 
is involved in rapid recycling from the early/sorting endosome (Sheff et al., 1999; 
Sonnichsen et al., 2000), and via its sorting function also regulates the recycling 
endosome pathways (van der Sluijs et al., 1992). The potential role of Rab4 in recycling 
of internalised HA-CCR2B was investigated using transient over-expression of wild-
type and mutant fluorescently labelled Rab4 proteins. 
Some colocalisation of internalised HA-CCR2B with fluorescent wild-type Rab4 is 
observed (Figure 4.5), and is more common in peripheral vesicles than in the main 
endocytic recycling area. Treatment with the microtubule disrupting agent nocodazole 
was tested to investigate if the apparent colocalisation represented true localisation in 
the same vesicles, however the results were inconclusive (data not shown). 
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Figure  4.5 Colocalisation study using HEK HA-CCR2B cells and fluorescent Rab4. 
HEK HA-CCR2B cells transfected to transiently express Rab4-YFP (green) were labelled for HA-CCR2B 
using HA.11 (red) and then treated with 100 nM CCL2 for 60 minutes at 37 °C. Scale bar = 10 μm.  
4.3.2.2 Recycling Assay 
The partial colocalisation of HA-CCR2B with Rab4 and transferrin could indicate some 
recycling of HA-CCR2B. Therefore, recycling assays were carried out using a 60 
minute agonist stimulation followed by acid stripping and a 60 minute recovery period 
in medium before flow cytometric analysis of cell surface CCR2 staining. Acid stripping 
using elution buffers of pH < 4.0 is employed as a technique to remove any molecules of 
chemokine remaining on cell surface receptors, which could interfere with antibody 
binding or lead to re-internalisation of the receptor (Signoret et al., 2000).  The required 
pH is dependent on the receptor and ligand being studied, as pH 2.0 removes more than 
80 % of surface bound CCR5 ligands CCL4 and CCL5 (Signoret et al., 2004) whereas 
pH 3.0 can be used to remove the CXCR4 ligand CXCL12 (Amara et al., 1997). The 
highest effective pH should be used in order to reduce cellular damage and thus pH3.5 
was chosen for this study as it had been used previously for CCL2 removal (Ge et al., 
2008). The same cell surface expression level for untreated cells and the same level of 
down-modulation for CCL2-treated cells was observed for stripped and non-stripped 
THP-1 cells. This suggests that the acid strip has no effect on the R&D α-CCR2 
antibody binding.  
Partial recycling was observed with the cell surface receptor level increasing after the 
recovery period to on average 1.4 times the level observed after agonist treatment 
(Figure 4.6). 
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Figure  4.6 HA-CCR2B recycling in HEK HA-CCR2B cells. 
HEK HA-CCR2B cells were either treated with medium (black histogram) or 100 nM CCL2 (red 
histogram) for 60 minutes at 37 °C, then acid stripped and immunolabelled for cell surface HA-CCR2B 
using R&D α-CCR2. Other medium treated cells were labelled with the relevant isotype control antibody 
(grey histogram). A separate sample of cells were treated with 100 nM CCL2 for 60 minutes at 37 °C, 
then acid stripped and treated with medium at 37 °C for a 60 minute recovery period before labelling cell 
surface HA-CCR2B (blue histogram). The cells were analysed by flow cytometry.  (A) shows a single set 
of samples representative of five separate experiments. (B) shows all five experiments, using the average 
receptor surface expression where multiple replicates were performed in the same experiment. % receptor 
surface expression is expressed as the percentage of the expression observed for medium treated cells.  
This level of recycling is quite low compared to what has been observed for some other 
chemokine receptors (Signoret et al., 2004). To address the possibility of the increase in 
cell surface expression being due to replenishment from intracellular stores rather than 
internalised and recycled CCR2B, I carried out the same experiment using THP-1 cells, 
which endogenously express CCR2 and do not show massive accumulation of CCR2 in 
the biosynthetic pathway like observed in HEK HA-CCR2B. In these cells more cell 
surface CCR2 recovery, to an average of 3.4 times the level observed after agonist 
treatment, was observed, which confirms CCR2’s ability to recycle (Figure 4.7). The 
greater cell surface recovery may reflect a more efficient recycling pathway in THP-1 
cells. The level of recycling observed is much higher on stripped THP-1 cells (Figure 
4.7A) compared to those that were washed in a neutral pH medium (Figure 4.7B). 
Recycling levels could be increased by the use of a CCR2 antagonist, TAK-779, that 
blocks recycled CCR2 at the plasma membrane (Figure 4.7). This suggests under the 
conditions used here, the pH3.5 elution buffer used for the acid strip may not remove all 
CCL2, resulting in re-internalisation/re-endocytosis of some recycled receptors. 
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Figure  4.7 CCR2 recycling in THP-1 cells. 
THP-1 cells were either treated with medium (black histogram) or 100 nM CCL2 (red, blue and green 
histograms) for 60 minutes at 37 °C, then acid stripped (A) or washed in neutral pH medium (B) and 
treated with medium (black and blue histograms), 400 nM TAK-779 (green histogram) or 100 nM CCL2 
(red histogram) at 37 °C for 60 minutes. Cells were then immunolabelled for cell surface HA-CCR2B 
using R&D α-CCR2. Other medium treated cells were labelled with the relevant isotype control antibody 
(grey histogram). The cells were analysed by flow cytometry. The histograms each show a single set of 
samples representative of a single experiment carried out in triplicate. The graphs show the mean ± SD of 
all replicates. % receptor surface expression is expressed as the percentage of the expression observed for 
medium treated cells.  
As some colocalisation of the internalised HA-CCR2B is observed with Rab4 (Figure 
4.5), further work was carried out to determine if Rab4 plays a role in the HA-CCR2B 
recycling. Three fluorescently labelled Rab4 constructs, wild-type Rab4 (Rab4WT), 
dominant negative Rab4 (Rab4N121I) and consitutively active Rab4 (Rab4Q67L), were 
transiently transfected into the HEK HA-CCR2B cells. As the Rab4 constructs are 
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tagged with YFP, cells expressing the construct and non-expressing cells could be 
differentiated by flow cytometry using a 488 nm laser and detection in the fluorescein 
isothiocyanate (FITC) channel. The transfection efficiency was approximately 28 % 
without lethal effects on the cells. Therefore, by gating on either FITC positive or FITC 
negative cells, Rab4 expressing and non-expressing cells could be compared within the 
same sample. The recycling assay used previously for HEK HA-CCR2B cells was 
repeated on these Rab4 transfected HEK HA-CCR2B cells.  The level of recycling seen 
for transfected cells, both Rab4 expressing and non-expressing, was generally higher 
than previously observed for the non-transfected HEK HA-CCR2B cells but was 
slightly inconsistent between the different Rab4 constructs. Cells transfected with GFP 
used as a control also showed higher levels of recycling, suggesting that the transfection 
process may impact on the endocytic and intracellular trafficking pathways. Therefore, 
to enable analysis the recycling level observed in Rab4 expressing cells was normalised 
to the Rab4 non-expressing cells in the same sample and compared to GFP transfected 
cells not non-transfected cells. The ratio of recycling in FITC positive (Rab4 expressing) 
compared to FITC negative (Rab4 non-expressing) cells was slightly greater than 1 for 
all Rab4 constructs (Figure 4.8). However, no significant difference was observed 
between the HA-CCR2B recycling in GFP transfected and all of the Rab4 construct 
transfected cell samples (Figure 4.8) suggesting that Rab4 does not play a role in HA-
CCR2B recycling. 
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Figure  4.8 Involvement of Rab4 in HA-CCR2B recycling in HEK HA-CCR2B cells. 
(C) HEK HA-CCR2B cells were transfected to express YFP-tagged wild type Rab4 (Rab4WT), dominant 
negative Rab4 (Rab4N121I), constitutively active Rab4 or, as a control, GFP. The cells were either treated 
with medium (i) or 100 nM CCL2 (ii) for 60 minutes at 37 °C then acid stripped and immunolabelled for 
cell surface HA-CCR2B using R&D α-CCR2 or treated with 100 nM CCL2 for 60 minutes at 37 °C then 
acid stripped and treated with medium at 37 °C for a 60 minute recovery period (iii) before labelling cell 
surface HA-CCR2B. The cells were analysed by flow cytometry. The cell surface expression for (ii) and 
(iii) is expressed as a percentage of that observed in (i) and the recycling is expressed as (cell surface 
expression of [iii])/(cell surface expression of [ii]). The transfection efficiency is approximately 28 % and 
so each sample contains both Rab4/GFP expressing cells (FITC positive) and cells not expressing 
Rab4/GFP (FITC negative). As the transfection process itself appears to result in higher apparent levels of 
recycling, the ratio of recycling in FITC positive cells compared to FITC negative cells is shown on the 
graph. Graphs show the means ± SD of  2 to 4 experiments each carried out in triplicate. Comparison of 
all three Rab4s to GFP using a one-way ANOVA followed by a Dunnett’s multiple comparison tested 
show no significant difference. Comparison of all three Rab4s to GFP using a one-way ANOVA followed 
by a Dunnett’s multiple comparison tested show no significant difference.  
 
As only partial recycling was observed for CCR2, this suggests that receptors may also 
follow another fate. Endocytosed endothelial growth factor (EGF) and its receptor can 
undergo different fates in a ligand concentration-dependent manner (Sigismund et al., 
2008).  At low EGF concentrations (typically 1.5 ng/ml) most of the internalised EGF 
ligand-receptor complex is recycled to the cell surface (Sigismund et al., 2008). 
However, at higher, but still physiological (reviewed in Sigismund et al., 2005), EGF 
concentrations (typically 20 – 100 ng/ml), the level of recycling is reduced and instead 
the majority of the complex enters the lysosomal degradation pathway (Sigismund et al., 
2008). The epidermal growth factor receptor (EGFR) is constitutively expressed on 
many cell lines including low levels on HEK293 cells (Lin et al., 2006). Therefore high 
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concentrations of fluorescent EGF are commonly used as a marker for the degradative 
pathway. In this study HEK HA-CCR2B cells, pre-labelled for cell surface HA-CCR2B, 
were treated with both CCL2 and 2 μg/ml fluorescent EGF before being studied by 
immunofluorescence following the endocytosis assay. Partial colocalisation of 
internalised HA-CCR2B with EGF is observed following the endocytosis assay at all 
time points tested up to 60 minutes suggesting that at least a proportion of HA-CCR2B 
may follow the same pathway as EGF (Figure 4.9). Co-labelling with fluorescent EGF 
and fluorescent transferrin showed that HA-CCR2B that does not colocalise with EGF 
often colocalises with transferrin (Figure 4.10) confirming that CCR2 can enter both the 
recycling and degradative pathways. 
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Figure  4.9 Colocalisation study using HEK HA-CCR2B cells and fluorescent EGF. 
HA-CCR2B was pre-labeled using HA.11 (red) and the cells were treated with 100 nM CCL2  and 2 
µg/ml fluorescent EGF (green) for the indicated time at 37 °C.  Cells were counterstained with DAPI 
(blue). Scale bar = 10 μm. Open arrow heads indicate examples of colocalisation. 
  
108 
 
Figure 4.10 Colocalisation study using HEK HA-CCR2B cells, fluorescent transferrin and 
fluorescent EGF. 
HA-CCR2B was pre-labeled using HA.11 (red) and the cells were treated with 100 nM CCL2, 25 µg/ml 
transferrin-594 (green) and 2 µg/ml EGF-488 (white) for the indicated time at 37 °C. Cells were 
counterstained with DAPI (blue). Scale bar = 10 μm. Arrows indicate the location of inset 2X zoom 
panels. 
4.3.3 Agonist-induced CCR2B degradation 
4.3.3.1 Colocalisation with late endosomal and lysosomal markers 
Two late endosome/lysosome markers, CD63 and Lamp1, were used to investigate if 
internalised HA-CCR2B enters the lysosomal degradation pathway. After 5 and 15 
minutes of agonist treatment almost no colocalisation of pre-labelled HA-CCR2B with 
CD63/Lamp1 is observed (Figures 4.11 and 4.12).  At later time points HA-CCR2B dots 
can be observed adjacent to CD63 dots and this is greatest at 60 minutes (Figure 4.11). 
However, as visual inspection of these images showed very little overlap of the adjacent 
dots, they were further analysed out using Volocity 3D Image Analysis Software to 
investigate if the dots were actually colocalised or just in close proximity. A single line 
was drawn through the middle of both of the dots and the intensity profiles of the red 
(HA-CCR2B) and green (CD63) fluorescence were measured at regular frequent 
intervals along this line. The most intense red and green points mark the centres of 
intensity of the two dots and the distance between these centres was measured. This 
distance was typically greater than 200 nm, which is above the 70 – 100 nm threshold 
commonly used to define colocalisation (Anantharam et al., 2011; Barysch et al., 2009; 
Koyama-Honda et al., 2005). This suggests that the HA-CCR2B and CD63 proteins are 
not in the same vesicles, but in adjacent structures. 
The lack of colocalisation of HA-CCR2B with lysosomal degradation pathway markers 
contrasts with the colocalisation observed with EGF (Figure 4.9). This could be due to 
slight technical differences in the assays. EGF marks the entire trafficking pathway 
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whereas CD63 and Lamp1 only mark the later part of the pathway. The endocytosis 
assay is dependent on a maintained antibody-HA-CCR2B interaction to visualise HA-
CCR2B in the later part of the pathway.  
To address the possibility of pH change-induced antibody dissociation during trafficking 
through the pathway, the effect of ammonium chloride, used to neutralise endosomal 
pH, was tested (data not shown). The results were inconclusive and highly variable from 
cell to cell. However, the general view was that there was no major increase in the level 
of colocalisation of HA-CCR2B and CD63 after 30 or 60 minutes of agonist 
stimulation, compared to cells without ammonium chloride treatment.  
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Figure  4.11 Colocalisation study using HEK HA-CCR2B cells and the late endosome 
marker CD63. 
HA-CCR2B was pre-labeled using HA.11 (red) and the cells were treated with 100 nM CCL2 for the 
indicated time at 37 °C. After fixation the cells were co-stained with an antibody against CD63 (green) 
and counterstained with DAPI (blue). Scale bar = 10 μm. Open arrow heads indicate examples of 
colocalisation. Closed arrow heads indicate examples of adjacent dots. 
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Figure  4.12 Colocalisation study using HEK HA-CCR2B cells and the lysosomal marker 
Lamp1. 
HA-CCR2B was pre-labeled using HA.11 (red) and the cells were treated with 100 nM CCL2 for the 
indicated time at 37 °C. After fixation the cells were co-stained with an antibody against Lamp1 (green) 
and counterstained with DAPI (blue). Scale bar = 10 μm. Open arrow heads indicate examples of 
colocalisation. 
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Another possibility is that the antibody is rapidly degraded upon entry into the 
lysosome. This was addressed by pretreatment of the cells with the lysosomal-specific 
protease inhibitor leupeptin. As prolonged inhibition of lysosomal degradation can lead 
to enlargement of lysosomes and result in a block of entry into the lysosomal 
degradative pathway, both overnight and 90 minute pretreatment with leupeptin were 
tested. No increase in colocalisation of HA-CCR2B with CD63 is observed in cells 
pretreated with leupeptin overnight (Figure 4.13). Some limited colocalisation is 
observed when pretreating with leupeptin for 90 minutes only (Figure 4.13). 
 
Figure  4.13 Colocalisation study using leupeptin-treated HEK HA-CCR2B cells and the 
late endosome marker CD63. 
HEK HA-CCR2B cells were treated with 100 µM leupeptin overnight or for 90 minutes during pre-
labelling as indicated. HA-CCR2B was then pre-labeled using HA.11 (red) and the cells were treated with 
100 nM CCL2 and 100 µM leupeptin for 60 minutes at 37 °C. After fixation the cells were co-stained 
with an antibody against CD63 (green) and counterstained with DAPI (blue). Scale bar = 10 μm. Arrows 
indicate the location of inset 2X zoom panels. 
Taken in combination the ammonium chloride and leupeptin treatment results did not 
give a clear answer and so a different complementary down-modulation assay was 
employed to assess the distribution of total CCR2 molecules. The down-modulation 
assay has the advantage of not being dependent on a maintained antibody-HA-CCR2B 
interaction, however it does visualise all HA-CCR2B, both receptors trafficking from 
the cell surface and those from the biosynthetic pathway and so is only useful to 
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compare treated and untreated cells. An increase in the proportion of HA-CCR2B that 
colocalises with CD63 is observed in agonist-treated cells compared to medium-treated 
cells (Figure 4.14). This indicates that a proportion of the internalised HA-CCR2 may 
enter the degradative pathway. 
 
Figure  4.14 Colocalisation study using HEK HA-CCR2B cells and the late endosome 
marker CD63 following the down-modulation assay. 
HEK HA-CCR2B cells treated with medium or 100 nM CCL2 for 60 minutes at 37 °C. After fixation the 
cells were co-labelled with HA.11 (HA-CCR2B, red) and α-CD63 (green) and counterstained with DAPI 
(blue). Images represent single sections cut through the CD63 compartment. Scale bar = 10 μm. Arrows 
indicate the location of inset 2X zoom panels. 
4.3.3.2 Biochemical analysis of agonist-induced degradation 
As some colocalisation with degradative pathway markers was observed, a biochemical 
assay was carried out to check if HA-CCR2B is actually degraded following agonist-
induced internalisation. Cell lysates, from HEK HA-CCR2B cells treated with 
cycloheximide and either medium or agonist for various time points (up to 8 hours), 
were analysed for the presence of HA-CCR2B by immunoblotting. Three different 
forms of the receptor were identified, here termed the low, “normal” and high molecular 
weight forms based on comparison to the expected molecular weight of CCR2 (Figure 
4.15). Treatment of the cells with cycloheximide, to stop de novo protein synthesis, 
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showed that there is a basal level of degradation of HA-CCR2B over the 4 or 8 hours for 
which the experiments were carried out, even for cells that were treated with medium 
only (Figure 4.15). The half-lives of the three different forms of HA-CCR2B appear to 
vary, but are within the range of hours (Figure 4.15) rather than days in accordance with 
what has been reported for several other chemokine receptors including CCR5 
(Percherancier et al., 2001; Signoret et al., 2000; Weber et al., 2004)  and CXCR4 
(Marchese and Benovic, 2001). However the high molecular weight form of HA-
CCR2B, unlike the other two forms, is degraded faster in response to agonist treatment 
(Figure 4.15). After 4 hours of treatment there is a significant difference in the 
percentage of the high molecular weight HA-CCR2B receptor remaining in medium- 
(80 ± 14 %) and agonist- (32 ± 21 %) treated cells (Figure 4.15C). In contrast, this is not 
the case for the “normal” (medium, 22 ± 12 %; agonist, 34 ± 18 %) or low (medium, 21 
± 22 %; agonist, 29 ± 23 %) molecular weight forms (Figure 4.15C).Treatment weith 
either leupeptin or ammonium chloride resulted in 22 % or 90 %, respectively of the 
high molecular weight HA-CCR2B band remaining after 4 hours of CCL2 stimulation, 
compared to only 13 % for untreated cells in the same experiment (Figure 4.15D). This 
reduction in the level of degradation suggests that the high molecular weight HA-
CCR2B form undergoes lysosomal degradation. 
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Figure  4.15 Degradation of HA-CCR2B in response to agonist treatment. 
(A) Cell lysates, from HEK HA-CCR2B cells treated with 10 µg/ml cycloheximide and either medium 
(BM) or 100 nM CCL2 for 0, 1, 4 or 8 hours were analysed for the presence of HA-CCR2B by SDS-
PAGE and immunoblotting using HA.11. β-catenin and the transferrin receptor were used as loading 
controls.  Cell lysates from untreated HEK HA-CCR5 cells were analysed in the same way. (B) 
Densitometry analysis of the percentage of receptor remaining after 0, 1, 2, 3 or 4 hours of medium 
(black) or 100 nM CCL2 (red) treatment was carried out for each band identified in (A) using ImageJ. 
Graphs show the means ± SD of 2 experiments. A 2-way ANOVA was carried out to test for interaction. 
*, p<0.05; ns, non-significant. (C) Densitometry analysis of the percentage of receptor remaining after 4 
hours of medium (black) or 100 nM CCL2 (white) treatment was carried out for each band identified in 
(A) for 4 experiments using ImageJ. A 2-way ANOVA followed by a Bonferroni multiple comparisons 
test was used to check for differences between medium and agonist treatment. ****, p<0.0001; ns, non 
significant. (D) Comparison of cell lysates from HEK HA-CCR2B cells treated with either medium (BM) 
or 100 nM CCL2 and 10 µg/ml cycloheximide alone (untreated) or in combination with 100 µM leupeptin 
or 50 mM ammonium chloride for 4 hours. Arrows indicate the high (red), “normal” (green) and low 
(blue) molecular weight forms of HA-CCR2B. 
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4.3.3.3 Identification and characterisation of the different forms of CCR2B 
Figure 4.15 identifies at least three forms of HA-CCR2B present in HEK HA-CCR2B 
cells. The predicted molecular weight for HA-CCR2B is 44 kDa, which corresponds to 
the middle band, here termed the “normal” molecular weight band. Two lines of 
evidence suggest that the other bands are different forms of HA-CCR2B and not just 
non-specific bands. Firstly both the low and high molecular weight bands are detected 
using the α-HA antibody, HA.11, in cell lysate from HEK HA-CCR2B cells but not in 
cell lysate from the same parent cells transfected to express HA-CCR5 (Figure 4.15A). 
Secondly, the high molecular weight band responds differently to treatment with 
medium and the CCR2 agonist CCL2 (Figure 4.15). 
Subcellular fractionation of HEK HA-CCR2B cells shows that the three forms of the 
HA-CCR2B receptor are localised differently within the cell. The subcellular 
fractionation profile of the high molecular weight form has two peaks. The major peak 
represents to fractions co-labelling for the plasma membrane markers CD49b and Na/K 
ATPase α-1, whereas the minor peak encompasses intracellular marker-containing 
fractions and corresponds best to that of the ER marker binding immunoglobulin protein 
(BiP; Figure 4.16). 
The “normal” and low molecular weight forms are not found in plasma membrane 
positive fractions. The low molecular weight form corresponds best to BiP-containing 
fractions but also partially overlaps with fractions positive for Lamp1 and TGN46. The 
“normal” molecular weight form shows a similar pattern but with greater overlap with 
Lamp1- and TGN46-containing fractions (Figure 4.16). 
Upon agonist-stimulation, the high molecular weight form, but not the other two forms, 
significantly changes its distribution within the fractions. The major peak that previously 
fractionated with plasma membrane markers is no longer easily detectable and a single 
peak that corresponds to intracellular markers, in particular Lamp1, is observed (Figure 
4.17). This suggests that the high molecular weight plasma membrane HA-CCR2B form 
is internalised and degraded in response to agonist treatment. 
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Figure  4.16 Subcellular fraction of the HA-CCR2B forms in untreated HEK HA-CCR2B 
cells. 
HEK HA-CCR2B cells were lysed using a ball bearing homogeniser and used for subcellular 
fractionation. Samples were loaded onto 0 – 22 % continuous Optiprep gradients and centrifuged at 
200000 xg for 3 hours. Twelve 1 ml fractions were collected and probed for the presence of different 
organelle markers by SDS-PAGE and immunoblotting. Densitometry analysis of the marker and HA-
CCR2B bands present in each fraction was carried out using ImageJ and presented as a percentage of the 
most intense band for that marker.  
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Figure  4.17 Subcellular fraction of the HA-CCR2B forms in CCL2-treated HEK HA-
CCR2B cells 
HEK HA-CCR2B cells, treated with 100 nM CCL2 for 30 minutes at 37 °C, 5 % CO2, were lysed using a 
ball bearing homogeniser and used for subcellular fractionation. Samples were loaded onto 0 – 22 % 
continuous Optiprep gradients and centrifuged at 200000 xg for 3 hours. Twenty-four 0.5 ml fractions 
were collected and probed for the presence of different organelle markers by SDS-PAGE and 
immunoblotting. Densitometry analysis of the marker and HA-CCR2B bands present in each fraction was 
carried out using ImageJ and presented as a percentage of the most intense band for that marker.  
In summary, it is the high molecular weight form that is present at the plasma membrane 
of the cells and that is internalised following agonist treatment and then degraded. 
Therefore, this is the form that is of interest for studying intracellular trafficking 
following agonist-induced internalisation. 
The high molecular weight form is likely to be a post-translationally modified form of 
HA-CCR2B. By western blotting it is observed as a large band that appears to actually 
consist of several bands with spacing between some that could be consistent with mono- 
and poly-ubiquitinated forms of the receptor (Figure 4.18A). Immunoprecipitation 
experiments carried out with HEK HA-CCR2B cells transfected to express FLAG-
ubiquitin show no co-immunoprecipitation of HA-CCR2B with FLAG-ubiquitin (Figure 
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4.18C). This suggests that the post-translational modification is not ubiquitination, 
however no positive control was available. 
 
Figure  4.18 Testing for post-translational modifications of HA-CCR2B. 
(A) Long and short exposures of the same immunoblot of HEK HA-CCR2B cell lysates probed using 
HA.11 to show the high molecular weight form of HA-CCR2B as a single or multiple bands. (B) HEK293 
cells transiently transfected to express FLAG-ubiquitin analysed by immunofluorescence using M2 (α-
FLAG) to show the expression pattern. Cells were counterstained with DAPI (blue). Scale bar = 10 µm 
(C) HEK293 cells transfected to express HA-CCR2B and/or FLAG-ubiquitin were used for 
immunoprecipitation by M2 (α-FLAG) and the cell lysates and immunoprecipitated protein were analysed 
by SDS-PAGE and immunoblotting with HA.11 to detect HA-CCR2B. The membrane was stripped and 
re-blotted with M2 to detect proteins that had incorporated FLAG-ubiquitin. (D) Lysates from HEK HA-
CCR2B cells, untreated or pretreated with 5 µM GF109203X (PKC inhibitor) or 100 ng/ml PMA for 60 
minutes at 37 °C, 5 % CO2, analysed by SDS-PAGE and immunoblotting using HA.11 to detect HA-
CCR2B.  Arrows indicate the high (red), “normal” (green) and low (blue) molecular weight forms of HA-
CCR2B. 
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A common post-translational modification observed for chemokine receptors is 
phosphorylation of the cytoplasmic tail, usually in response to specific ligand binding. 
The increase in molecular weight due to the addition of phosphate groups can be 
detected on a western blot as a band shift as reported for CCR5 (Signoret et al., 2000).  
Therefore it is possible that the “normal” and modified forms of HA-CCR2B could 
represent non-phosphorylated and phosphorylated forms of the receptor respectively, 
however the results of several different experiments suggest that this is unlikely.  The 
high molecular weight band is present on western blots using cell lysate from both 
untreated and agonist-treated HEK HA-CCR2B cells, and no increase in band intensity 
is observed following agonist treatment (Figure 4.15A). This suggests that unlike typical 
chemokine receptor phosphorylation, the modification resulting in the high molecular 
weight form of HA-CCR2B is probably not agonist-induced. Treatment of HEK HA-
CCR2B cells with a PKC inhibitor to prevent PKC-mediated phosphorylation, did not 
appear to result in a significant reduction in intensity of the high molecular weight HA-
CCR2B band. Accordingly, treatment with PMA, which activates PKC, did not lead to 
an increase in the intensity of the high molecular weight band (Figure 4.18D). These 
results suggest that the post-translational modification is unlikely to be phosphorylation.  
Glycosylation can also result in an increase in protein molecular weight that can be 
observed on a western blot. Pretreatment of HEK HA-CCR2B cells with tunicamycin, 
an N-glycosylation inhibitor, resulted in a change in band pattern suggesting that the 
receptor is N-glycosylated (Figure 4.19A). A reduction in intensity of the “normal” band 
and the appearance of a slightly lower molecular weight band is observed suggesting 
that the “normal” form of HA-CCR2B is partially N-glycosylated. The high molecular 
weight band appears to be mainly replaced by intermediate bands. This result differs 
slightly from the discrete band shift from a fully N-glycosylated to a non-glycosylated 
form that would be typically expected. As there is only one consensus NXS/T potential 
N-glycosylation site motif on HA-CCR2B, this suggests that the high molecular weight 
band is due to elaboration of the N-glycan present on the “normal” form carried out in 
the Golgi and that the intermediate bands represent different stages in the glycosylation 
process. Tunicamycin blocks the transfer of N-acetylglucosamine-1-phosphate from 
uridine diphosphate N-acetylglucosamine to dolichol phosphate leading to a reduction in 
formation of the dolichol pyrophosphate N-acetylglucosamine precursor (Esko and 
Bertozzi 2009). This precursor donates its entire glycan to the protein during the first 
121 
step of N-glycosylation, which is carried out in the endoplasmic reticulum and 
subsequent remodeling steps are carried out in the endoplasmic reticulum and in the 
Golgi. The required tunicamycin concentration for effective inhibition of N-
glycosylation is cell type dependent (Esko and Bertozzi, 2009) and the total cellular 
expression level of HA-CCR2B is relatively high. It is therefore likely that the 
intermediate bands are present due to incomplete inhibition of precursor formation, 
allowing some limited partial N-glycosylation to take place resulting in a small amount 
of the “normal” form, which can be further remodelled in the Golgi. Higher 
concentrations of tunicamycin or longer treatment were not tested due to the toxic effect 
on the cells that was observed. 
Two different approaches were used to test for O-glycosylation: treatment of cell lysate 
with neuraminidase, an enzyme that cleaves off sialic acids from the Gal-β(1-3)-
GalNAc core, and pretreatment of cells with benzyl-α-GalNAc, an inhibitor of part of 
the O-glycosylation pathways. Both treatments gave a band pattern change when used 
individually suggesting that HA-CCR2B is O-glycosylated (Figure 4.19A). When used 
in combination with tunicamycin, neuraminidase treatment resulted in the complete 
absence of the high molecular weight band and also the intermediate bands (Figure 
4.19A). Absence of the high molecular weight form was also observed using benzyl-α-
GalNAc (Figure 4.19A). These results suggest that the high molecular weight form of 
HA-CCR2B is both N- and O-glycosylated. 
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Figure  4.19 Glycosylation of HA-CCR2B 
(A) HEK HA-CCR2B cells were untreated or pretreated with DMSO, 10 µg/ml tunicamycin or 2 mM 
benzyl α-GalNAc for 24 hours at 37 °C, 5 % CO2. The cells were then lysed and where indicated the cell 
lysate was incubated with 50 mU neuraminidase for 20 hours at 37 °C. Cell lysates were analysed by 
SDS-PAGE and immunoblotting using HA.11 to detect HA-CCR2. Arrows indicate the high (red), 
“normal” (green) and low (blue) molecular weight forms of HA-CCR2B. (B) HEK HA-CCR2B cells were 
pretreated with DMSO, 2 mM benzyl α-GalNAC, 10 µg/ml tunicamycin or tunicamycin and benzyl α-
GalNAC for 24 hours at 37 °C, 5 % CO2, and then the cell surface expression was measured by flow 
cytometry using α-CCR2 and compared to untreated cells. The means ± SD of 1 representative 
experiment with 3 replicates is shown.  
The high molecular weight form of HA-CCR2B is glycosylated and was shown by 
subcellular fractionation to be localised at the plasma membrane. The importance of 
glycosylation for trafficking to the plasma membrane was tested by pretreating with 
glycosylation inhibitors for 24 hours before measuring the cell surface expression level 
of HA-CCR2B by flow cytometry. Compared to untreated cells, pretreatment with 
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benzyl-α-GalNAc appears to have no effect, however pretreatment with tunicamycin 
reduced the cell surface HA-CCR2 expression level dramatically (Figure 4.19B). This 
suggests that glycosylation aids trafficking of HA-CCR2B to the cell surface. 
4.4 Discussion 
4.4.1 Comparison of CCR2B trafficking to CCR5 trafficking and overview of 
pathway 
In response to CCL2 ligand stimulation, CCR2B is internalised in early endosomes and 
then a proportion is degraded and a proportion is recycled to the cell surface (Figure 
4.20). Unlike CCR5, which undergoes 50 % recovery in 60 min in CHO-CCR5 cells 
(Signoret et al., 2000) and almost 100 % recovery in 120 minutes (Mueller et al., 
2002a), in HEK HA-CCR2B cells the surface CCR2 level only partially recovers after 
60 min. Unlike CCR5, but similar to several other chemokine receptors, a proportion of 
CCR2B appears to undergo lysosomal degradation following agonist-induced 
internalisation. 
4.4.2 CCR2B internalisation 
The limited research published on CCR2 internalisation has been mainly carried out on 
brain tissue or astrocytes with a single study using HEK293 and THP-1 cells. These 
studies suggest that the receptor can be internalised in response to ligand-stimulation via 
clathrin or caveolae-dependent endocytosis (Figure 4.20) and that the route followed 
may be cell type specific. Endocytosis studies in the past have suffered from the limited 
specificity or off-target effects of the drugs used to inhibit these two pathways. This 
study attempted to use a broader panel of inhibitors to enable greater certainty about the 
pathways involved. 
The observed colocalisation of internalised receptor with transferrin and the inhibitory 
effect of ikarugamycin and hypertonic sucrose on receptor down-modulation support a 
clathrin-mediated endocytosis pathway for HA-CCR2B in HEK293 cells, which is in 
agreement with complementary studies using clathrin shRNA and colocalisation with 
Lamp1 (Garcia Lopez et al., 2009). However, none of these assays showed a complete 
block in receptor down-modulation suggesting that either they were not efficient or 
specific enough or that there could be a second pathway that functions to some extent. 
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Other approaches to test the first possibility include using the new more specific PitStop 
inhibitors, which act on the clathrin terminal domain to immobilise CCPs (von Kleist et 
al., 2011) or using siRNA against clathrin or the crucial adaptor protein AP2. Acting on 
AP2 instead of on clathrin directly should only affect clathrin-mediated endocytosis and 
not other important roles played by clathrin including sorting of cargo within the 
early/sorting endosomes for entry into the degradative pathway (Raiborg et al., 2002).  
An alternative recently developed approach, the knocked sideways technique (Robinson 
et al., 2010), involves rapid inactivation of AP2 via rerouting it to the mitochondria, a 
subcellular compartment that is not involved in the endocytic pathway. This technique 
exploits the ability of the drug rapamycin to cause dimerisation of rapamycin-domain 
containing proteins. Cells are firstly stably transfected to express two proteins: a siRNA-
resistant form of the AP-2 α subunit with a FKBP tag that can bind rapamycin, and a 
protein containing a mitochondrial localisation domain and a FRB domain that can bind 
rapamycin and FKBP. The endogenous AP2 α subunit is then knocked down using 
siRNA and is compensated for by the overexpressed form until the addition of 
rapamycin, which results in dimerisation of the two proteins and thus relocalisation of 
AP2 to the mitochondria. The knocked sideways technique has the advantage of acting 
much more rapidly than siRNA-mediated knockdown as following the addition of 
rapamycin you do not need to wait for existing protein to be degraded. For transferrin 
the AP2 knocked sideways inhibition of uptake is as efficient as siRNA knockdown but 
takes place on a time scale that is three to four orders of magnitude faster. However, this 
is a labour-intensive approach that could not be carried out within the time frame of this 
study.  
The inhibitory effect of methyl-β-cyclodextrin and nystatin on receptor down-
modulation support the existence of an additional lipid-dependent, possibly caveolar, 
pathway of internalisation previously described for astrocytes using filipin and caveolin-
1 siRNA. Contrary to these results, the single experiment using filipin showed no effect 
on HA-CCR2 down-modulation, however several possible explanations exist for this. 
This could just be due to a difference in stringency of the efficiency of the inhbitors used 
in this experiment. Alternatively, it could be the result of the differing mode of action of 
the inhibitors. The extraction of cholesterol by methyl-β-cyclodextrin could impact on 
the ligand binding to the receptor and indirectly affect its down-modulation. Further 
experiments would be required to reach a definitive conclusion on the contribution of 
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membrane lipids to agonist-induced CCR2 internalisation. A radiolabelled ligand 
binding study in the presence and absence of methyl-β-cyclodextrin could be used to 
detect the influence of the drug on ligand binding. To determine the involvement of the 
caveolar pathway in HA-CCR2B internalisation, caveolin-1 siRNA treatment could be 
used as it has been used for astrocytes (Ge and Pachter, 2004). C-terminally tagged 
caveolin-1-GFP and N-terminally tagged GFP-caveolin-1 constructs have been 
generated and exhibit wild-type and dominant-negative inhibitor behaviour in the 
caveolar-dependent endocytosis pathway (Pelkmans et al., 2001). Transient expression 
of these constructs in the transfected HEK293 cells could be used to further investigate 
the potential caevolin-1 dependence of HA-CCR2B endocytosis in these cells. Attempts 
to detect caveolin-1 by immunofluorescence on cells co-stained for HA-CCR2B and on 
immunoblots of subcellular fractions from HEK HA-CCR2B cells showed no signal. 
Other caveolin-1 antibodies are commercially available and have been used successfully 
on astrocytes by immunofluorescence (Andjelkovic et al., 2002) and mink lung 
endothelial cells by electron microscopy (Signoret et al., 2005) and could therefore be 
tested to check the expression level of caveolin-1 on HEK293 cells and if it colocalises 
with HA-CCR2B. 
4.4.3 CCR2B degradation 
A proportion of CCR2 appears to be degraded following agonist-induced internalisation 
(Figure 4.20). This study showed colocalisation of internalised HA-CCR2B with EGF 
and an increase in the proportion of total HA-CCR2B that colocalised with CD63 in 
agonist-treated as compared to untreated cells. Another study (Garcia Lopez et al., 2009) 
reported partial colocalisation of a Cherry-tagged CCR2B with Lamp1. Although almost 
no colocalisation with Lamp1 was observed in this study when using the endocytosis 
assay, it was probably a result of the problems with using antibodies to label CCR2B 
instead of a fluorescent tag. This possibility could be addressed by using the down-
modulation assay to compare the level of colocalisation of total HA-CCR2B with 
Lamp1 in untreated and agonist-stimulated cells as done for CD63. 
In support of the immunofluorescence colocalisation studies, biochemical studies 
showed that CCR2B is degraded in response to agonist stimulation. Preliminary studies 
using ammonium chloride and leupeptin indicate that internalised CCR2B undergoes 
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lysosomal degradation as is the case for the majority of degraded chemokine receptors 
studied so far (Borroni et al., 2010) with the exception of CXCR3 (Meiser et al., 2008). 
CXCR3 has been suggested to undergo proteasomal degradation instead. Repeat of the 
degradation experiments using proteasome inhibitors such as MG132 would be required 
to exclude this route for CCR2. Additional lysosomal inhibitors, such as chloroquine 
and concanamycin A, are also available to complement the leupeptin and ammonium 
chloride treatment. 
4.4.4 CCR2B recycling 
Partial colocalisation with the transferrin receptor and the results of the recycling assays 
suggest that a proportion of the internalised HA-CCR2B is recycled in HEK HA-
CCR2B cells. As these cells have an accumulation of HA-CCR2B in their biosynthetic 
pathway, the possibility of replenishment from internal stores cannot be ruled out. 
However, recycling experiments carried out on THP-1 cells suggest that this is not the 
case as recycling appears to occur in THP-1 cells, which express endogenous levels of 
CCR2. Indeed, early binding studies using 
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I-CCL2 on THP-1 cells showed rapid 
replenishment of ligand binding sites within 20 minutes that was not dependent on de 
novo synthesis of the receptor suggesting recycling (Wang et al., 1993a). However, in 
that study the level of recycling was not quantified and so cannot be compared to that 
observed in HEK HA-CCR2B cells. 
Despite partial colocalisation of internalised HA-CCR2B with Rab4, over-expression of 
Rab4s had no effect on recycling of the receptor. This suggests that like for CCR5 
(personal communication from Nathalie Signoret, University of York, UK), HA-CCR2B 
recycling is not Rab4-dependent. In addition to its role in recycling endosomes, Rab4 is 
also present at the early/sorting endosome (Sonnichsen et al., 2000). Therefore this 
colocalisation could represent an earlier point in the endocytic pathway where HA-
CCR2B transits through the sorting endosome on its way to the degradative pathway or 
back to the cell surface (Figure 4.20). Recycling could potentially take place from the 
sorting endosome in Rab4-independent vesicles. 
The level of recycling observed in HEK HA-CCR2B cells is quite low suggesting that 
this is a minor pathway following internalisation. There is also quite a lot of variability 
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in the level of recycling observed suggesting that an unknown factor or factors may 
influence the recycling potential. 
4.4.5 Choice of recycling or degradation 
Internalised CCR2B can undergo one of two fates; either recycling back to the cell 
surface where it can potentially be restimulated by new ligand or alternatively being sent 
to the lysosome for degradation halting its ability to signal (Figure 4.20).  Several other 
chemokine receptors, such as CXCR2 and CXCR4, have been shown to enter either 
pathway depending on cell type and duration of ligand treatment respectively. In 
common with at least eleven other chemokine receptors, CXCR2 contains a PDZ ligand 
motif at its extreme C-terminus (Marchese et al., 2008). For CXCR2 it appears that this 
PDZ ligand motif is involved in determining the fate of the receptor as it serves to delay 
degradation by preventing lysosomal sorting, probably due to an interaction with an as 
yet unknown PDZ-containing protein. CCR2 however, does not have a C-terminal PDZ 
ligand motif and it appears to be able to undergo, at least to some extent, both fates in 
the same cell type suggesting that there may be more currently undetermined factors 
influencing the post-internalisation trafficking and that they may be receptor specific. In 
fact it has been observed for CCR5 that the choice of agonist itself can impact on the 
fate of the receptor by causing the receptor to accumulate at various points along the 
recycling pathway (Bennett et al., 2011). The experiments presented here have been 
carried out using the main CCR2 ligand, CCL2, however the receptor does have several 
other ligands and it would be interesting to observe the influence of these on the 
trafficking of the receptor. 
4.4.6 Different forms of CCR2B 
Three different forms of HA-CCR2B have been described in this study: high, “normal” 
and low molecular weight. Based on subcellular fractionation studies, the high 
molecular weight form localises both to the plasma membrane and to an intracellular 
pool whereas the other two forms are localised intracellularly. This study supports 
previous work, which proposed that CCR2 is N-glycosylated (Preobrazhensky et al., 
2000) and suggests that CCR2 also undergoes O-glycosylation. The involvement of 
glycosylation in GPCR trafficking to the cell surface is thought to vary between 
receptors (Dong et al., 2007). For some GPCRs, such as the AT1a angiotensin receptor, 
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glycosylation appears to be essential for cell surface expression (Jayadev et al., 1999) 
yet for other receptors, such as the M2-muscarinic receptor, glycosylation appears to 
play no role (van Koppen and Nathanson, 1990). There is another group of GPCRs for 
which glycosylation may play an important but non-essential role in the receptor 
trafficking to the cell surface. An example of this group of GPCRs is the β-adrenergic 
receptor, where mutation of the two N-terminal N-glycosylation sites reduced the 
percentage of the receptor present at the cell surface by approximately 50 % (Rands et 
al., 1990). Both my study and previously published work (Preobrazhensky et al., 2000) 
showed partial but incomplete reduction in cell surface CCR2 expression following 
tunicamycin treatment suggesting that CCR2 may belong to this group. However 
mutation studies would be required to confirm that it is glycosylation of CCR2 and not 
any other trafficking machinery proteins involved in its export that is responsible. HA-
CCR2B appears to also be O-glycosylated but this modification does not seem to play a 
role in its cell surface expression. 
Observing the fractions from most to least dense, the low molecular weight form of HA-
CCR2B appears first followed by the “normal” form and then the intracellular peak of 
the high molecular form. All three forms overlap to some degree with the ER (BiP), 
Golgi (TGN46) and lysosome (Lamp1) markers, which appear in that order from most 
to least dense. However, the separation between the markers is not very good and there 
is quite a lot of overlap. To determine where precisely the intracellular high, “normal” 
and low molecular weight forms are localised a modified fractionation protocol and 
narrower gradient would be required. 
These results could suggest that the “normal” molecular weight form of HA-CCR2B is a 
non-mature form that is produced and N-glycosylated in the ER and then traffics to the 
Golgi for N-glycan remodelling and O-glycosylation before trafficking to the plasma 
membrane. The identity of the low molecular weight form is unclear although it is likely 
to be either a truncation or degradation product. It is usually present but the level varies 
from experiment to experiment. It shows more colocalisation with BiP than with Lamp1 
and does not accumulate following agonist-induced degradation of the high molecular 
weight form, which suggests that it is more likely to be a truncation product. 
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Figure  4.20 Trafficking of internalised CCR2B. 
In response to agonist stimulation, CCR2 can be internalised via clathrin and caveolin-dependent 
pathways. It can then either be recycled back to the cell surface or be sent to the lysosome for degradation. 
Arrows show the proposed paths followed by internalised CCR2.  
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5 Identification of interacting partners 
5.1 Introduction 
The previous chapters show that internalised CCR2B and CCR5 localise differently 
within the cell and that whereas CCR5 is recycled to the cell surface, CCRB appears to 
be both recycled and sent for degradation. This difference could be due to interactions 
with different elements of the trafficking machinery. 
Multiple examples of interactions with specific proteins being important for the 
intracellular trafficking of agonist stimulated chemokine receptors have been 
demonstrated. Interaction of the chemokine receptor with kinases is required for 
phosphorylation of the cytoplasmic tail, which is involved in the initial step of clathrin-
mediated endocytosis (Neel et al., 2005). Subsequently, sorting of internalized 
chemokine receptors to the recycling or degradative pathways requires complex 
interactions with the machinery mediating movement of molecules between intracellular 
compartments. For CCR5, post-endocytic sorting to the recycling pathway is dependent 
on interaction of its PDZ ligand motif with a protein implicated in receptor recycling 
called EBP50/NHERF-1 (Hammad et al., 2010). The post-translational modification 
ubiquitination has emerged as being important for sending CXCR4, but not other 
chemokine receptors, to degradation presumably due to modulation of protein-protein 
interactions.  
In addition, specific protein-protein interactions involving the cytoplasmic domains of 
chemokine receptors can influence the signalling activity of these receptors. Indeed, it 
has emerged that GPCRs can also elicit G protein-independent signals through 
interaction with the scaffolding proteins β-arrestins, linking activated receptors to 
various signalling pathways that act independently of, in synergy with or in opposition 
to, G protein-mediated signals.   
Therefore, identification of novel common and/or distinct interacting partners of 
CCR2B and CCR5 could help to further our understanding of receptor specific 
trafficking and signalling mechanisms. 
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5.1.1 Choice of techniques  
Other groups have used various techniques to try to identify proteins interacting with the 
two chemokine receptors. Several proteins have been found (Table 5.1) but it is likely 
that many remain to be identified. Indeed recent work on another chemokine receptor, 
CXCR2, has shown that there are still novel interacting proteins to be found using 
proteomics approaches (Neel et al., 2009). 
This project employed two different but complementary techniques with the aims of 
identifying novel interacting proteins for CCR2B and CCR5 under resting and 
chemokine or LTA stimulated conditions. The GST pull down technique, using the 
cytoplasmic tails of the receptors fused to GST, was chosen to target proteins whose 
binding sites are within the tail, whereas, receptor co-immunoprecipitation, targets 
proteins that bind to any region of the receptor. This is important as it has been shown 
that although many proteins interact with the cytoplasmic tail of GPCRs (Heydorn et al., 
2004), some proteins require other parts of the receptors, such as the intracellular loops, 
for binding (Luttrell, 2006). 
The cytoplasmic tail of CCR5 has been shown to interact with α-catenin (Schweneker et 
al., 2004), β-arrestin (Huttenrauch et al., 2002), DRiP78 (Kuang et al., 2012), 
EBP50/NHERF-1 (Hammad et al., 2010), FROUNT (Toda et al., 2009) and Jena-
Muenchen 4 (Schweneker et al., 2005), whereas the cytoplasmic tail of CCR2B has been 
shown to bind to filamin A (Minsaas et al., 2010) and FROUNT (Terashima et al., 
2005). Both receptors can be phosphorylated on their cytoplasmic tails by GRKs or 
second messenger-activated kinases. Four phosphorylation sites (S336, S337, S342, 
S349) have been identified for CCR5 (Oppermann et al., 1999; Pollok-Kopp et al., 
2003) and the CCR2B cytoplasmic contains four serines and six threonines that can be 
phosphorylated (Franci et al., 1996). In addition, the last four amino acids (SVGL) of 
the CCR5 cytoplasmic tail form a PDZ ligand (Delhaye et al., 2007) although no 
equivalent sequence has been identified for CCR2B. As chemokine receptors are 7 
trans-membrane receptors, it is not feasible to express the entire CCR2B or CCR5 
protein fused to GST in bacteria. However, the importance of the cytoplasmic tail for 
protein interactions and the success of yeast-2-hybrid screens using the cytoplasmic tails 
suggest that this part of the receptors is suitable to address the aims of this project.  
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Table  5.1 Cellular proteins identified as interacting with CCR2B or CCR5 in previously 
published work. 
 
Receptor Protein 
Identified 
Identification 
Technique 
Cells Validation 
Technique 
Cells Ref 
CCR2 β-arrestin CO-IP MonoMac1 (E)   (Aragay et 
al., 1998) 
CCR2B Filamin A Y2H Human 
leukocyte cDNA 
library 
Pull down 
 
CO-IP 
A7, M2 
 
HEK293 (O) 
(Minsaas et 
al., 2010) 
CCR2B FROUNT Y2H THP-1 cell 
cDNA library 
Pull down In vitro (Terashima 
et al., 
2005) 
CCR2 GRK2 CO-IP MonoMac1 (E)   (Aragay et 
al., 1998) 
CCR2B Importin 7 SEC-IP then 
MS/MS 
HEK293 (O)   (Favre et 
al., 2008) 
CCR2B Importin 9 SEC-IP then 
MS/MS 
HEK293 (O)   (Favre et 
al., 2008) 
CCR2B Importin 
β1 subunit 
SEC-IP then 
MS/MS 
HEK293 (O)   (Favre et 
al., 2008) 
CCR2B TCP-1γ SEC-IP then 
MS/MS 
HEK293 (O) SEC-IP 
then WB 
HEK293 (O) (Favre et 
al., 2008) 
CCR2B TRN-1 SEC-IP then 
MS/MS 
HEK293 (O) GST pull 
down, SEC-
IP then WB 
CO-IP 
 
HEK293 (O) 
 
 
THP-1 HA-
CCR2B (O) 
(Favre et 
al., 2008) 
CCR5 α-catenin Y2H Human B cell 
cDNA library 
CO-IP Cf2Th (O), 
HEK293 (O) 
(Schwenek
er et al., 
2004) 
CCR5 β-arrestin CO-IP HEK-293 (O)   (Vila-Coro 
et al., 
1999a) 
CCR5 DRiP78 BiFc-BRET HEK-293 (O) CO-IP 
GST pull 
down 
HEK293 (O) (Kuang et 
al., 2012) 
CCR5 EBP50/NH
ERF-1 
BiFc-BRET HEK-293 (O) CO-IP HEK293 (O) (Hammad 
et al., 
2010) 
CCR5 FROUNT Y2H cDNA encoding 
FROUNT aa 
500-656 
CO-IP HOS (O) (Toda et 
al., 2009) 
CCR5 GRK2 CO-IP 
 
CO-IP 
RBL (O) 
 
HEK293 (O) 
  (Opperman
n et al., 
1999)  
(Vila-Coro 
et al., 
1999a)  
CCR5 JM4 Y2H Human pre-B 
cell cDNA 
library 
CO-IP Cf2Th (O), 
HEK293 (O) 
(Schwenek
er et al., 
2005) 
CCR5 NMMHC-
IIA 
GST pull 
down 
Peer T cells    (Rey et al., 
2002) 
cDNA, complementary deoxyribonucleic acid; CO-IP, co-immunoprecipitation; E, cells 
endogenously expressed the chemokine receptor; HOS, human osteosarcoma cell line; JM4, Jena-
Muenchen4; N/A, not applicable; NMMHC-IIA, nonmuscle myosin H chain-IIA; O, cells were 
transfected to over-express the chemokine receptor; SEC-IP, size exclusion chromatography 
followed by immunoprecipitation; TCP-1γ , T-complex protein 1 γ subunit; TRN-1, transportin-1; 
WB, western blotting; Y2H, yeast-2-hybrid screen 
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Previous approaches have concentrated on finding novel binding partners of CCR2 and 
CCR5 in their un-stimulated state, either by yeast-two-hybrid assays or by co-
immunoprecipitation, followed in some cases by investigation into whether there is any 
change in the binding of these proteins following chemokine agonist-stimulation (Favre 
et al., 2008; Schweneker et al., 2004, 2005; Terashima et al., 2005). However, there is 
no published work carried out to specifically identify novel proteins that interact with 
the receptors following ligand-stimulation in cells endogenously expressing both 
receptors, such as monocytes. Therefore, this project initially aimed to use monocytic 
cell lines to identify interacting partners for the receptors. However, due to problems 
identified with the CCR5 expression on monocytic cell lines described in Chapter 3, 
transfected HEK293 cells were also used. 
5.1.1.1 GST pull down  
The GST pull down technique is commonly used to confirm suspected protein-protein 
interactions. A recombinant protein consisting of GST fused to a part or the whole of 
one protein of interest is produced in bacteria and then incubated with either a purified 
form of the other protein of interest or extracts containing this protein. The GST tag 
provides a simple way for “pulling out” the tagged protein and its interacting partners 
using glutathione coated beads. The technique can however also be used to fish for 
novel interacting proteins when using total lysate from the cells or tissue of interest. The 
present study aimed to produce and purify fusion proteins consisting of GST fused to the 
cytoplasmic tail of either CCR2B or CCR5 and then to use these proteins in a pull down 
assay with lysates from a monocytic cell line to identify novel endogenous interacting 
partners for the two receptors. Note that these experiments were planned before the lack 
of functional CCR5 on these cell lines (reported in Chapter 3) was fully investigated. 
The initial stages of this project, including the production of a construct coding for the 
cytoplasmic tail of CCR2B fused to GST and two initial pull down experiments, were 
carried out during my undergraduate final year research project in the Signoret 
Laboratory at the Department of Biology, University of York. These experiments led to 
the detection of five potential CCR2B-interacting proteins as bands on an SDS-PAGE 
gel showing the potential of using this GST pull down technique. 
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5.1.1.2 Immunoprecipitation 
Co-immunoprecipitation has also been widely used to confirm suspected protein-protein 
interactions. However, there have been some recent examples of co-
immunoprecipitation being used to identify novel interacting partners of chemokine 
receptors, including CXCR2 (Neel et al., 2009) and CCR2 (Favre et al., 2008), 
demonstrating the potential for this technique. 
Although the chemokine receptor cytoplasmic tail has been found to be essential for 
interaction with several proteins, some other receptor domains have also been shown to 
be involved in protein binding. Both CCR2B and CCR5 contain a DRY motif in their 
second intracellular loop, which is involved in the interaction of the receptor with its G 
protein (Lagane et al., 2005; Mellado et al., 1998). Additionally, β-arrestin can bind to 
both the DRY motif and the phosphorylated cytoplasmic tail of the receptor 
(Huttenrauch et al., 2002; Marion et al., 2006). This highlights the importance of using 
co-immunoprecipitation, in addition to the GST pull down, to identify proteins that fall 
into this category. 
Co-immunoprecipitation offers some technical advantages over the GST pull down. 
Firstly, the GST pull down experiment is carried out on cell lysate and so false 
interactions or fewer interactions may be experienced due to the loss of spatial 
organization and addition of detergent during lysis. This risk is reduced when using the 
co-immunoprecipitation technique as the protein-protein interactions happen in the cell 
itself, prior to lysis, where the proteins should be in their correct spatial environment. 
Secondly, interactions of some proteins, such as kinases, with chemokine receptors may 
be transient and/or weak and so could be lost during the washing steps of the GST pull 
down experiment, but the co-immunoprecipitation technique offers the potential to use 
various crosslinking methods to fix protein-protein interactions before lysis. 
Co-immunoprecipitation experiments can be carried out using either two purified 
proteins, a purified protein and a cell lysate containing the second protein of interest or 
alternatively a cell lysate containing both proteins of interest. The proteins used can be 
either endogenously expressed or over-expressed tagged or untagged versions of the 
proteins of interest, and the choice is often dependent on the availability of antibodies 
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targeting the protein. The use of lysates from cells endogenously expressing the proteins 
of interest provides greater confidence in the physiological relevance of the interactions.  
Therefore, as an antibody with a previously demonstrated ability to immunoprecipitate 
CCR5 (MC5; Signoret et al., 2004) and a panel of antibodies against CCR2 were 
available, the initial focus of this study was to use monocytic cell lines. However, recent 
observations about the lack of functionality of CCR5 expressed on these cells, as 
discussed in Chapter 3, lead to a change in the cell type used.  
HEK293 cell lines expressing TLR2 were transfected to express HA-tagged forms of 
CCR2B and CCR5 with the aim of enabling co-immunoprecipitation assays to be 
carried out on resting, chemokine agonist and/or LTA stimulated cells. Unfortunately, as 
discussed in chapter 3, the LTA cross-desensitisation of CCR2 and CCR5 discovered in 
monocytes was not sufficiently replicated in these cells. Nevertheless, the transfected 
HEK293 cells did provide several potential advantages over the monocytic cell lines in 
regards to agonist-induced down-modulation and so therefore were used for the 
immunoprecipitation set up experiments. Firstly, as both of the receptors had a HA-tag 
the same antibody could be used for co-immunoprecipitation experiments for each 
receptor. This would enable a fairer comparison of the proteins identified as interacting 
with each receptor by reducing influencing factors dependent on the antibody used. The 
system has extra advantages for CCR2, as using antibodies against the N-terminus of 
endogenous CCR2 in monocytic cells lines targets both isoforms of CCR2 present 
(CCR2A and CCR2B),whereas using the transfected cell lines would enable the study of 
CCR2B only. Additionally, as discussed in Chapter 3, the antibodies that I had available 
to target CCR2 were not very good, whereas the anti-HA antibody 12CA5 has been 
previously used for successful immunoprecipitation (Schweneker et al., 2005). This 
antibody could be produced in-house thus we could produce sufficient quantities for the 
scale of immunoprecipitation required. 
5.1.2 Objectives 
The initial objective of this chapter was to develop the GST pull down and co-
immunoprecipitation techniques to be used in combination with MS/MS for the 
identification of novel protein interactions for the two receptors. The second objective 
was to then use these techniques to compare the protein interactions between the two 
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receptors and under different conditions including resting, chemokine agonist or LTA 
stimulation.  
5.2 Relevant methodology 
5.2.1  Molecular biology techniques 
The CCR2B and CCR5 cDNA, with a N-terminal triple HA tag, cloned into the 
pcDNA3.1+ vector were purchased from the UMR cDNA Resource Centre. Constructs 
summarized in Table 5.2 were created encoding the cytoplasmic tails of the two 
receptors (residues 309 – 360 for CCR2B and residues 302 – 352 for CCR5) by standard 
molecular cloning techniques. 
Table  5.2 Constructs created or used in this project. 
 
 
Construct Encoded 
protein  
Cleavage site 
after GST 
How it was generated 
pGEX-4T-1 GST Thrombin Purchased from GE Healthcare. 
pGEX-4T-1-
CCR2Bct 
GST-CCR2Bct Thrombin Created during undergraduate project. 
pGEX-2T-CCR5ct GST-CCR5ct Thrombin Created previously by Nathalie Signoret 
(MRC-LMCB, UCL, London, UK). 
pGEX-4T-1-
CCR2Bct-HIS6 
GST-CCR2Bct-
HIS6 
Thrombin cDNA encoding CCR2Bct/CCR5ct amplified 
by PCR from pGEX-4T-1-CCR2Bct/CCR5ct 
with addition of a HIS6 tag, stop codon and 
EcoRI (CCR2) or XhoI (CCR5) site to the 3’ 
end. Cloned in to pGEX-4T-1 following 
BamHI and EcoRI/XhoI. 
pGEX-4T-1-
CCR5ct-HIS6 
GST-CCR5ct-
HIS6 
Thrombin 
pGEX-6P-1 GST Prescission 
Protease 
A gift from Gareth Evans (Department of 
Biology, University of York, UK). Originally 
purchased from GE Healthcare. 
pGEX-6P-1-
CCR2Bct 
GST-CCR2Bct Prescission 
Protease 
cDNA encoding CR2Bct/CCR5ct was excised 
from pGEX-4T-1-CCR2Bct/CCR5ct using 
BamHI and XhoI/EcoRI and cloned into 
pGEX-6P-1 vector digested with the same 
enzymes. 
pGEX-6P-1-CCR5ct GST-CCR5ct Prescission 
Protease 
pGEX-6P-1-
CCR2Bct-HIS6 
GST-CCR2Bct-
HIS6 
 
Prescission 
Protease 
cDNA encoding CR2Bct/CCR5ct-HIS6 was 
excised from pGEX-4T-1-CCR2B/CCR5ct-
HIS6 using BamHI and EcoRI/XhoI and 
cloned into pGEX-6P-1 vector digested with 
the same enzymes. 
pGEX-6P-1-
CCR5ct-HIS6 
GST-CCR5ct-
HIS6 
Prescission 
Protease 
pGEX-6P-1-gly-
CCR2Bct-HIS6 
GST-gly-
CCR2Bct-HIS6 
Prescission 
Protease 
Two complementary oligos encoding a 
glycine-rich linker (PGISGGGGG) were 
annealed and ligated into the BamHI site in 
pGEX-6P-1-CCR2Bct/CCR5ct-HIS6.  
pGEX-6P-1-gly-
CCR5ct-HIS6 
GST-gly-
CCR5ct-HIS6 
Prescission 
Protease 
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5.2.1.1 Oligos 
Custom oligos were purchased from Sigma-Aldrich. Oligos used for sequencing were 
provided by the relevant sequencing service. 
Table  5.3 Oligos used in this project. 
 
 
5.2.1.2  PCR 
The pGEX-4T-1-CCR2Bct construct was created during my undergraduate project. 
The PCR reagents used for amplification of the cDNA encoding CCR2Bct or CCR5ct 
and addition of a HIS6 tag are described in Table 5.4. Table 5.5 shows the PCR 
programme used. 
  
Oligo Name Oligo Sequence (5’ to 3’) Application Extra Information 
pGEX 5’ 
cloning 
forward 
primer 
GCC TTT GCA GGG CTG GCA 
AGC CAC GTT TGG T 
 Amplification of the cDNA 
encoding CCR2Bct from 
pGEX-4T-1-CCR2Bct with 
addition of a HIS6 tag, stop 
codon and EcoRI site to the 
3’ end. 
Binds pGEX at 861,  
upstream of the 
BamHI site used for 
cloning 
CCR2Bct 
HIS6 reverse 
primer 
GCG AAT TCC TCA CAC TAC 
TAC CAC CAC TAC TAA ACC 
AGC CGA GAC TTC C 
 
pGEX 5’ 
cloning 
forward 
primer 
GCC TTT GCA GGG CTG GCA 
AGC CAC GTT TGG T 
 Amplification of the cDNA 
encoding CCR5ct from 
pGEX-2T-CCR5ct with 
addition of a HIS6 tag, stop 
codon and XhoI site to the 
3’ end. 
Binds pGEX at 861, 
upstream of the 
BamHI site used for 
cloning 
CCR5ct HIS6 
reverse 
primer 
AGA CTC GAG TTA CAC TAC 
TAC CAC CAC TAC CAA GCC 
CAC AGA TAT TTC CTG C 
 
BamHI 
glycine linker 
1 
GA TCC CCA GGT ATT TCC 
GGT GGT GGT GGT GGA G 
 Addition of DNA encoding 
a glycine-rich linker 
between GST and 
CCR2B/5ct 
 
Contains a BsaWI 
site  
BamHI 
glycine linker 
2 
GA TCC TCC ACC ACC ACC 
ACC GGA AAT ACC TGG G 
Contains a BsaWI 
site  
pGEX 
5’/forward 
primer 
GGG CTG GCA AGC CAC GTT 
TGG TG 
 Sequencing pGEX 
constructs. 
Binds 869-891 of 
pGEX 
pGEX 
3’/reverse 
primer 
CCG GGA GCT GCA TGT GTC 
AGA GG 
Binds downstream of 
the multiple cloning 
site in pGEX 
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Table  5.4 PCR reagents. 
 
  
Table 5.5 PCR programme used in this project. 
 
 
5.2.1.3  Annealing oligos 
As the DNA encoding the glycine linker was short, two complementary oligos encoding 
the glycine linker with a BamHI site at either end were annealed together instead of 
using PCR. 0.5 pmol/µl of each oligo were incubated together in DNA ligase buffer in a 
thermocycler at 95 °C for 5 minutes. The temperature was then reduced by 1 °C every 
minute prior to incubation at the calculated nearest neighbour melting temperature (56 
°C) for 30 minutes and subsequent temperature reduction of  1 °C per minute until 4 °C 
was reached. 
5.2.1.4  Restriction enzyme digests 
Restriction enzyme digests of PCR products and recipient vectors were carried out using 
BamHI, EcoRI and XhoI (all from New England BioLabs [NEB], Hitchin, UK) prior to 
ligation steps to create the constructs described in Table 5.2. Typically the maximum 
possible volume of DNA was digested using 1 µl of each restriction enzyme using the 
appropriate buffer, and BSA if required, in a total volume of 20 µl by incubation at 37 
°C for 2 hours. 
Reagent Concentration in reaction mixture (total volume of 20 µl) 
Template DNA 10 ng 
Forward primer 1 µM 
Reverse primer 1 µM 
dNTPs (Invitrogen) 200 µM of each dNTP 
Buffer (Minerva Biolabs, Berlin, 
Germany) 
1 X 
Taq polymerase (Minerva Biolabs) 2 Units 
Magnesium chloride (Minerva 
Biolabs) 
1.5 mM 
PCR steps Temperature Duration 
a. Denature 94 °C 3 minutes 
b. Anneal 47 °C 1 minute 
c. Repeat the following cycles 36 times  
 Extend 72 °C 1 minute (2 minutes for first cycle only) 
 Denature 94 °C 1 minute 
 Anneal 64 °C 1 minute 
d. Extend 72 °C 8 minutes 
e. Store 4 °C Overnight 
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Restriction enzyme digests of constructs were carried out using BamHI, EcoRI, XhoI, 
BsaWI (NEB), Aat II (NEB), SwaI (NEB) and AfeI (SibEnzyme, Novosibirsk, Russia) 
to check the presence and orientation of inserts. Enough mini-prep or midi-prep DNA to 
visualise all of the digest fragments by gel electrophoresis, at least 200 ng DNA in most 
cases, was digested as described above using different temperature conditions or 
sequential incubations where advised by the manufacturer for specific enzymes.  
5.2.1.5  Ligation 
Prior to ligation, restriction enzyme-digested DNA fragments were run on an agarose 
gel, the correct bands were excised and the DNA was purified from the gel using the 
QIAquick gel extraction kit (Qiagen, Crawley, UK). Ligations were carried out using 
insert: vector ratios of 2:1 and 1:1 in a total volume of 10 µl using 3 units of T4 DNA 
ligase (Promega, Southampton, UK) for 1 hour at room temperature. 
5.2.1.6  Transformation 
Chemically competent DH5α, BL21, BL21 pLysS and BL21 Rosetta cells were 
prepared and transformations were carried out as follows. To prepare competent cells, a 
bacterial culture grown in 2xTY, with an OD600 of 0.4 – 0.8, was pelleted and the cells 
resuspended in 100 mM CaCl2, incubated on ice for 60 minutes before spinning down 
again and resuspending in 100 mM CaCl2 containing 20 % glycerol and freezing at – 80 
°C. For transformation, an aliquot of bacterial cells was mixed with 20 ng DNA, 
incubated at 4 °C for 30 minutes before being subjected to a 70 second 42 °C heat 
shock, then chilled and incubated in SOC medium at 37 °C for 60 minutes, plated on to 
LB agar with the appropriate antibiotic and grown overnight at 37 °C. BL21 and 
variants were selected using 25 µg/ml chloramphenicol. Ampicillin was used at 50 
µg/ml to select for bacteria containing the plasmid of interest.  
5.2.1.7  Purification of plasmid DNA 
Plasmid DNA was purified from transformed DH5α using either minipreparations 
following the alkaline lysis protocol from Molecular Cloning (Sambrook and Russell, 
2001) or mini, midi and maxi preparations (using the Plasmid kits from Qiagen). 
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5.2.1.8  DNA quantification 
DNA concentration of solutions was assessed by measuring the absorbance at 260 nm 
using the a spectrophotometer (6505 UV/Vis spectrophotometer, Jenway, Stone, UK) or 
the NanoDrop 1000 (NanoDrop Products, Thermo Scientific, Wilmington, DE, USA). 
In some cases, concentration was estimated from the band intensity of linearized 
plasmid (following restriction enzyme digest as described in Section 5.2.1.4) in 
comparison to bands of known mass in the 1 kb and 100 bp DNA ladders (NEB). 
5.2.1.9  Agarose gel electrophoresis 
1 - 1.5 % agarose gels containing SYBR Safe
TM
 (Invitrogen) or 0.5 µg/ml ethidium 
bromide in TAE buffer were used for most analytical gels. NuSieve GTG low-melting 
point agarose (Cambrex Bio Science Wokingham, Ltd, Wokingham, UK) was used for 
preparative gels. Gels were migrated at 50 V for 40 minutes and then visualised using 
UV light. 
5.2.2  DNA sequencing 
DNA sequencing of plasmid constructs was carried out either by the University of York 
Technology Facility or Geneservice (Source BioScience, Nottingham, UK) using pGEX 
5’/forward and/or pGEX 3’/reverse primers (Table 5.3), which binds either side of the 
insert. Sequences were aligned using Align (http://xylian.igh.cnrs.fr/bin/align-guess.cgi). 
5.2.3  GST fusion protein production and purification 
Constructs were transformed into BL21 DE3 pLysS, plated on LB Agar containing 50 
µg/ml ampicillin and 25 µg/ml chloramphenicol and incubated at 37 °C overnight. BL21 
DE3 (not chloramphenicol resistant) and BL21 Rosetta were also tested. One colony 
was used to inoculate LB containing 50 µg/ml ampicillin and 25 µg/ml chloramphenicol 
(LB amp+ cam+) and incubated at 37 °C overnight with agitation. This overnight 
preculture was then diluted 100 fold in LB amp+ cam+ and grown until the specified 
OD600 (typically OD600=0.9). Isopropyl-β-D-thiogalactopyranoside (IPTG) was added to 
a final concentration of 0.1 mM and the culture was incubated at 37 °C for the specified 
induction time (optimised to 15 minutes). The bacteria were harvested by centrifugation 
at 3500 rpm for 30 minutes at 4 °C. The bacterial pellet was resuspended in 45 ml (per 
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litre of culture) PBS containing a complete protease inhibitor cocktail and lysed using 
either a french press at 25 kpi or sonication (4 - 6 cycles of 30 seconds at 20 % 
amplitude with 45 seconds resting between each) as indicated, followed by the addition 
of 1 % Triton X-100 and incubation on ice for 30 minutes. Alternatively, where 
indicated the pellet was resuspended in 1/5
th
 culture volume of BugBuster
TM
 Protein 
Extraction Reagent (Merck) containing a complete protease inhibitor cocktail and 25 
U/ml DNase, and incubated for 30 min at RT. Following centrifugation at 10000 x g for 
15 minutes, the supernatant was used for purification of the fusion proteins. Fusion 
protein purification was trialled using both glutathione sepharose 4B beads (GE 
Healthcare) and cobalt resin (Pierce, Perbio Science UK Ltd). For purification using 
glutathione sepharose 4B beads, the supernatant was incubated with a 500 µl bed 
volume (per litre of culture) of beads at 4°C under rotation for between 1 and 16 hours 
as specified. The beads were washed 4 – 8 times with PBS 0.1 % Triton X-100 
containing a complete protease inhibitor cocktail. The bead-bound fusion protein was 
either used directly for the pull down or eluted with glutathione elution buffer and 
dialysed prior to the pull down. 
Where indicated, thrombin cleavage was carried out by incubation with 1 U thrombin 
per 100 µg fusion protein at 37 °C for 2 hours. Alternatively, Prescission Protease 
cleavage was carried out by incubation with one bed volume of 320 U/ml Prescission 
Protease at 4 °C overnight with end-over-end rotation and the eluate was kept for 
analysis.  
For purification using cobalt resin, the bacterial cell lysate supernatant was produced as 
mentioned above but using an EDTA-free protease inhibitor cocktail. The sodium 
chloride concentration was adjusted to 300 mM, 10 mM imidazole was added and the 
pH was adjusted to pH 7.4. The fusion protein from a 0.5 l culture was bound to a 0.5 or 
1 ml bed volume of cobalt resin either by applying the filtered supernatant to a column 
twice or by batch purification for 30 min at 4 °C with end-over-end rotation. The resin 
was washed with wash buffer (50 mM sodium phosphate, 300 mM NaCl, 10 mM 
imidazole, EDTA-free protease inhibitor cocktail; pH 7.4) and the fusion protein was 
eluted three times with a 2X bed volume of elution buffer (50 mM sodium phosphate, 
300 mM sodium chloride, 150 mM imidazole, EDTA-free protease inhibitor cocktail; 
pH 7.4) and analysed by SDS-PAGE. 
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5.2.4  GST pull down technique 
1.8 x 10
8
 THP-1 cells per pull down were washed in PBS and then lysed at 2 x 10
7
 
cells/ml in 1 % Triton lysis buffer containing a protease inhibitor cocktail at 4 °C for 30 
minute with end-over-end rotation followed by mild sonication.  After centrifugation, at 
2970 x g. for 5 minutes, the supernatant was kept and pre-cleared by two 30 minute 
incubations with 50 μl glutathione sepharose beads/ 108 cells at 4 °C with end-over-end 
rotation. The indicated amount of fusion protein bound beads, or already eluted fusion 
protein and glutathione sepharose beads was incubated with the pre-cleared lysate at 4 
°C with end-over-end rotation for the indicated time. The beads were then washed twice 
with 1% Triton lysis buffer. Proteins were eluted using reducing sample buffer. The 
same amount of GST-bound beads normalised to the same bead bed volume was used as 
a control. The same amount of fusion protein-bound beads was analysed to allow 
elimination of contaminant proteins. Samples were analysed by SDS-PAGE followed by 
mass spectrometry (MS) of individual bands where relevant. 
5.2.5 Protein identification by mass spectrometry 
Unique bands were excised from gels and destained, then subjected to in gel tryptic 
digest and analysed by MALDI-MS and MS/MS in the University of York Technology 
Facility (http://www.york.ac.uk/biology/technology-facility/proteomics/pr-
services/protein-id/). A Mascot (Perkins et al., 1999) search of the NCBInr database was 
then carried out to identify proteins. 
5.2.6 Immunoprecipitation 
Initial immunoprecipitation assays were carried out using protein A/G-coated agarose 
beads (Pierce, Perbio Science UK Ltd). 1 x 10
7
 MonoMac1 cells were lysed in RIPA 
buffer containing a complete protease inhibitor cocktail on ice with regular vortexing 
and mechanical disrubtion by pipetting. Lysis was confirmed by visual inspection using 
a brightfield microscope. Alternatively, 2 plates of approximately 70 % confluent HEK 
HA-CCR2B or HEK HA-CCR5 cells were harvested by scrapping in RIPA buffer 
containing a complete protease inhibitor cocktail. The cells were lysed by sonication 
using three 10-second cycles at 40 % amplitude with 30 seconds rest between cycles. 
Cell lysates were centrifuged to remove unbroken cells. In some experiments a pre-
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clearing step consisting of a 20 minute incubation of the cell lysate with an aliquot of 
protein A/G agarose was carried out at 4 °C with end-over-end mixing. The 
immunoprecipitation assay was then carried out following one of two protocols. In the 
original method, the cell lysate was first incubated with antibody, typically 5 µg/ml, for 
4 or 16 hours at 4 °C with end-over-end mixing, followed by a second incubation with 
20 µl bed volume of protein A/G agarose for 1.5 or 16 hours at 4 °C with end-over-end 
mixing. Alternatively the antibody was pre-bound to the beads before being incubated 
with the cell lysate. A 15 µl bead volume of beads was washed in PBS 1% BSA and 
incubated with the stated quantity of antibody (typically 5 µg) diluted in PBS containing 
protease inhibitors for 1 hour with end-over-end mixing. The antibody bound-beads 
were then washed in RIPA buffer containing 1 % BSA and incubated with the cell lysate 
containing 0.1 % BSA for 2 hours at 4 °C with end-over-end mixing. In both cases the 
beads were then washed four times in RIPA buffer followed by a final wash in 150 mM 
NaCl/20 mM TRIS before eluting bound proteins by addition of non-reducing sample 
buffer and a 5-minute incubation at 95 °C. Samples were analysed by SDS-PAGE 
followed by western blotting. 
Immunoprecipitation using protein A/G agarose leads to contamination of 
immunoprecipitated proteins with large amount of immunoglobulin and this can 
interfere with subsequent analysis by mass spectrometry as it may mask the presence of 
other less abundant proteins. Therefore two alternatives based on covalent 
immobilization of the antibody to a support were tested: BioMag® Amine (Bangs 
Laboratories, Indiana, USA) and AminoLink
®
 Plus Coupling Resin (Pierce, Perbio 
Science UK Ltd). 
When testing BioMag Amine, each antibody was coupled to pre-activated BioMag 
Amine at a ratio of 100 µg antibody and 150 µg BSA carrier protein to 100 µl 
BioMagAmine following the manufacturer’s standard protocol. The coupling efficiency 
was estimated by measuring the absorbance at 280 nm using a spectrophotometer (6505 
UV/Vis spectrophotometer) of the pre and post-coupling solutions. The BioMag Amine 
particles were washed with RIPA buffer followed by RIPA buffer containing 1 % BSA 
and protease inhibitors before use. Typically four 70 % confluent 10 cm plates of 
transfected HEK293 cells cells per sample were washed with PBS and harvested in 0.35 
ml RIPA buffer containing a complete protease inhibitor cocktail per plate using a cell 
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scraper. The cells were lysed by sonication using three 10-second cycles at 40 % 
amplitude with 30 seconds resting between each, and then centrifuged to remove 
unbroken cells and an aliquot was taken for analysis. The cell lysate was pre-cleared by 
a 20-minute incubation with 10 µl BioMag Amine at 4 °C with end-over-end mixing. 
BSA was added to the pre-cleared cell lysate at a final concentration of 1 % and this was 
incubated with 10 µg antibody coupled to BioMag Amine particles for 2 hours at 4 °C 
with end-over-end mixing. Four washes were carried out over 30 minutes in RIPA 
buffer followed by a final wash in 150 mM NaCl/20 mM TRIS. Immunoprecipitated 
proteins were removed from the antibody and BioMag Amine by a two stage acid 
elution process, either using 0.1 M glycine pH2.4 for the first 1-minute and second 10-
minute steps or by using 0.1 M glycine pH2.8 followed by pH2.4. After addition of 
sample buffer, the acid pH was neutralised using 1M TRIS and eluted 
immunoprecipitation samples, but not cell lysate samples, were incubated at 95 °C for 5 
minutes before analysis by SDS-PAGE and western blotting. 
When testing AminoLink
®
 Plus Coupling Resin, each antibody was coupled to beads at 
a ratio of 1 µg antibody to 1 µl beads following the manufacturer’s standard protocol. 
The coupling was checked by Coomassie (0.1 % Phast Gel
TM
 Blue K from GE 
Healthcare) staining of the antibody solution used for coupling and the flow-through 
from the coupling column spotted onto filter paper. A plate of transfected HEK293 cells 
was washed twice in PBS and the cells were scraped into 1 ml 1 % NP-40 lysis buffer, 
incubated on ice or at 4 °C with end-over-end rotation for 10 to 20 minutes and then 
centrifuged to remove the unbroken cells and debris and an aliquot taken for analysis. 
Typically the cell lysate from half of a 70 % confluent 10 cm plate was incubated with 
100 µg antibody coupled to beads for 2 hours at 4 °C with end-over-end mixing. The 
beads were then transferred to a column and washed four times in 1 % NP-40 lysis 
buffer followed by a wash in Pierce conditioning buffer. Two sequential elutions were 
carried out; first an incubation with 300 µl Pierce elution buffer for 1 min at 4 °C, then a 
second incubation with 700 µl Pierce elution buffer for 10 minutes at room temperature. 
The eluate was neutralised by addition of 1 M Tris-HCl, pH8 until approximately pH7 
was reached. After addition of non-reducing sample buffer, aliquots of the eluted 
immunoprecipitation samples, but not the cell lysate samples, were incubated at 95 °C 
for 5 minutes before analysis by SDS-PAGE and western blotting. 
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Elutions using 30 µl then 70 µl of the following elution buffers were also tested using 
12.5 % of the beads from a single immunoprecipitation experiment: 100 mM 
triethylamine pH 11.5, 100 mM glycine pH 2.5, 5 M LiCl/10 mM phosphate pH7.2 and 
3.5 M MgCl2/10 mM phosphate pH7.2. 
When required, eluate was concentrated using a Vivaspin 500 with a 5 kDa molecular 
weight cut off (Generon, Maidenhead, UK) and the sample was centrifuged for 110 
minutes at 15000 xg, 4 °C. Dialysis against Aquacide II (Calbiochem) using a dialysis 
cassette with a 10 kDa molecular weight cut off (Pierce, Perbio Science UK Ltd) for 40 
minutes at 4 °C was also tested. Alternatively, samples were subjected to trichloracetic 
acid (TCA) precipitation for 30 minutes at 4 °C using a 20 % w/v trichloroacetic acid 
solution and then pelleted by centrifugation for 15 minutes at 22000 xg. The pellet was 
washed twice with cold acetone and pelleted again by centrifugation for 5 minutes at 
22000 xg, 4 °C, dried by incubation at 95 °C for 10 minutes, resuspended in sample 
buffer and incubated at 95 °C for 5 minutes. 
5.3 Results 
5.3.1 GST pull down: Optimization of GST-fusion protein production and 
purification 
The starting point for this project was to use the previously created constructs encoding 
GST fused to the cytoplasmic tail of CCR2B or CCR5 (GST-CCR2Bct and GST-
CCR5ct) to improve the assay for the production and purification of these fusion 
proteins. 
5.3.1.1 GST fusion proteins are produced but are contaminated with GST 
The GST-CCR2Bct and GST-CCR5ct fusion proteins were expressed in the BL21 DE3 
strain of E.coli, as this is deficient in Ion and OmpT proteases, and purified from the 
bacterial cell lysates using glutathione sepharose beads. Expression of the fusion 
proteins was confirmed by the western blot detection of bands of the expected molecular 
weights (32 kDa) in bacterial cell lysates and/or bound to the beads following 
purification, using antibodies against both GST and the receptor cytoplasmic tails 
(Figure 5.1). However, probing with the α-GST antibody (Figure 5.1) also showed the 
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presence of a couple of significant contaminating lower molecular weight products of 
approximately the same size as GST (~26 kDa).   
 
Figure  5.1 Production and purification of GST-CCR2B/5ct fusion proteins. 
GST-CCR2Bct (A) and GST-CCR5ct (B) fusion proteins were produced in BL21 DE3 following a 1 hour 
induction at OD600 = 0.6 (CCR2) or 0.8 (CCR5) using IPTG. Following lysis by sonication, the bacterial 
cell lysate was centrifuged to give the pellet (insoluble, I) and supernatant (soluble, S) fractions. The 
fusion protein was purified from the supernatant by a 2 hour incubation with glutathione sepharose beads. 
Equal fractions of the pellet and supernatant and a portion of the beads were analysed by SDS-PAGE 
followed by Coomassie staining or western blotting using α-GST, α-CCR2  (CCR2 C-20) or α-CCR5 
(RC-10) antibodies, to enable identification of the fusion protein and contaminants. 
 
After confirming the lack of contamination with parental plasmid DNA by enzyme 
digests, the question of whether the GST contamination was due to the production of a 
truncated fusion protein during translation or due to degradation of the intact fusion 
protein was addressed. As nearly 10 % of the DNA encoding the CCR2B cytoplasmic 
tail is made up of codons that are rarely used in E.coli, it was hypothesized that 
translation of the fusion protein may be halted  after translating the GST. Production 
using E.coli BL21 Rosetta, which is optimised for translation of DNA containing rare 
codons, did not reduce the amount of GST (Figure 5.2), thus suggesting that the GST is 
not a truncated product due to premature termination of translation. Finally, western 
blots have shown that the GST is present at the end of the induction step before lysis and 
that the degradation increases with induction time (Figure 5.3). Taken together these 
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experiments suggest that the fusion proteins are unstable and that the GST is a 
degradation product produced by C-terminal degradation by exoproteases during the 
production in E.coli. 
 
 
Figure  5.2 Production and purification of GST-CCR2B in different strains of E.coli. 
GST-CCR2Bct (A) and GST-CCR5ct (B) fusion proteins were produced in BL21 DE3, BL21 Rosetta and 
BL21 pLysS as indicated following a 1 hour induction at OD600 = 0.5 – 0.8 using IPTG. Following lysis 
by sonciation, the bacterial cell lysate was centrifuged and the fusion protein was purified from the 
supernatant by a 2 hour incubation with glutathione sepharose beads. An equal fraction of the beads from 
each experiment were analysed by SDS-PAGE followed by Coomassie staining. 
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Figure  5.3 The GST-CCR2Bct fusion protein is degraded during production. 
(A) GST-CCR2Bct and GST-CCR5ct fusion proteins were produced in BL21 pLysS following a 15 
minute induction at OD600 = 0.9 using IPTG. A sample of bacteria was taken before lysis and lysed in 
SDS-PAGE loading buffer (BL). Following lysis using BugBuster, the bacterial cell lysate was 
centrifuged to give the pellet (insoluble, I) and supernatant (soluble, S) fractions. Equal fractions of I, S 
and BL were analysed by SDS-PAGE followed by western blotting using α-GST. (B) GST-CCR2Bct 
fusion proteins were produced in BL21 pLysS following induction for the indicated time at OD600 = 0.65 
using IPTG. Following lysis using Bug Buster, the bacterial cell lysate was centrifuged to give the pellet 
(insoluble, I) and supernatant (soluble, S) fractions. Equal fractions of I and S were analysed by SDS-
PAGE followed by western blotting using α-GST. 
 
5.3.1.2 Approaches tested to reduce GST contamination 
The use of mass spectrometry as the downstream analysis method following GST pull 
downs requires the removal of the large amounts of contaminating GST (Daulat 2009). 
Three different approaches were trialled: (a) to reduce the level of degradation during 
production, (b) performing extra purification steps to enable isolation of the GST fusion 
protein only after production, (c) to remove the contaminating GST at a later stage. 
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(a) Various inductions times were tested to try to reduce the degradation during 
production. Shorter induction times were shown to lead to less GST contamination 
(Figure 5.3B). The optimal conditions were found to be a 15 minute induction starting 
with bacteria at OD600=0.9. 
(b) Isolation of the intact fusion protein from the degradation product would lead to a 
large reduction in the amount of GST present. Doubly-tagged constructs coding for the 
CCR2B/CCR5 cytoplasmic tail with the original N-terminal GST tag and an extra C-
terminal poly-histidine (HIS6) tag were produced. A second version of each fusion 
protein was created with a glycine linker (Guan and Dixon, 1991; Hakes and Dixon, 
1992) between GST and CCR2Bct/CCR5ct. As the fusion protein is degraded from the 
C-terminus, purification using cobalt resin to bind to the C-terminal HIS6 tag should 
enable isolation of only intact fusion proteins. However, very little or no fusion protein 
was successfully isolated (Figure 5.4A). Isolation of the fusion protein using glutathione 
beads instead showed that the fusion protein and the degradation product were still 
present (Figure 5.4B). Western blots confirmed the presence of the fusion protein 
(Figure 5.4B) but not the HIS6 tag (data not shown). These results suggest that the HIS6 
tag is partially degraded during the fusion protein production. However, it does appear 
to have a protective effect in reducing the level of degradation product (Figure 5.7). 
(c) An alternative approach is to carry out the GST pull down using the fusion protein in 
the presence of the contaminating GST and then to remove the GST prior to downstream 
analysis. The GST-CCR2Bct fusion protein contains a thrombin cleavage site between 
GST and CCR2Bct and so thrombin was tested for its ability to cleave off the CCR2Bct 
part of the fusion protein leaving the GST bound to the beads. Following a 2 hour 
incubation at 37 °C, the ratio of fusion protein:GST remaining on the beads was 
compared to a controls incubated without thrombin at 4 °C and 37 °C (Figure 5.5). No 
difference was observed, showing that the cleavage was not successful. Longer 
incubation times were not tested due to the tendency of the fusion protein to be 
degraded. Instead a different enzyme, Precission Protease, which is optimally active at 4 
°C, was tested.  This enzyme has the added advantage of a GST tag, which should 
facilitate its removal from the sample, thus reducing the amount of contaminating 
proteins. CCR2Bct was cloned into an alternative vector, pGEX6P1, which contains the 
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Precission Protease site after GST. Overnight incubation at 4°C with at least 320 U/ml 
beads of Prescission Protease was sufficient for cleavage (Figure 5.6). 
 
Figure  5.4 Production and purification of GST-CCR2B/5ct-HIS6. 
(A)The indicated fusion proteins were produced in BL21 pLysS following a 1 hour induction at OD600 = 
0.6 – 0.7 (GST-CCR2Bct-HIS6 and GST-CCR5ct-HIS6) or a 15 minute induction at OD600 = 0.9 (GST-
GLY-CCR5ct-HIS6) with IPTG. Following lysis by sonication (GST-CCR2Bct-HIS6 and GST-CCR5ct-
HIS6) or french press (GST-GLY-CCR5ct-HIS6),  the bacterial cell lysate was centrifuged and the fusion 
protein was purified from the supernatant by batch purification (GST-CCR2Bct-HIS6 and GST-CCR5ct-
HIS6) or on a column (GST-GLY-CCR5ct-HIS6)  using cobalt resin. Following elution, the purified 
protein was analysed by SDS-PAGE and Coomassie staining. (B) GST-CCR2Bct-HIS6 and GST-CCR5ct-
HIS6 were produced in BL21 pLysS following a 1.5 hour induction at OD600 = 0.6 – 0.7 using IPTG. 
Following lysis by sonication the fusion proteins were purified from the supernatant by an 18 hour 
incubation with glutathione sepharose beads. An equal fraction of the beads from each experiment was 
analysed by SDS-PAGE followed by Coomassie staining or western blotting using α-GST, α-CCR2  
(CCR2 C-20) or α-CCR5 (RC-10) antibodies as indicated. 
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Figure  5.5 Testing thrombin cleavage of fusion proteins. 
GST-CCR2Bct fusion protein bound glutathione sepharose beads were incubated with or without (control) 
thrombin at 37 °C or 4 °C (control) as indicated for 2 hours. The beads and eluate were then analysed by 
SDS-PAGE and Coomassie staining. 
 
Figure  5.6 Testing Prescission Protease cleavage of fusion proteins. 
GST-CCR2Bct fusion protein bound glutathione sepharose beads were incubated with the indicated 
concentration of Prescission Protease for 15 hours at 4 °C. The beads were then analysed by SDS-PAGE 
and Coomassie staining.  
5.3.1.3 The GST fusion proteins are partially insoluble 
In addition to being rapidly degraded, the fusion proteins were also partially insoluble.  
For GST-CCR2Bct the ratio of insoluble to soluble protein was approximately 2:1 when 
using a 2 hour induction (Figure 5.3B), however this was even higher for GST-CCR5ct. 
The ratio was improved by shortening the induction time to 15 minutes (Figures 5.3B 
and 5.7). The HIS6-tagged constructs were less soluble than their non-tagged versions 
(Figure 5.7), and for the CCR2 constructs this resulted in an approximately 10 fold 
lower yield after purification (Table 5.6).  
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Figure  5.7 Comparison of the solubility of the different GST fusion proteins for CCR2B  
(A) and CCR5 (B). 
The indicated CCR2B (A) or CCR5 (B) fusion proteins were produced in BL21 pLysS following a 15 
minute induction at OD600 = 0.9 using IPTG. Following lysis using Bug Buster, the bacterial cell lysate 
was centrifuged to give the pellet (insoluble, I) and supernatant (soluble, S) fractions. Equal fractions of I 
and S were analysed by SDS-PAGE followed by western blotting using α-GST. 
Several production conditions that are known to influence fusion protein solubility were 
tested. Changing the growth temperature, induction time and bacterial density at the 
time of induction gave no significant improvement in the fusion protein solubility 
(Figure 5.8). However, improving the lysis conditions used did increase the fusion 
protein solubility (data not shown). Producing the fusion protein in BL21 pLysS, which 
contains bacteriophage T7 lysozyme, improved the GST-CCR2Bct insoluble:soluble 
ratio from ~2:1 to ~1:1. Using a French press instead of sonication also gave better 
solubility. 
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Figure  5.8 Changing the growth temperature (A) or bacterial density at the time of 
induction (B) gave no significant improvement in the fusion protein solubility. 
(A) The GST-CCR2Bct fusion protein was produced in BL21 pLysS following an induction at the 
indicated temperature for the indicated time at OD600 = 0.7 (37 and 30 °C) or 0.6 (26 or 18 °C) using 
IPTG. Following lysis using Bug Buster, the bacterial cell lysate was centrifuged to give the pellet 
(insoluble, I) and supernatant (soluble, S) fractions. Equal fractions of I and S were analysed by SDS-
PAGE followed by western blotting using α-GST. (B) The GST-CCR2Bct fusion protein was produced in 
BL21 pLysS following an induction for the indicated time at the indicated OD600 using IPTG. Following 
lysis using Bug Buster, the bacterial cell lysate was centrifuged to give the pellet (insoluble, I) and 
supernatant (soluble, S) fractions. Equal fractions of I and S were analysed by SDS-PAGE followed by 
western blotting using α-GST. 
5.3.1.4 GST fusion protein yields 
Following various optimization experiments, a successful assay has been developed for 
production of the GST-CCR2Bct fusion protein in E.coli BL21 DE3 pLysS followed by 
purification on glutathione sepharose beads. Although not all of the fusion protein binds 
to the beads, using a bed volume of 0.5 ml beads per litre of culture, this assay yields 2 – 
8 µg fusion protein/µl beads (Table 5.6). This yield is suitable for use in the GST pull 
down assay. Lower yields were obtained using other GST-CCR2Bct fusion proteins. 
The CCR5 fusion proteins appeared to be less stable and less soluble that their CCR2B 
equivalents. The maximum concentration of CCR5 fusion protein that could be obtained 
under the conditions used was at least 20 fold lower than for CCR2B and was 
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insufficient for GST pull down assays (Table 5.6). Therefore, this technique could not 
be used to identify and compare interacting partners of CCR2B and CCR5. 
Table  5.6 Yields of GST fusion proteins following production in E.coli BL21 and 
purification on glutathione sepharose beads. 
 
 
5.3.2 GST pull-down: Identification of interacting proteins 
The GST-CCR2Bct fusion protein was used for an initial set of four pull down 
experiments using cell lysate from monocytic THP-1 cells. Following separation of 
bound proteins by SDS-PAGE, eleven bands (Figure 5.9) were identified as specific to 
the GST-CCR2Bct pulldown and were analysed by MALDI-MS and MS/MS.  
The majority of the proteins were identified as GST due to the large amount of fusion 
protein and contaminant GST loaded on the gel. However, two proteins of interest, 
human β-tubulin and importin 7, were identified through a Mascot search using the 
NCBInr database with probability based Mowse scores of 450 and 201 respectively.  
Due to technical difficulties in the production of GST-contaminant free fusion proteins, 
no further work was carried out using this technique to identify CCR2B interacting 
partners in chemokine agonist or LTA-stimulated cells. 
 
 
 
Fusion Protein Glutathione sepharose bead-
bound Yield (µg/µl beads) 
Yield (mg/L culture produced) 
when purified on glutathione 
sepharose beads 
GST-CCR2Bct 
(1)
 2 – 8 1 – 4 
GST-CCR2Bct-HIS6 
(2)
 0.2 - 0.8 0.1 – 0.4 
GST-gly-CCR2Bct-HIS6 
(3)
 0.3 0.15 
GST-CCR5ct 
(4)
 0.08 0.042 
GST-CCR5ct-HIS6 Not estimated but < for GST-CCR2Bct-HIS6 
GST-gly-CCR5ct-HIS6 
(5)
 0.1 0.05 
Constructs used to produce fusion proteins: (1) pGEX-4T-1-CCR2Bct and pGEX-6P-1-CCR2Bct, 
(2) pGEX-4T-1-CCR2Bct-HIS6 and pGEX-6P-1-CCR2Bct-HIS6, (3) pGEX-6P-1-gly-CCR2Bct-
HIS6, (4) pGEX-2T-CCR5ct, (5) pGEX-6P-1-gly-CCR5ct-HIS6 
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Figure  5.9 GST pull down experiment. 
A GST pull down experiment was carried out using equal amounts of GST-CCR2Bct bound glutathione 
sepharose beads (pull down), GST bound glutathione sepharose beads (control 1) or just glutathione 
sepharose beads (control 2) incubated with THP-1 cell lysate. These pull down samples, a sample of the 
GST-CCR2ct bound glutathione sepharose beads and a sample of the THP-1 cell lysate used for the pull 
down were analysed by SDS-PAGE and Coomassie staining. Arrows 1 – 11 mark bands that are unique to 
the pull down and are not found in either of the controls. These bands were submitted for analysis by 
MALDI-MS and MS/MS. Bands A and B were identified as human β-tubulin and importin 7 through a 
Mascot search using the NCBInr database with probablility based Mowse scores of 450 and 201 
respectively.  
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5.3.3 Immunoprecipitation 
5.3.3.1 Immunoprecipitation of receptors from monocytic cell lines 
A selection of anti-CCR2 antibodies (E68, H-40) and anti-CCR5 antibodies (2D7, 3A9, 
CCR5 NT, HEK/1/85a, MC5, T21/8) were tested for their ability to immunoprecipitate 
the receptors from the monocytic cell-line MonoMac 1. None of the antibodies tested 
were successful in the conditions used for immunoprecipitation (Figure 5.10). 
 
Figure  5.10 Testing a selection of α-CCR2 (E68, H-40) and α-CCR5 (2D7, 3A9, CCR5 NT, 
HEK/1/85a, MC5, T21/8) antibodies for immunoprecipitation of the receptors from the 
monocytic cell line MonoMac 1. 
For each antibody tested, pre-cleared MonoMac cell lysate from 1 x 10
7
 cells was incubated with 2 μg (H-
40, T21/8), 5 μg (2D7, 3A9, CCR5 NT, HEK/1/85a), 7.5 μg (MC5) or a 1:50 dilution (E68) of the 
indicated antibody for 16 hours at 4 °C, followed by a 1.5 hour incubation at 4 °C with protein A/G 
agarose beads. After washing, the beads were boiled in non-reducing loading buffer for 5 minutes to 
eluate any bound proteins and this was analysed by SDS-PAGE followed by western blotting using α-
CCR2 (CCR2 C-20) or α-CCR5 (CCR5 C-20) as indicated. The red arrow indicates the expected 
molecular weight (41 kDa) for CCR2B and CCR5 based on their primary amino acid sequences.  
5.3.3.2 Immunoprecipitation of receptors from transfected HEK293 cells 
Due to the lack of functional CCR5 expressed on the monocytic cell-lines THP-1 
(Chapter 3) and MonoMac1, subsequent immunoprecipitation assay development was 
carried out for transfected HEK293 cells. 
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This work was performed prior to the identification of the existence of multiple forms of 
HA-CCR2B in transfected HEK293 cells. The ‘normal’ forms of HA-CCR2B and HA-
CCR5 were successfully immunoprecipitated from transfected HEK293 cells using the 
anti-HA antibody 12CA5 (HA-CCR2B) and MC5 (CCR5) (Figure 5.11). However, the 
higher molecular weight modified forms of HA-CCR2B were either not 
immunoprecipitated at all or only immunoprecipitated in very low amounts that could 
not be detected by western blot under the conditions used. At the time it was not known 
that the plasma membrane form of CCR2B is the higher molecular weight glycosylated 
form and further work was carried out into immunoprecipitation of the intracellular 
‘normal’ molecular weight form. In retrospect this was unlikely to yield any interacting 
proteins of interest to this project. 
 
 
Figure  5.11 : Immunoprecipitation of HA-CCR2B and HA-CCR5 from transfected 
HEK293 cells using 12CA5 (CCR2B) or MC5 (CCR5). 
Pre-cleared HEK, HEK HA-CCR2B or HEK HA-CCR5 cell lysate was incubated with 5 μg (12CA5, 
mouse IgG2b) or 7.5 μg (MC5, mouse IgG2a) antibody pre-bound to protein A/G-coated agarose beads 
for 2 hours at 4 °C. After washing, the beads were boiled in non-reducing loading buffer for 5 minutes to 
eluate any bound proteins and this was analysed by SDS-PAGE followed by western blotting using α-HA 
(HA.11,for HA-CCR2) or α-CCR5 (MC5, for HA-CCR5). 
An experiment comparing the amount of HA-CCR2B and HA-CCR5 remaining in cell 
lysates incubated with protease inhibitors at 4°C overnight, showed that the receptors 
are rapidly degraded (Figure 5.12).  Therefore, optimisation of the immunoprecipitation 
conditions was vital. 
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Figure  5.12 Degradation of HA-CCR2B and HA-CCR5 in cell lysate over time. 
HEK HA-CCR2B and HEK HA-CCR5 cells were lysed in RIPA buffer containing a complete protease 
inhibitor cocktail, sonicated and centrifuged to remove unbroken cells. Cell lysate samples from before 
(time = 0 h) and after (time = 23 h) an incubation at 4 °C for 23 hours were analysed by SDS-PAGE 
followed by western blotting using α-HA (HA.11). Arrows mark the high (red) and “normal” (green) 
molecular weight forms of HA-CCR2B.  
Immunoprecipitation of HA-CCR2B using 12CA5 bound to protein A/G beads resulted 
in major contamination of the immunoprecipitated HA-CCR2B with immunoglobulin, 
which is observed by western blot as multiple contaminating bands (Figure 5.13). Cross-
linking the antibody to AminoLink
®
 Plus Coupling Resin or covalently binding it to 
BioMag® Amine particles resulted in much cleaner immunoprecipitated HA-CCR2B 
(Figure 5.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5.13 Immunoprecipitation of HA-CCR2B using 12CA5 and different bead 
supports. 
Pre-cleared HEK or HEK HA-CCR2B  cell lysate from four 70 % confluent plates was incubated with 16 
μg 12CA5 or IgG2b pre-bound to protein A/G agarose (12CA5) or 16 μg 12CA5 covalently coupled to 
AminoLink Plus Coupling Resin (cross-linked 12CA5), for 2 hours at 4 °C. (B) Pre-cleared HEK HA-
CCR2B cell lysate from four 70 % confluent plates was incubated with 10 µg 12CA5 covalently coupled 
to BioMag Amine for 2 hours at 4 °C. After washing, all beads were boiled in reducing loading buffer for 
5 minutes to elute any bound proteins and this was analysed by SDS-PAGE followed by western blotting 
using α-HA (HA.11). 
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Several different ratios of 12CA5 antibody to cells were tested to find the best ratio to 
use to enable immunoprecipitation of the majority of the HA-CCR2B in a 2 hour 
incubation. Using a ratio of 200 μg 12CA5 antibody per 10 cm plate (70 % confluent) of 
transfected HEK293 cells was found to result in immunoprecipitation of approximately 
97 % of the ‘normal’ HA-CCR2B band (Figure 5.14). Immunoprecipitation using 10 μg 
12CA5 was sufficient to visualise the immunoprecipitated HA-CCR2B by western blot. 
However, identification of novel interacting proteins by MS following co-
immunoprecipitation ideally requires sufficient protein for visualisation on a SDS-
PAGE gel by Coomassie staining.  No HA-CCR2B was observed by SDS-PAGE 
following immunoprecipitation using up to 100 µg 12CA5 suggesting that further scale 
up would be necessary. Based on the western blot results and the knowledge that 
western blotting is more than 100 fold more sensitive than Coomassie staining (Gillespie 
and Hudspeth, 1991), it was estimated that at least 1 mg 12CA5 antibody would be 
required to immunoprecipitate enough receptor to visualise on a Coomassie stained gel.  
Figure  5.14 Immunoprecipitation of HA-CCR2B from HEK HA-CCR2B cell lysates. 
HEK HA-CCR2B cell lysate from half of a 70 % confluent plate was incubated with 100 µg 12CA5 
covalently coupled to AminoLink Plus Coupling Resin for 2 hours at 4 °C. Equal fractions of the cell 
lysate before and after this immunoprecipitation were analysed by SDS-PAGE followed by western 
blotting using α-HA (HA.11). The green arrow indicates the “normal” molecular weight form of HA-
CCR2B that is immunoprecipitated.  
Following the identification of conditions for successful immunoprecipitation of HA-
CCR2B, I encountered the unexpected technical problem of being unable to efficiently 
elute the immunoprecipitated receptor and interacting proteins. This elution step is 
necessary to enable reuse of the 12CA5 linked beads due to the large amount of 12CA5 
antibody and AminoLink
®
 Plus Coupling Resin required per immunoprecipitation 
experiment and to allow downstream MS analysis that is not dependent on SDS-PAGE. 
However, the standard Pierce elution buffer gave low recovery of the 
immunoprecipitated HA-CCR2B in the eluate (Figure 5.15A). A range of other elution 
conditions based on different principles, including altered pH and salt concentration, 
were tested but none gave an efficient elution (Figure 5.15B). Boiling the beads after 
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elution confirmed that only a small proportion of the immunoprecipitated bound 
receptor is actually eluted, the rest remains bound to the 12CA5 linked beads. 
  
Figure  5.15 Recovery of immunoprecipitated HA-CCR2B following elution. 
(A) HEK HA-CCR2B cell lysate from half of a 70 % confluent plate was incubated with 100 µg 12CA5 
covalently coupled to AminoLink Plus Coupling Resin for 2 hours at 4 °C. After washing, bound proteins 
were eluted using Pierce elution buffer. Equal fractions of the cell lysate before and after this 
immunoprecipitation and of the eluate were analysed by SDS-PAGE followed by western blotting using 
α-HA (HA.11). The green arrow indicates the “normal” molecular weight form of HA-CCR2B  that is 
immunoprecipitated. (B) HEK HA-CCR2B cell lysate from half of a 70 % confluent plate was incubated 
with 100 µg 12CA5 covalently coupled to AminoLink Plus Coupling Resin for 2 hours at 4 °C. After 
washing, the resin was split into eight portions and each was used for elution with either none or one of a 
range of elution buffers as inducated. The beads were then boiled in non-reducing buffer and analysed 
alongside the eluates as for (A). 
The inefficient elution resulted in a low concentration eluate, which required 
concentration to enable analysis by SDS-PAGE or mass spectrometry. Several mass 
spectrometry compatible concentration methods were tested including the VivaSpin 
concentrator, using a dialysis cassette in conjuction with Aquacide and TCA 
precipitation. The Vivaspin and dialysis cassette concentration methods were both 
unsuccessful in retaining HA-CCR2B in the sample, however TCA precipitation 
resulted in some recovery of HA-CCR2B.  
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5.4 Discussion 
5.4.1 GST pull-down: successful outcomes 
Reasonable yields of the GST-CCR2Bct fusion protein were obtained and used for a set 
of initial GST pull down experiments using THP-1 cells under resting conditions. These 
experiments identified two potential CCR2B interacting partners: the structural protein 
β-tubulin and the nuclear import protein importin 7. Importin 7 was previously 
identified as a possible CCR2B interacting partner by co-immunoprecipitation, although 
this potential interaction was not further characterised (Favre et al., 2008). 
β-tubulin is a structural protein that is present in large amounts in the cell and so may be 
hypothesised to bind non-specifically to GST-CCR2Bct. However, actin, another major 
structural protein was not identified and the β-tubulin-containing band was consistently 
present in all of the pull down samples whilst not being observed with either of the two 
controls. β-tubulin has been shown to be a non-GPCR substrate of GRK2 (Pitcher et al., 
1998), which is also responsible for the agonist-induced phosphorylation of CCR2 
(Aragay et al., 1998). As GPCR substrates have been shown to activate GRK2 upon 
binding (Kim et al., 1993), it is possible that β-tubulin may interact with CCR2 via 
GRK2. However, the identification of tubulin as a common protein in the sepharose 
beadome (Trinkle-Mulcahy et al., 2008) suggests that, despite not being obviously 
present in the controls, it is likely that β-tubulin binds non-specifically to the beads used 
for the pull down. 
Importin 7 is a member of the importin β family, which are involved in translocation of 
proteins across the nuclear membrane. Therefore, its interaction with CCR2B might 
suggest the possibility of CCR2B localising to the nucleus. The idea of a chemokine 
receptors trafficking to the nucleus is controversial and currently under debate. Agonist 
binding of a GPCR at the cell surface leads to various intracellular signaling cascades 
and can result in transcriptional regulation within the nucleus. Over the last decade there 
have however emerged several reports of ligand–bound GPCRs trafficking to the 
nucleus where they can initiate different and sometimes opposite functional responses to 
the signaling from cell surface receptors (Goetzl, 2007). CXCR4 is commonly expressed 
by tumour cells where it has been observed to localise to the nucleus in addition to the 
cytoplasmic and some limited plasma membrane expression (Speetjens et al., 2009; 
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Wang et al., 2005). However, it is important to bear in mind that most studies showing 
nuclear localisation of CXCR4 were carried out on fixed cells (Na et al., 2008; Speetjens 
et al., 2009; Wang et al., 2009; Wang et al., 2010a; Wang et al., 2005; Woo et al., 2008; 
Yao et al., 2011). In some circumstances, fixation processes can cause the collapse of 
intracellular membranes and organelles (Hoetelmans et al., 2001; LaJeunesse et al., 
2004), thus rendering it difficult to distinguish between ER and nuclear membranes. It 
has been suggested that under certain conditions CXCR4 can traffic to the nucleus 
following long-term agonist stimulation (Wang et al., 2009). As this study did not use 
cell surface labelled receptors, it cannot be determined that the CXCR4 observed in the 
nucleus was actually derived from the cell surface pool of receptor. Therefore the 
possibility of receptor transport from the ER to the nucleus during biosynthesis remains 
to be explored. A single study reported for CCR2 shows nuclear expression in 
transfected HEK and HeLa cells that is increased upon agonist stimulation (Favre et al., 
2008).  
The role played by nuclearly localised chemokine receptors is currently unknown. For 
CXCR4 it is believed to be different to that played by the cytoplasmic receptor and has 
been frequently linked to poor prognosis for cancer patients (Na et al., 2008; Speetjens 
et al., 2009; Wang et al., 2009; Wang et al., 2010b; Woo et al., 2008; Xiang et al., 2009; 
Yao et al., 2011). It has recently been suggested that nuclear CXCR4 may promote 
tumour metastasis, as its presence has been associated with metastasis of multiple 
cancers including renal cell carcinoma (Wang et al., 2009), gall bladder cancer (Yao et 
al., 2011), non-small cell lung cancer (Na et al., 2008), hepatocellular carcinoma (Xiang 
et al., 2009) and breast cancer (Woo et al., 2008). For nuclear CCR2 no role has yet 
been proposed. Nuclearly localised metabotropic glutamate 5 receptor was suggested to 
signal via a G protein-dependent mechanism (Kumar et al., 2008). However, as β-
arrestin 1 has been recently shown to traffic to the nucleus (Hoeppner et al., 2012), it is 
possible that any nuclear chemokine receptor signalling may alternatively utilise the β-
arrestin-dependent signalling pathways.  
How chemokine receptors or other GPCRs could enter the nucleus is not yet established. 
Conventional nuclear import of large proteins involves binding of a classical nuclear 
localisation signal (NLS) in the protein that is being imported to the adaptor protein 
importin α, which then interacts with importin β to enable interaction with the nuclear 
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pore complex and translocation into the nucleus. More recently it has been shown that 
some proteins can bind directly to importin β1 itself or to one of the 18 other (Chook 
and Suel, 2011) other members of the importin β family. These interactions are not 
dependent on the presence of classical NLSs, rather on a diverse and still expanding 
selection of non-classical NLSs.  
Analysis of the CCR2B primary amino acid sequence shows a couple of putative NLSs. 
A classical monopartite NLS (KRHR) is present in the third intracellular loop but if it 
acts as an actual NLS has not yet been investigated. However, the same sequence is 
present in the third intracellular loop of the better characterised chemokine receptor 
CCR5, for which no evidence of nuclear localisation has been reported. Additionally, as 
the third intracellular loop of CCR2 is quite short and is also a site of G protein (Arai 
and Charo, 1996) and probably β-arrestin binding (Cheng et al., 2000; Zheng et al., 
2010), it is unlikely to be readily accessible for interactions with the nuclear import 
machinery. Accessibility is a key feature of an NLS (Xu et al., 2010). Indeed, despite the 
presence of a functional NLS in the relatively large third intracellular loops of the α1A 
and B adrenergic receptors (Wright et al., 2012), in general when present, putative 
classical NLSs are more commonly found in the eighth helix located between the 
seventh transmembrane domain and the cytoplasmic tail (Lee et al., 2004). 
In contrast to the consensus sequences that form classical NLSs, the non-classical NLSs 
are less well defined and highly variant, although NLSs for transportin-1 and importin 7 
have been suggested and the CCR2B sequence was screened for these. A 
phosphorylated S/T-P-S/T motif has been shown to be responsible for interaction of 
several proteins, including ERK2 (Chuderland et al., 2008) and early growth response 1 
(Chen et al., 2011), with importin 7 leading to nuclear import. A version of this motif 
(TPS) is present in the CCR2B cytoplasmic tail and the serine/threonine residues are 
known to be phosphorylated in response to CCL2 stimulation. However, this short 
sequence is also present in several other typical chemokine receptors (CCR1/3/4/9/10 
and CXCR7), which have not been shown to localise to the nucleus, suggesting that it 
alone is not sufficient for nuclear localisation. A search for the R/K/H-X(2,5)-P-Y 
consensus motif that has been reported to make up part of the PY-NLS  responsible for 
binding to transportin-1 (Lee et al., 2006), showed no hits for CCR2B. An earlier report 
showing interaction of CCR2B with transportin-1 by CO-IP suggested that the 
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interaction was not direct and was instead mediated via a complex possibly involving 
TCP-1γ (Favre et al., 2008). The identification of both importin 7 and transportin-1 as 
proteins that interact with CCR2B is not inconsistent, as some proteins that are imported 
via the non-classical nuclear import pathways have been shown to be able to utilise 
various members of the importin β family (Chook and Suel, 2011; Jakel and Gorlich, 
1998).  
As GPCRs contain seven transmembrane domains, they are unlikely to be transported 
into the nucleus as for soluble cytoplasmic proteins, rather their insertion in the nuclear 
envelope is the more likely scenario. This raises the question of if the conventional 
nuclear translocation machinery can be adapted in an undetermined way to also play this 
role, or if it happens via a novel mechanism such as fusion of vesicle membranes with 
the nuclear membrane or lateral diffusion through the ER membrane. 
The suggested interactions of CCR2 with several nuclear import proteins does not 
necessarily imply that the receptor actually undergoes nuclear localisation. Some 
nuclear transport proteins are known to moonlight and there thus remains the possibility 
that importin 7 may interact with CCR2 as part of a different function. For example, 
FROUNT is a member of the Nup107-160 complex where it plays a role in nuclear pore 
complex assembly, however, it also interacts with ligand-bound CCR2 and CCR5 at the 
plasma membrane  and links them to the PI(3)K-Rac-lamellipodium protrusion cascade 
(Loiodice et al., 2004; Terashima et al., 2005; Toda et al., 2009). 
5.4.2 GST pull-down: limitations 
The main limitation for the GST pull-down was the inability to produce and purify 
sufficient GST-CCR5ct fusion proteins due to degradation and insolubility problems. 
Coupled with the lack of functional CCR5 in THP-1 cells, this meant that the second 
objective of comparing interacting proteins for these two receptors following agonist or 
LTA stimulation could not be carried out. The reason for the difference in stability of 
the two fusion proteins is currently unclear. When endogenously expressed, 
palmitoylation of the cysteines in the CCR5 cytoplasmic tail is thought to enable 
interaction with the plasma membrane creating an extra pseudo forth intracellular loop 
(Blanpain et al., 2001; Kraft et al., 2001; Percherancier et al., 2001) and this more rigid 
conformation may control the normal accessibility of parts of the tail protecting them 
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against degradation. When expressed as part of a GST fusion protein in E.coli, the 
CCR5 cytoplasmic tail would not retain this same conformation and so may be more 
accessible to proteases. In contrast, there are no palmitoylated cysteines in the CCR2B 
cytoplasmic tail and so its conformation may be less affected by expression as a GST 
fusion protein.  
The identification of importin 7, which had been previously corroborated as an 
interacting partner for CCR2B (Favre et al., 2008), validated the use of this GST pull-
down technique. However, my study failed to identify the other known binding partners 
of CCR2B: FROUNT (Terashima et al., 2005), filamin A (Minsaas et al., 2010), other 
nuclear import proteins including in particular TRN-1, TCP-1γ (Favre et al., 2008), 
GRK2 or β-arrestin (Aragay et al., 1998). For GRK2 and β-arrestin this is likely to be 
simply explained by the use of non-stimulated cells as these proteins have been reported 
to interact with CCR2 following CCL2 stimulation (Aragay et al., 1998). An important 
difference between the GST pull-down and other methods such as CO-IP (Favre et al., 
2008), previously used to identify CCR2B interacting partners, is that the GST pull-
down only uses the cytoplasmic tail of CCR2B. Reports for GPCRs, including 
chemokine receptors, have identified other receptor domains as playing important roles 
in specific protein interactions. A key example is the DRY motif, which is highly 
conserved in second intracellular loops of almost all typical chemokine receptors, 
including CCR2, and is required for interaction with a heterotrimeric G protein for 
signalling (Mellado et al., 1998). Other intracellular loop residues, especially those at 
the N and C-terminal ends of the third intracellular loop are also important for G protein 
binding to GPCRs (Wess, 1997). Additionally, residues in the second intracellular loop 
encompassing the DRY motif (Huttenrauch et al., 2002; Marion et al., 2006) and in the 
third intracellular loop (Cheng et al., 2000; Zheng et al., 2010) of GPCRs including 
chemokine receptors, in addition to phosphorylated serines/thereonines in their 
cytoplasmic tail, can all contribute to β-arrestin binding. Precisely how CCR2B interacts 
with the nuclear import proteins and TCP-1γ is not yet clear and so the cytoplasmic tail 
alone may not be sufficient for these interactions. However, as FROUNT (Terashima et 
al., 2005) and filaminA (Minsaas et al., 2010) were first identified in a yeast-2-hybrid 
screens using the CCR2B cytoplasmic tail, they would be expected to also be identified 
in the GST pull-down experiment and this was not the case. This could be due to these 
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proteins either not being present at all or only in undetectable amounts/concentrations in 
the samples analysed by MS. There are several potential reasons why this might be. 
The design of the GST pull-down experiment MS analysis was partially determined by 
the in-house facilities available at the start of the project, which have since improved in 
terms of sample type that can be analysed and capacity for identifying low abundance 
proteins. The conditions dictated that MS analysis could only be carried out on bands 
excised from a gel where they must be visible using a low sensitivity Coomassie stain.  
The bands analysed were chosen based on both their presence in the GST pull down 
coupled with absence in controls and their reproducibility between experiments. It is 
possible therefore, that known CCR2 interacting partners were actually pulled down but 
were not analysed as they were not present in the bands chosen for analysis. This could 
be because their concentration was insufficient to be revealed by the low sensitivity 
Coomassie stain and so no band was observed. Or known CCR2 interacting partners 
could localise to a band that was not analysed as it was also present in the controls due 
to the presence of another protein that interacts non-specifically with GST or the support 
bead matrix. Alternatively, the known CCR2 interacting partners could be present at low 
concentrations in a band that was analysed and so were not identified due to masking by 
more abundant proteins. GST contamination due to smearing throughout the gel was a 
problem for the analysis as all bands were identified as containing GST and for most 
bands this was the major protein identified.  
5.4.3 CO-IP: outcomes and limitations 
The first approach used in this study to try to immunoprecipitate endogenous CCR2 and 
CCR5 from monocytic cell lines using a variety of anti-CCR2 and anti-CCR5 antibodies 
was unsuccessful under the conditions tested. This may be due to the lack of good CCR2 
antibodies commercially available, and the level of epitope recognised by the anti-CCR5 
antibody, MC5, being very low on THP-1 cells. However, the recent discovery that the 
CCR5 present on THP-1 cells is not functional (described in Chapter 3), meant that 
using this cell line for comparing the proteins co-immunoprecipitated with CCR2 and 
CCR5 would not be useful for addressing the aims of this study. In contrast, suitable 
conditions to immunoprecipitate HA-CCR5 and the non-modified form of HA-CCR2B 
from the HEK HA-CCR2B/5 cell lines using the anti-HA antibody 12CA5 were 
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successfully identified. Unfortunately, several limitations to the planned co-
immunoprecipitation experiments were found. The main problems were that the 
immunoprecipitated HA-CCR2B was unexpectedly difficult to elute from the antibody-
bound AminoLink
®
 Plus Coupling Resin, and more importantly that no conditions were 
found to efficiently immunoprecipitate the glycosylated form of the receptor. 
CCR2B and CCR5 appear to express some of the innate stickiness associated with 7TM 
receptors. The only condition found to efficiently elute HA-CCR2B from the antibody-
bound AminoLink
®
 Plus Coupling Resin was boiling in SDS-PAGE sample buffer. 
Sample concentration techniques involving membranes led to low retention of HA-
CCR2B, presumeably due to interaction with the membranes. 
Studies in Chapter 4 have shown that the glycosylated form of HA-CCR2B is present at 
the cell surface, whereas the non-modified form is believed to be in the biosynthetic 
pathway. In addition, it is the glycosylated form of HA-CCR2B that responds to agonist 
stimulation. Therefore, it is the glycosylated form of HA-CCR2B that is of interest for 
identifying proteins interacting with the receptor during desensitisation. Precisely why 
this form of the receptor is not immunoprecipitated is currently unclear, however there 
are several possible explanations, which are discussed here. 
The non-modified and glycosylated forms of HA-CCR2B are differentially localised 
within the cell. The lipid composition and thus the susceptibility to detergents differs 
between cellular membranes suggesting that the different HA-CCR2B forms may be 
solubilised to varying extents during the lysis conditions used for the 
immunoprecipitation assay. However, a major difference in solubility is unlikely to be 
the explanation for why the non-modified form is immunoprecipitated whilst the 
glycosylated form is not, as they were both present at similar concentrations in the 
soluble fraction of the cell lysate used for the immunoprecipitation assay. 
The glycosylation modification itself could be responsible for the lack of 
immunoprecipitation of the glycosylated HA-CCR2B. The N-glycosylation site is 
believed to be on the N-terminus of CCR2B and it is likely that the O-linked 
glycosylation also takes place here. It is possible that the glycosylated N-terminus of the 
receptor is more likely to fold back on itself and interact with another part of the 
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receptor making the N-terminal triple HA-tag inaccessible to the 12CA5 antibody due to 
steric hinderance or masking. 
5.4.4 Recommendations for future studies to identify binding partners for 
CCR2B 
This chapter has shown that techniques that work for confirming protein-protein 
interactions do not necessarily work well for identifying unknown interactions without 
extensive adaptation. Various modifications that may improve future proteomics 
approaches to identifying interacting partners of CCR2B are discussed here. 
The small number of interacting proteins identified through the GST pull-down assay 
suggests that cells endogenously expressing CCR2 may not yield sufficient material for 
identifying interacting partners. This illustrates the requirement to enrich the 
concentration of proteins of interest in the starting material. One approach to this is to 
use transfected cells expressing higher levels of CCR2. However, as described in 
Chapter 3, whilst the HEK HA-CCR2B cells over-expressed the HA-CCR2B receptor, 
the cell surface receptor level was similar to that observed in monocytic cells, with the 
excess receptors confined to the biosynthetic pathway. For CO-IP experiments, an 
alternative but more complex approach would be to immunoprecipitate HA-CCR2B 
directly from the cell surface, by pre-binding the antibody prior to cell lysis, or from a 
membrane fraction following sub-cellular fractionation. 
As fractionation could lead to a loss of transient interactions, crosslinking prior to cell 
lysis may be required. Traditional crosslinking methods have various limitations, and 
often the most suitable crosslinker needs to be determined empirically (Kaake et al., 
2010). Chemical crosslinking methods are not all protein specific, such is the case for 
formaldehyde, or may be dependent on larger specific distances between the interacting 
proteins, as for other bifunctional chemical crosslinkers with spacer arms (Sutherland et 
al., 2008). Site specific photochemical crosslinking is dependent on the incorporation of 
a photoactivatable amino acid into a peptide or protein, which can be carried out by 
chemical synthesis (Kauer et al., 1986), in vitro synthesis (Cornish et al., 1994), or in 
vivo synthesis in E.coli (Chin et al., 2002) or mammalian cells (Hino et al., 2005) by 
addition of a mutated cDNA and a specific orthogonal aminoacyl tRNA 
synthetase/tRNA pair. This therefore limits the number of proteins and sites that can be 
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used for photochemical crosslinking and thus the identification of proteins involved in 
complexes.  An alternative photocrosslinking method has been developed, which 
involves growing cells in a medium containing modified photoactivatable leucine and 
methionine, which can be incorporated by the endogenous protein translation machinery 
thus enabling labelling of the majority of cellular proteins (Suchanek et al., 2005). 
CCR2 and CCR5 both contain leucine in their cytoplasmic tail and CCR5 has leucine 
and methionine residues in its cytoplasmic loops. Hence this crosslinking technique 
would be suitable for investigating proteins that interact directly or indirectly with the 
two receptors. 
Due to improvements in MS sensitivity and resolution, there has been a general shift 
away from identifying proteins using individual bands or spots excised from a gel, 
towards utilising whole affinity purification, such as CO-IP or pull-down, samples for 
gel-free  MS analysis (Gingras et al., 2007; Goudreault et al., 2009; Kaake et al., 2010; 
Raman et al., 2009). This should theoretically increase many fold the number of proteins 
identified from one sample. Carrying out MS analysis of whole samples instead of 
individual bands should therefore increase the likelihood of finding known interacting 
partners that were missed using the GST pull-down gel-based MS analysis in this study. 
However due to the increase in sensitivity of MS, the identification of large numbers of 
non-specific binding proteins would be a greater issue when analysing affinity 
purification samples directly (Kaake et al., 2010). Various quantitative proteomics 
methods are available to reduce the problem of false positives caused by non-specific 
binding proteins whilst minimising the loss of real but weak interactions (Trinkle-
Mulcahy, 2012). These methods work by differentially labelling specific and control 
samples used for affinity purification, either chemically or metabolically, and then 
determining the ratio of a candidate interacting protein indentified in both samples. Non-
specific binding proteins should be present equally in both samples giving a 1:1 ratio, 
whereas those that bind specifically should show a greater presence in the specific 
sample. SILAC is a popular metabolic labelling method as it uses incorporation of 
isotopic versions of essential amino acids (lysine and/or arginine) in vivo and so labels 
all proteins and has little impact on their functions (Ong et al., 2002; Trinkle-Mulcahy, 
2012). The use of SILAC should enable the identification of some interactions that were 
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missed in this study due to their presence in control and specific GST pull-down sample 
lanes. 
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6 General discussion 
One of the major factors controlling the activation status of chemokine receptors is the 
regulation of their cell surface expression. The three main trafficking steps regulating 
cell surface receptor expression, namely biosynthesis, internalisation and degradation or 
recycling, have been considered for CCR2B in this thesis. This work presents an 
analysis of the intracellular trafficking of CCR2B using a HEK HA-CCR2B cell line 
created for this project. Certain aspects of the trafficking (endocytosis, recycling) are 
also supported by experiments using the monocytic cell line THP-1. The CCR2B post-
endocytic trafficking pathway is compared to that of the related chemokine receptor 
CCR5, in part through my study of HEK HA-CCR5 cells and also other cell types, 
including monocytes, used in published work. Novel work showing some of the 
limitations of using monocytic cell lines for the study of functional CCR5 is also 
presented. 
6.1 Biosynthesis 
Chapter 4 presents the first evidence that in addition to undergoing N-linked 
glycosylation (this study and Preobrazhensky et al., 2000), CCR2 can also be O-
glycosylated. The predominant localisation of glycosylated CCR2 in the plasma 
membrane and the reduction in cell surface expression of the receptor when 
glycosylation is inhibited, suggest that this post-translational modification enhances 
trafficking of the newly synthesised CCR2 to the plasma membrane. The involvement of 
glycosylation in GPCR trafficking to the cell surface is thought to vary between 
receptors (Dong et al., 2007; Duvernay et al., 2005). Predominantly N-, but also O-, 
linked glycosylation has been shown to enhance the cell surface expression of some 
GPCRs and for certain receptors it is essential, whilst for others it has no effect. How 
precisely glycosylation regulates cell surface expression has not yet been fully explained 
although for several receptors it has been suggested to act by aiding the trafficking of 
newly synthesised GPCRs to the cell surface (Angelotti et al., 2010; Ge et al., 2009), or 
by protecting existing cell surface GPCRs from proteolytic attack (Ludwig et al., 2000). 
Glycosylation can provide binding sites for certain chaperone proteins, which may be 
important for CCR2B trafficking to the plasma membrane. Lectin chaperones, such as 
calnexin and calreticulin, bind glycans and are involved in promoting correct protein 
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folding. For the α2c-AR receptor it has been suggested that glycosylation improves the 
cell surface receptor expression by increasing the efficiency of protein folding 
(Angelotti et al., 2010). Another receptor, the μ-opioid receptor (MOR), is dependent on 
N-glycosylation for interaction with Ribophorin I (RPNI), which regulates its cell 
surface expression (Ge et al., 2009). The molecular mechanism is currently unknown 
but it has been suggested that in addition to its role in protein N-glycosylation as part of 
the oligosaccharide transferase complex (OST), RPNI may act in conjunction with BiP 
as a chaperone playing a role in ER quality control thus regulating MOR translocation 
out of the ER (Ge et al., 2009). In contrast, it has been reported that N-glycosylation of 
CXCR2 at two different sites is not required for the trafficking of the receptor to the cell 
surface, but is required for maintenance of its cell surface expression on human 
neutrophils (Ludwig et al., 2000). The addition of glycan chains was suggested to 
protect CXCR2 from proteolytic attack. Unlike CCR2, despite also being localised to 
the cell surface, CCR5 is not reported to be N-glycosylated but does undergo direct O-
linked glycosylation (Bannert et al., 2001), thus reinforcing the variability in the role of 
glycosylation.  
Glycosylation is not the only post-translational modification involved in trafficking of 
newly synthesised chemokine receptors to the plasma membrane. Palmitoylation is 
important for cell surface expression of CCR5 and this modification is believed to act by 
protecting against CCR5 degradation (Blanpain et al., 2001; Percherancier et al., 2001). 
Despite the presence of suitable cysteines in its cytoplasmic tail, the CCR2B receptor is 
not thought to undergo palmitoylation and thus this post-translational modification is 
unlikely to play a role in CCR2B cell surface expression. This demonstrates that even 
with closely related chemokine receptors, cell surface expression pathways dependent 
on post-translational modifications described for one receptor are not necessarily 
generic. 
6.2 Internalisation 
Chapters 3 and 4 confirmed the agonist-induced internalisation of CCR2 using THP-1 
and HEK HA-CCR2B cell lines. The results of inhibition and colocalisation studies 
shown in this thesis support a role of clathrin-mediated endocytosis in agonist-mediated 
internalisation. Based on the lack of complete inhibition of internalisation by clathrin-
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mediated endocytosis inhibitors and conflicting results when modulating the membrane 
lipid composition, a role for clathrin-independent lipid-dependent endocytosis pathways 
cannot be ruled out but probably do not play the predominant role in HEK HA-CCR2B 
cells. This work is in agreement with previous groups that reported the use of both 
pathways for CCR2 and suggested that there may be a level of cell type specificity 
(Andjelkovic et al., 2002; Garcia Lopez et al., 2009; Ge and Pachter, 2004). However, 
caution must be exerted in the interpretation of lipid modulation studies as for some 
receptors changing the lipid composition can have an indirect effect on receptor 
internalisation by changing receptor conformation and thus affecting ligand binding. 
Binding studies using radiolabelled chemokine have been used to show that this is the 
case for CCR5 (Nguyen and Taub, 2002; Nguyen and Taub, 2003a, b; Signoret et al., 
2005), and would be required before any final conclusions could be drawn for CCR2.  
If indeed CCR2 can use multiple endocytic pathways, how the choice of which pathway 
to use is regulated remains to be explored. It is becoming apparent that chemokine 
receptor internalisation is a complex process that can be modulated by multiple factors 
such as cell type and ligand used for stimulation. As the plasma membrane lipid 
composition differs between cell types, the influence of lipid on the internalisation of 
CCR2 could also be expected to differ. Caveolae are described as a subdomain of lipid 
rafts enriched in sphingolipids, cholesterol and caveolin proteins, and endocytosis via 
this route is sensitive to cholesterol depletion (Le Roy and Wrana, 2005). On the other 
hand, cholesterol depletion in general does not significantly inhibit clathrin-mediated 
endocytosis (Doherty and McMahon, 2009). In addition, different cellular protein 
content may lead to cell type variation in the availability of key endocytic pathway 
proteins. For example, β-arrestin expression has been shown to vary between different 
cell types at both the mRNA and protein levels (Komori et al., 1998; Menard et al., 
1997; Parruti et al., 1993). Therefore, as clathrin-mediated endocytosis is dependent on 
interaction of the GPCR with β-arrestin (Luttrell and Lefkowitz, 2002), the proportion 
of CCR2B endocytosis using this pathway may be cell type-dependent. Indeed for β2-
AR, a GPCR whose internalisation is predominantly clathrin-dependent (Goodman et 
al., 1996; Moore et al., 1995), a positive correlation between the cellular β-arrestin 
expression and the level of receptor internalisation has been demonstrated (Menard et 
al., 1997). Thus it could be hypothesised that the choice of endocytic route used may be 
in part dictated by availability of endocytic pathway proteins in the cell type studied.   
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In contrast, differences in the internalisation response of a specific chemokine receptor 
when stimulated with different ligands but using the same cell type, have also been 
reported for CCR4 (Mariani et al., 2004), CCR7 (Byers et al., 2008) and CXCR2 
(Feniger-Barish et al., 2000). Indeed recent work for CCR2 has reported the existence of 
a ligand-dependent bias in the extent and rate of receptor internalisation and suggested 
that this bias was due to the stabilisation of different CCR2 homodimer conformations 
and differential β-arrestin recruitment (Berchiche et al., 2011). It would be interesting to 
determine if the observed positive correlation between β-arrestin recruitment and CCR2 
internalisation supports uniquely a clathrin-mediated endocytic pathway, or if there are 
additional ligand-specific contributions of clathrin-independent pathways.  
Whilst agonist-induced CCR2 internalisation appears to occur independent of cell type, 
there seem to be differences in internalisation resulting from receptor cross-talk from 
TLR2. In contrast to monocytes, LTA stimulation does not lead to efficient rapid CCR2 
down-modulation/internalisation in HEK TLR2 HA-CCR2B cells. However, dose-
dependent down-modulation of CCR2B was observed at relatively high concentrations 
of a different TLR2 ligand, Pam3CSK4, with slightly higher down-modulation observed 
in cells expressing the TLR1/2 dimer compared to the TLR2/6 dimer. The reason for 
this ligand-specific difference in the cross-talk response with CCR2B remains unclear. 
TLR2 can homo- and hetero-dimerise, and has been shown to partner with TLR1 
(Wyllie et al., 2000), TLR6 (Takeuchi et al., 2001) and TLR10 (Hasan et al., 2005) 
resulting in different ligand specificity. TLR1/2 and TLR2/6 complexes are believed to 
generally bind triacylated (e.g. Pam3CSK4) and diacylated (e.g. LTA) lipoproteins and 
glycolipids respectively (Takeuchi and Akira, 2010). TLR1 and TLR6 are both 
expressed in monocytes (Chang et al., 2007) and it is not known which TLR2 
heterodimer is responsible for the LTA-induced chemokine receptor down-modulation 
(personal communication from Nathalie Signoret, University of York, UK). The HEK 
TLR2 HA-CCR2B cell lines used in the present study expressed mouse TLR2 in 
combination with either mouse TLR1 or mouse TLR6, however HEK293 cells have also 
been shown to express endogenous human TLR1 and TLR6 (Kurt-Jones et al., 2004). 
As Pam3CSK4 has been reported to be able to induce responses in HEK293 cells only 
transfected with human TLR2 (Mandell et al., 2004), there remains the possibility that in 
my study the mouse TLR2 may partner with endogenous human TLR1 explaining the 
observation of Pam3CSK4 induced HA-CCR2B down-modulation regardless of which 
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other mouse TLR is expressed. The Pam3CSK4-induced HA-CCR2B down-modulation 
observed in my study was only observed at levels of Pam3CSK4 much higher than 
normally required to induce cytokine production (Mandell et al., 2004), unlike the LTA 
concentration required to down-modulate CCR2 in monocytes (Fox et al., 2011). As 
high concentrations of LTA gave no response, it is possible that mouse TLR1 is better 
suited than mouse TLR6 for acting in combination with TLR2 for transducing signals, 
thus enabling a response to very high Pam3CSK4 concentrations. These results suggest 
that the TLR2 is functional and that a TLR2-CCR2 cross-talk pathway is present to 
some extent but that it may be ligand-dependent and less efficient than in monocytes. 
On monocytes, LTA cross-talk induced CCR5 internalisation utilises the same 
machinery involved in agonist-induced internalisation, but following a much slower 
kinetic (Fox et al., 2011). Although not tested, this may also be the case for CCR2. The 
pathways downstream of TLR2 that lead to the recruitment of this machinery remain to 
be elucidated and may be in part cell type-specific. 
The apparent importance of cell type specificity for the LTA-dependent TLR2 CCR2/5 
cross-talk pathway but not for agonist-induced desensitisation illustrates the huge 
complexity of the processes that regulate chemokine receptor activity. There is thought 
to be a single agonist-induced homologous desensitisation pathway that is dependent on 
receptor cytoplasmic tail phosphorylation by a member of the GRK family. In contrast, 
multiple cross-talk pathways have been partially described, that utilise GRKs or second 
messenger kinases, with no single consensus pathway. In some cases, such as for the 
LTA induced cross-desensitisation of CCR2 and CCR5 described by our group, the 
cross-talk pathway is thought to utilise the homologous desensitisation machinery. 
However, there must still be a unique cross-talk pathway that feeds into the homologous 
desensitisation pathway, and proteins involved in this first step could be expressed in a 
cell type-specific manner. 
6.3 Degradation 
My study (Chapter 4) provides the first biochemical evidence that at least some CCR2 
undergoes lysosomal degradation in response to agonist stimulation. This is supported 
by colocalisation immunofluorescence studies. Colocalisation of internalised HA-
CCR2B with a marker of the degradative pathway, coupled with the fact that only 
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glycosylated HA-CCR2B is degraded, suggest that it is cell-surface derived HA-CCR2B 
that is internalised and undergoes degradation following agonist stimulation. N- or O-
linked glycosylation has been shown to be required for efficient ligand binding to some 
chemokine receptors including CCR5 (Bannert et al., 2001), CCR8 (Gutierrez et al., 
2004) and CXCR4 (Wang et al., 2004b). Therefore either of the CCR2 glycosylation 
modifications may be important for agonist-induced internalisation and subsequent 
intracellular trafficking leading to receptor degradation. These studies were carried out 
using HEK HA-CCR2B cells. Unfortunately, the commercial CCR2 antibodies currently 
available are not sufficient to confirm if endogenously expressed CCR2B in monocytic 
cell lines or monocytes is also degraded, or if this is a cell type-specific process. In 
contrast, CCR5 has been shown not to undergo enhanced degradation in response to 
agonist stimulation, and instead internalised receptors have been shown to be recycled 
back to the cell surface (Signoret et al., 2004; Signoret et al., 2000).  
Agonist-induced receptor degradation and recycling provide temporally different levels 
of receptor desensitisation, with degradation leading to more long term inhibition of 
future signalling than the transient desensitisation observed for receptors that recycle. 
This thesis provides evidence that internalised CCR2B undergoes both degradative and 
recycling fates, as opposed to the single recycling pathway followed by internalised 
CCR5. Coupled with the fact that CCR2, but not CCR5, is down-regulated on non-
activated leukocytes at the gene level in response to TLR2 stimulation with bacterial 
lipoprotein (McKimmie et al., 2009), this raises the question of why CCR2 requires 
more long-term desensitisation than CCR5? Although their overall functions in the 
immune system are complementary, the two receptors do differ in their precise roles in 
leukocyte recruitment. Monocytes and macrophages exhibit complementary cellular 
expression profiles for CCR2 and CCR5 and these receptors show reciprocal functions. 
CCR2 is expressed on human peripheral blood monocytes but not macrophages 
(Fantuzzi et al., 1999), whereas CCR5 shows a low level of expression on human 
monocytes, which is increased upon differentiation into macrophages (Kaufmann et al., 
2001). Thus it is not surprising that CCR2 plays a predominant role in the initial 
recruitment of monocytes to tissues, where following differentiation into macrophages, 
CCR5 plays an important role in maintaining and retaining them (Zhao, 2010).   
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Unless degradation is the default pathway following internalisation, there must be a 
motif or modification of the receptor that is responsible for its sorting into this pathway. 
Ubiquitination has been shown to be important for degradation of CXCR4 (Marchese 
and Benovic, 2001) and some other GPCRs (Marchese et al., 2008). At the same time, 
this modification plays no role in the degradation of CXCR2 (Baugher and Richmond, 
2008) or CXCR3 (Meiser et al., 2008) and no ubiquitination of CCR2B was observed in 
my study. The CCR2B cytoplasmic tail contains a putative tyrosine based motif (YLSV) 
of the type that can play a role in lysosomal targeting (Bonifacino and Traub, 2003). 
However, the localisation of the motif away from the C-terminal and the lack of the 
common preceeding glycine residue (Bonifacino and Traub, 2003), coupled with the 
presence of a very similar motif (YLLV) at the same location in CCR5 suggest that this 
motif is unlikely to play a function role in lysosomal sorting of CCR2B. In addition, the 
CCR2B tail does not contain a functional acidic dileucine motif, which is the other motif 
commonly associated with lysosomal sorting (Bonifacino and Traub, 2003). This 
suggests that there may be at least one other less common motif or modification 
responsible for sorting of chemokine receptors into the degradation pathway and this 
may not be generic to all degraded chemokine receptors. 
6.4 Recycling 
I have shown that following internalisation of CCR2 from the plasma membrane, the 
cell surface receptor levels are partially recovered within a 60 minute period in both 
HEK HA-CCR2B and THP-1 cells. The results of experiments shown in Chapter 4 
suggest that not all internalised CCR2 is degraded and instead a portion is recycled back 
to the cell surface. This data supports previous suggestions of varying levels of CCR2 
cell surface recovery in astrocytes (Andjelkovic et al., 2002) and THP-1 cells (Wang et 
al., 1993a). The level of recycling observed in HEK HA-CCR2B cells is quite low 
suggesting that, at least in these cells, this is a minor pathway following internalisation. 
The level of recovery was considerably higher in THP-1 cells, suggesting that 
endogenous CCR2 also has the capability to recycle. Although it has been reported that 
CCR2B is the dominant isoform of CCR2 in THP-1 cells, the possibility of the post-
internalisation cell surface recovery being enhanced by the presence of a low level of 
CCR2A cannot be ruled out, as the R&D α-CCR2 antibody used recognises both 
isoforms. Partially contrasting results regarding the main cellular localisation of CCR2A 
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have been reported (Tanaka et al., 2002; Wong et al., 1997). In stably transfected cells, 
N-terminal FLAG-tagged CCR2A has been shown by immunofluorescence on intact 
and permabilised cells to be predominantly located intracellularly unlike the plasma 
membrane localised CCR2B, although a small amount of CCR2A cell surface 
expression was observed by flow cytometry and ELISA (Wong et al., 1997). The 
CCR2A intracellular localisation was suggested to be dependent on an unidentified 
cytoplasmic retention signal in the C-terminal tail of CCR2A (Wong et al., 1997). 
Predominantly intracellular localisation of CCR2A has also been shown in transfected 
COS-7 cells by flow cytometry on intact and permabilised cells (Tanaka et al., 2002). In 
contrast, in THP-1 cells and monocytes, the ratio of intracellular and cell surface 
CCR2A has been shown, by a chemiluminescence immunoassay using total or plasma 
membrane fractions and by flow cytometry, to reflect that of CCR2B, although at an 
almost 10 fold lower expression level (Tanaka et al., 2002). However, the antibodies 
used by Tanaka et al. (Tanaka et al., 2002) for this work are not available commercially 
to confirm the relative CCR2A and CCR2B levels and localisations on our THP-1 cells. 
The recycling pathway back to the cell surface utilised by internalised CCR2 is currently 
unclear. The partial colocalisation of internalised CCR2 observed with Rab4 and 
transferrin in the present study could represent the potential presence of the small 
proportion of CCR2B that is recycled in recycling endosomes. However, experiments 
using over-expression of Rab4 suggested that as for CCR5 (personal communication 
from Nathalie Signoret, University of York, UK), but unlike for some other receptors, 
CCR2B recycling is not Rab4-dependent. Based on this information and the disperse 
punctuate pattern of intracellular HA-CCR2B containing vesicles, it may be more likely 
that the colocalisation happens in the sorting endosome and that recycling takes place 
from here via a Rab4-independent pathway (Stenmark, 2009).  
The molecular mechanisms responsible for sorting of chemokine receptors into the 
recycling pathway have not been established in all cases. For CCR5 and CXCR2, the 
presence of a PDZ ligand binding motif has been suggested to facilitate interactions with 
proteins of the sorting machinery. However, this motif is not present in CCR2B, again 
showing the lack of a conserved mechanism. 
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6.5 Nuclear localisation 
Proteomics experiments in the present thesis suggested that CCR2B may interact with 
importin 7, implying the potential for nuclear localisation of CCR2B. This is in 
agreement with a previous study showing increased nuclear localisation of CCR2 upon 
agonist-stimulation, which is reportedly mediated by a related protein TRN-1 (Favre et 
al., 2008). Nuclear localisation of HA-CCR2B was not directly investigated by 
colocalisation experiments using nuclear markers in the present thesis. However, it is 
interesting to note that no localisation of internalised HA-CCR2B at the nucleus, as 
marked by DAPI staining, was observed in any of the immunofluorescence endocytosis 
experiments carried out using agonist-stimulated HEK293 transfectants. Although 
nuclear localisation has been reported for CXCR4 in tumour cells (Wang et al., 2005), it 
is not currently widely accepted as a general feature of the chemokine receptor response 
to stimulation. 
The number of reports of nuclear localisation of various transmembrane receptors 
including GPCRs is increasing at a rapid rate (Boivin et al., 2008; Gobeil et al., 2006; 
Goetzl, 2007; Pickard et al., 2007; Planque, 2006; Wang and Hung, 2012; Wright et al., 
2012). However, there is a distinct lack of knowledge of how this nuclear localisation 
could physically come about and what trafficking pathways and mechanisms are 
involved. As GPCRs contain seven transmembrane domains, they are unlikely to be 
transported actually into the nucleus as for soluble cytoplasmic proteins, rather their 
insertion in the nuclear envelope is the more likely scenario. Although for D-Frizzled 2 
it was reported that a C-terminal fragment of the receptor is cleaved off and actually 
enters the nucleus (Mathew et al., 2005). Insertion of a transmembrane protein in to the 
nuclear envelope is a very different process to the conventional translocation of a 
soluble cytosolic protein through the nuclear pore complex into the nucleus. Some 
studies have identified nuclear localisation sequences in the GPCRs (Lee et al., 2004; 
Wang et al., 2010a; Wright et al., 2012) but so far there has been little focus on the 
actual relocation and insertion processes.  
What triggers the receptor relocation to the nucleus is unknown for some GPCRs, 
whereas for others the trigger has been suggested to be agonist stimulation (Favre et al., 
2008; Mathew et al., 2005; Wang et al., 2009). Therefore it is possible that GPCRs 
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could traffic to the nucleus from either the biosynthetic pathway or from endocytic 
vesicles derived from the plasma membrane. In both cases, the first step would be 
insertion of the GPCR into the outer nuclear membrane. For GPCRs direct from the 
biosynthetic pathways this step could be simply envisaged to be lateral diffusion through 
the rough endoplasmic reticulum that is continuous with the outer nuclear membrane. 
For proteins trafficking from the plasma membrane it could be dependent on fusion of 
endocytic vesicle membranes with the outer nuclear membrane. The second step 
involving delivery from the outer to the inner nuclear membrane is more complex. Two 
different pathways have been proposed for the delivery of integral inner nuclear 
membrane proteins including those with multiple transmembrane domains, namely 
passive diffusion through the pore membrane surrounding nuclear pore complexes or 
utilisation of part of the nuclear pore complex itself (Lusk et al., 2007). Presumably, 
GPCRs hijack one of these pathways although this remains to be explored. 
If nuclear signalling of CCR2 were confirmed to exist, this would offer more 
opportunities for therapeutically targeting this receptor but at the same time increase the 
complexity of doing so. The pharmaceutical industry is under pressure from the 
increasing requirement for the development of new assays to identify and test potential 
therapeutics in light of the emerging unexpected complexity of chemokine receptor 
regulation. 
6.6 Factors responsible for trafficking 
The work presented here, showing that agonist stimulation leads to internalisation of 
CCR2B followed by both degradation and recycling, raises several questions regarding 
CCR2B regulation. Firstly, what features, motifs or post-translational modifications of 
CCR2B are responsible for its utilisation of these intracellular signalling pathways? 
Secondly, what circumstances or conditions control/modulate which pathway CCR2B 
enters? Thirdly, is one pathway the default pathway? 
Regulation appears to be a complex process that is dependent on a combination of 
multiple factors. Certain motifs or post-translational modifications of GPCRs have been 
associated with their intracellular trafficking. Whilst some such as cytoplasmic tail 
phosphorylation are believed to act universally, it is not yet clear how generic or 
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receptor specific some others actually are. The sorting step where receptors are sent 
towards degradative or recycling fates appears to be a key point where the regulatory 
mechanisms identified so far differ considerably between chemokine receptors. Unlike 
CCR5, CCR2B recycling does not appear to be dependent on interaction with PDZ 
containing proteins as no PDZ ligand motif is present in its cytoplasmic tail. 
Additionally, unlike CXCR4, but similar to CXCR2 and CXCR3, CCR2B recycling 
does not appear to be dependent on the post-translational ubiquitination modification. 
The protein-protein interactions governing this important step remain to be identified 
and based on the array of different protein-chemokine receptor interactions that have 
been described so far (Table 1.4), these may involve proteins with a currently unknown 
role in intracellular trafficking. 
Several other chemokine receptors have been reported to be both degraded and recycled, 
with conditions modulating the pathway followed suggested for some only. For CXCR4, 
the dominant fate is thought to be dependent on the cellular background in which the 
receptor is expressed. An identical GFP-CXCR4 construct expressed in HeLa, UP37 and 
CEM cells resulted in quite varied but inefficient levels of recycling after agonist-
induced internalisation (Tarasova et al., 1998) and the authors suggested that the main 
fate of internalised receptors was probably degradation. In contrast, in human 
hematopoietic CD34+ cells, CXCR4 was found to colocalise with  markers of the 
recycling but not degradative pathways (Zhang et al., 2004). The HA-CCCR2B 
expressed in HEK293 cells appears to follow both pathways but degradation appears to 
be the dominant fate. It would be interesting to investigate if the ratio of degradation to 
recycling varies dependent on cell type as observed for CXCR4 in certain cells 
(Tarasova et al., 1998), however this would be time consuming with the tools currently 
available. Alternatively, the fate of CXCR2 has been suggested to be modulated by the 
duration of agonist stimulation, with short stimulation (up to 1 hour) resulting in 
recycling and longer stimulation (4 hours) leading to entry into the degradative pathway 
(Fan et al., 2003). This possibility would be simple to test using the HEK HA-CCR2B 
cells. As different ligands can determine the efficiency of CCR2B internalisation 
(Berchiche et al., 2011), the possibility of them also impacting on the downstream 
sorting process would be worth further investigation. 
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Many of these factors including cell type-, agonist- and post-translational modification-
dependency highlight that how a chemokine receptor is presented to its immediate 
cellular environment can determine its internalisation and intracellular fate. Chemokine 
receptor presentation is determined by conformation, modifications, accessibility of 
motifs and oligomerisation state. As seven transmembrane receptors, chemokine 
receptors have potential for more conformational states than single transmembrane 
proteins. In addition, the multiple intra- and extra-cellular loops and N- and C-terminal 
tails provide many parts of the receptor that can be modified or influenced in some way. 
The cellular background in which the receptor is expressed can impact on its 
conformation due to variability in the local membrane lipid composition or the 
availability of other membrane proteins that form oligomers with the chemokine 
receptor. Hetero-oligomerisation can change the behaviour of chemokine receptors, with 
reported examples of both negative and positive co-operativity for ligand binding, 
signalling and downstream functions including chemotaxis (Table 1.2). This co-
operativity is thought to be mediated through allosteric changes in receptor 
conformation following ligand binding (Milligan and Smith, 2007; Salanga et al., 2009; 
Smith and Milligan, 2010).  
Many cell surface GPCRs exist in an equilibrium between multiple inactive and active 
states with the equilibrium being shifted towards the former upon ligand binding and it 
is likely that the same scenario may exist for chemokine receptors (Thelen et al., 2010). 
Ligand binding has been shown to differentially influence cell surface chemokine 
receptor conformation. Indeed two CCR2 ligands, CCL2 and CCL11, have been 
suggested to induce different active conformations of CCR2 (Ogilvie et al., 2004).  It is 
also believed that chemokine binding can stabilise certain chemokine receptor oligomers 
(Martinez Munoz et al., 2009). The conformation of a chemokine receptor influences 
how it is seen by other potentially interacting proteins in the cell. 
Some motifs, such as the PDZ ligand motif, are present in multiple chemokine receptors 
(Marchese et al., 2008) but have only been shown to play a role in the regulation of 
certain receptors or under certain conditions (Baugher and Richmond, 2008; Delhaye et 
al., 2007). Other motifs, such as potential tyrosine motifs involved in lysosomal sorting, 
dileucine motifs, and putative nuclear localisation sequences, are present in multiple 
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GPCRs but do not always result in the associated action (Marchese et al., 2008; Meiser 
et al., 2008). In addition, GPCRs carry many putative sites for post-translational 
modifications, but these are not always utilised (Baugher and Richmond, 2008; Neel et 
al., 2005). Clearly accessibility of motifs is crucial to their potential roles and receptor 
conformation and oligmerisation could be envisaged to modulate the accessibility of 
specific motifs and receptor domains involved in protein-protein interactions that 
regulate the chemokine receptor. 
As degradation appears to be a more dominant fate for CCR2B, it is possible that this is 
the default pathway for the internalised receptor and that the recycled fraction of 
CCR2B is modified in an as yet undetermined way that enables it to follow the recycling 
pathway. The requirement of modification of CXCR4 by ubiquitination for degradation 
may argue against this suggestion, however there is the emerging possibility of receptor 
specific regulatory mechanisms. 
6.7 Conclusions 
In summary, the present thesis explored the regulation, trafficking and fate of CCR2B 
and identified the two different intracellular routes followed by the receptor in response 
to agonist treatment. This work and the methods that were developed provide a solid 
basis to enable further characterisation of the factors regulating the fates of this receptor. 
The differences identified with the post-endocytic trafficking of CCR5 support the 
concept of receptor specific behaviours. This idea highlights the difficulty of drawing 
conclusions about receptor behaviour based on analogy even to highly homologous 
receptors or based on the presence of primary sequence post-translational modification 
motifs. In addition to receptor specific behaviours, the differences in CCR2B recycling 
observed in the two cell types tested suggest that there may be a cell type dependency 
for certain aspects of the regulation. Added to previously proposed ideas of cell type-
dependent modes of internalisation (for CCR2) and recycling (for CXCR4), my findings 
suggest a greater influence of the cellular environment when investigating chemokine 
receptors. These new insights into the receptor and cell type dependency of the 
endocytic regulation of agonist treated CC chemokine receptors show that what was 
previously thought to be a relatively conserved process is now becoming established as 
more complex and influenced by a wide range of factors. 
184 
The post-endocytic trafficking path followed by chemokine receptors after agonist-
stimulated internalisation directly impacts on the type of receptor desensitisation that is 
observed. Recycling results in transient desensitisation, whereas degradation typically 
has a long-term negative impact on the level of active receptors at the cell surface. 
Regulation of receptor availability via these desensitisation processes is important for 
the fine-tuning of cellular responses and consequently chemokine receptor dysregulation 
has been implicated in a variety of autoimmune and allergic inflammatory diseases. 
Thus the ability to modulate the receptor behaviour is a key way of targeting these 
diseases.A comprehensive understanding of chemokine receptor specific behaviours in 
the relevant conditions is essential to help facilitate this approach. As has been 
demonstrated here, even receptors playing complementary biological roles, such as 
CCR2B and CCR5, can be regulated differently, and so may require different 
therapeutic strategies.  
Drugs designed against chemokine receptors commonly target the activation state of the 
cell surface receptor or its internalisation. However, these drugs are only acting on a 
single step of the regulatory process. The existence of two different possible fates for 
CCR2B provides the potential opportunity for alternative therapeutic targeting of the 
receptor. If the receptor is typically recycled, inventions that tip the balance in favour of 
receptor degradation may be a useful way to desensitise CCR2B to prevent 
overstimulation by agonists. It would be interesting to investigate whether the ligand 
itself can influence the post-endocytic trafficking of CCR2B. If so, natural ligands may 
provide a useful basis for design of therapeutics to manipulate receptor trafficking. A 
precedent for this lies in the previous development of modified forms of CCL5 that 
appear to block the recycling receptor at different intracellular locations (Bennett et al., 
2011). Modified forms of CCL2 are starting to be developed as potential therapeutics 
(Severin et al., 2012) but there remain several other ligands for CCR2B that could be 
exploited, possibly with different effects. 
It would be important to determine if the potential interaction with importin 7 translates 
into a nuclear role for CCR2B and if so, what is the involvement of nuclear CCR2B 
signalling in different diseases? This is a relatively new consideration as until recently 
all GPCR signalling responses were thought to be principally due to plasma membrane 
localised receptors. If CCR2B had different functional roles depending on its 
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localisation, it would be necessary to target the relevant form of the receptor when 
treating a disease. Investigation into where any nuclearly localised receptors could come 
from would be essential to decide how best to target them. Drugs designed to target cell 
surface receptors would not impact effectively on nuclear receptors derived from the 
biosynthetic pathway but may impact on receptors trafficking from the plasma 
membrane. This question regarding the origin of nuclear receptors and their subcellular 
trafficking is currently being addressed for some other types of cell surface receptors 
including RTKs (Wang and Hung., 2012).  
GPCRs, including CCR2B, can undergo various post-translational modifications and it 
is important to target the relevant form of the receptor for the function of interest. The 
roles of glycosylation in cell surface expression and agonist-induced degradation of 
CCR2B, highlight the importance of this modification for chemokine receptor 
regulation. Some previous studies have focussed on the “normal” molecular weight form 
of CCR2B (Favre et al., 2008; Minsaas et al., 2010), which appears at least in HEK HA-
CCR2B cells to be the immature form of the receptor. My investigations question the 
degree of relevance of these studies to the regulation of the mature cell surface receptor. 
The conclusions drawn for CCR2B regarding the importance of studying disease 
relevant cell types are also applicable to CCR5 and are likely to extrapolate to other 
chemokine receptors. THP-1 cells have been widely used to study CCR5 since they 
were identified as expressing a form of the receptor that facilitates HIV entry (Cassol et 
al., 2006). There is now a growing appreciation of the fact that chemokine receptors can 
have multiple varying roles that may be dependent on different signalling pathways. It is 
thus possible that the same receptor expressed in different cellular environments may 
only be functional for a subset of these roles. Indeed results presented in this thesis 
suggest that this appears to be the case for the form of CCR5 expressed on THP-1 cells. 
This knowledge is of vital importance as it shows that THP-1 cells are not a suitable 
model for studying the role of CCR5 in diseases involving signalling of this receptor. 
Although not focussed directly on drug development, this study made several novel 
observations regarding the factors influencing chemokine receptor regulation that may 
impact on future therapeutic development by highlighting a more relevant direction for 
the focus of the related basic research.  
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6.8 Future experimental directions 
Future experimental work would be required to answer the many questions raised in this 
thesis. Based on the important involvement of monocytes in many auto-immune and 
allergic inflammatory diseases, the next logical step would be to determine if the fates 
observed for CCR2 in the HEK HA-CCR2B and THP-1 cell lines reflect what actually 
occurs in monocytes. Due to the lack of widespread knowledge of the cell type influence 
on chemokine receptor trafficking at the time, this avenue of investigation was not 
initially pursued for CCR2 as the small size of monocytes makes it difficult to 
effectively employ colocalisation techniques. However, following the identification of 
the post-endocytic pathways followed by CCR2B presented here, subsequent work 
could be carried out using the alternative techniques that have been developed in this 
project.  
What precisely is responsible for the choice of fate undergone by CCR2B in a particular 
situation is currently unknown, although several possibilities have been addressed 
and/or highlighted during this project. Determining the ratio of recycling to degradation 
typically experienced by CCR2 in monocytes would enable subsequent investigation of 
any factors influencing the receptor fate. The first one to examine would be the 
influence of ligand, both identity and duration of stimulation, and could be directly 
tested using the experiments designed during this project. 
Further dissection of the factors influencing CCR2B fate would require identification of 
the protein-protein interactions experienced by this receptor using improved approaches 
as discussed in Chapter 5. This work would be important for identifying if and/or how 
CCR2B regulation could be targeted via manipulation of individual steps of the 
intracellular trafficking pathway. 
The essential next step to facilitate much of this work would be the development of a 
better anti-CCR2 antibody suited to various techniques, especially western blotting. This 
would enable experiments designed and used with HEK HA-CCR2B cells in this project 
to be extended to the endogenous receptor in work that would have more direct future 
application. 
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Definitions 
µg Microgram 
µl Microlitre 
µM Micromolar 
AC Adenylate cyclase 
AMPA GluR1 α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
Glutamate receptor 1 
ANOVA Analysis of variance 
AOP-RANTES Aminooxypentane-regulated on activation, normal T cell 
expressed and secreted 
ATCC American type culture collection 
ATP Adenosine triphosphate 
BiP Binding immunoglobulin protein 
BRET Bioluminescence resonance energy transfer 
BSA Bovine serum albumin 
C5aR Complement 5 a receptor 
CCP Clathrin coated pit 
CCV Clathrin coated vesicle 
CD4 Cluster of differentiation 4 
cDNA Complementary deoxyribonucleic acid 
cGMP Cyclic guanosine monophosphate 
CNS Central nervous system 
CO2 Carbon dioxide 
CO-IP Co-immunoprecipitation 
CREB cAMP response element-binding 
DAG Diacylglycerol 
199 
DAPI 4’,6-diamidino-2-phenylindole 
DARC Duffy antigen receptor for chemokines 
DCs Dendritic cells 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DSMZ Deutsche Sammlung von mikroorganismen und Zellkulturen 
(German Collection of Microorganisms and Cell Cultures) 
EAE Encephalomyelitis 
EBP50 ERM Binding Protein 50 
ECL Extracellular loop 
EDTA Ethylenediaminetetraacetic acid 
EE Early endosome 
EEA1 Early endosome antigen 1 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
ERC Endocytic recycling centre 
ERK Extracellular signal-regulated kinase 
FACS Fluorescence activated cell sorting 
FBS Foetal bovine serum 
FC Flow cytometry 
FITC Fluorescein isothiocyanate 
FPR Formyl peptide receptor 
FRET Fluorescence resonance energy transfer 
FSC Forward scatter 
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g Gram 
GalNAC N-Acetylgalactosamine 
G-CSF Granulocyte colony-stimulating factor 
GFP Green fluorescent protein 
GPCR G protein coupled receptor 
GRK G protein receptor kinase 
GTP Guanosine triphosphate 
HA Human influenza haemagglutinin 
HEK Human embryonic kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HIV Human immunodeficiency virus 
HRP Horseradish peroxidise 
ICL Intracellular loop 
IF Immunofluorescence 
IFN-γ Interferon-gamma 
Ig Immunoglobulin 
IGF-R1 Insulin-like growth factor receptor-1 
IP Imunoprecipitation 
IP3 Inositol-trisphosphate 
LE Late endosome 
LIMK LIM domain kinase 1 
LPS Lipopolysaccharide 
LSM Laser scanning microscopy 
LTA Lipoteichoic acid 
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LY Lysosome 
M Molar 
MAPK Mitogen-activated protein kinase 
MCAF monocyte chemotactic and activating factor 
MCP-1 monocyte chemotactic protein-1 
MET-RANTES N terminal Methionine RANTES 
MIP Macrophage inflammatory protein 
ml Millilitre 
mM Millimolar 
MOR µ-opioid receptor 
mRNA Messenger RNA 
MS Multiple sclerosis 
MVB Multivesicular body 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells  
NHERF-1 Na+/H+ Exchanger Regulatory Factor 
NK Natural killer 
NLS Nuclear localisation signal 
nM Nanomolar 
nm Nanometre 
ns Non significant 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PDZ Post synaptic density protein (PSD95), Drosophila disc large 
tumor suppressor (Dlg1), and zonula occludens-1 protein (zo-1)  
PE R-phycoerythrin 
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PFA Para-formaldehyde 
PKA Protein kinase A 
PKC Protein kinase C 
PLC Phospholipase C 
PMA Phorbol myristate acetate 
PSC-RANTES N
α
-(n-nonanoyl)-des-Ser
1
-[l-thioproline
2
,l-α-
cyclohexylglycine
3
] RANTES  
PY2R Bis (2-ethylpyridine) amine receptor 
RA Rheumatoid arthritis 
RANTES Regulated and normal T cell expressed and secreted 
RE Recycling endosome 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute 
RPNI Ribophorin I 
RT Room temperature 
RTK Receptor tyrosine kinase 
SD Standard deviation 
SDS Sodium dodecyl sulphate 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SE Sorting endosome 
SILAC Stable isotopes labelling by amino acids in cell culture 
siRNA Small interfering ribonucleic acid 
SSC Size scatter 
TCA Trichloracetic acid 
TGN Trans Golgi network 
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TIR Toll-interleukin 1 receptor 
TIRAP Toll-interleukin 1 receptor domain containing adaptor protein 
TLR Toll like receptor 
TM Transmembrane 
TNF-a Tumor necrosis factor alpha 
WB Western blotting 
Y2H Yeast two hybrid 
YFP Yellow fluorescent protein 
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